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Background The rate of obesity is increasing with an alarming rate worldwide. Obesity 
increases the risk of diabetes or atherosclerotic cardiovascular disease. Additionally, 
obesity associates with co-morbidities such as hypertension, non-alcoholic fatty liver 
disease predisposing to steatohepatitis, blood thrombosis, and incidence of certain cancers. 
Thus, obesity is posing a significant threat to public health. Several genes control body 
weight and the development of obesity-related metabolic complications. Certain genetic 
variants have been identified that predispose to the risk of developing obesity and obesity-
related diseases. However, environmental or acquired factors may modify gene function 
and unique individual habits may contribute to the development or outcome of metabolic 
disturbances. In population-based studies on obesity-related metabolic derangements, it is 
impossible to disentangle the contribution of genes from unique environmental factors. 
Nonetheless, monozygotic (MZ) twins carry identical genes. The comparison of MZ and 
dizygotic (DZ) twin pairs with discordance in obesity can help to elucidate the magnitude 
of acquired or environmental factors. In obesity, the underlying molecular mechanisms are 
complex with intertwining pathophysiology of metabolic pathways in different organ 
systems. Thus, there is a need for improved understanding regarding the role of adipose 
tissue distribution and function underlying the metabolic risk factors. 
 
Aims This thesis employs biomarker analyses to: 1) characterise the derangements in blood 
coagulation and fibrinolysis in acquired obesity; 2) capture the magnitude of alterations in 
lipid metabolism, serum lipoprotein particle profile, and its quality and quantity in obesity; 
3) examine the contribution of genetic and environmental factors impacting the association 
of abdominal obesity and serum NMR metabolites; and 4) describe the differences in the 
activation of the complement system between obesity-discordant MZ co-twins by analysing 
the plasma levels and the expression of the complement-system-related genes in 
subcutaneous fat and isolated adipocytes. 
 
Materials and methods The study subjects derive from two population-based cohorts of 
young Finnish twins – FinnTwin12 and FinnTwin16. The TwinFat cohort comprises 286 
monozygotic (MZ) and dizygotic (DZ) twin individuals. The rare cohort of obesity-
discordant (Body mass index (BMI) -difference > 3kg/m2) MZ twin pairs (n=14-26 pairs, 
age 23–36) underwent an intensive study protocol. Their control group comprised obesity-
concordant (within-pair BMI- difference < 3kg/m2) MZ twin pairs. The genetic and 
environmental contributions to the association between metabolism and abdominal obesity 
were determined from a larger group comprising MZ and DZ twins (n=1368) from 
FinnTwin cohort. The body fat mass and distribution was assessed with Dual-Energy X-
ray Absorptiometry (DEXA), magnetic resonance imaging (MRI), and proton magnetic 
spectroscopy to determine the liver fat content. Several biomarkers (lipid and glucose 
metabolism, inflammation, NMR metabolites) were measured from plasma. The expression 
of complement system-related genes was assessed with microarray from subcutaneous 
adipose tissue (AT) biopsies. Data on the habitual physical exercise and eating habits was 
collected using questionnaires. By comparing BMI-discordant MZ co-twins, it is possible 
to adjust for genetic background. 
 
Results Several metabolic derangements predisposing to cardiovascular diseases and 
diabetes emerged in acquired obesity. Obese co-twins of BMI-discordant pairs presented 
elevated blood coagulation activity and increased levels of fibrinogen and the activities of 




fibrinolysis. The lipoprotein particle number increased in acquired obesity. The most 
pronounced difference was the increase in pro-atherogenic LDL-particles and triglyceride-
rich VLDL particles. In contrast, the number of HDL particles and the amount of HDL 
cholesterol was reduced. The composition of the lipoprotein particles remained unchanged 
in obesity. The pro-atherogenic alterations in lipoprotein profile emerged only if obesity 
was accompanied by concomitant increase in liver fat. Both genetic and environmental 
factors contributed to the association between unhealthy NMR lipoprotein and metabolite 
profile and abdominal obesity. Shared genes were found to determine the co-occurrence of 
these phenotypic traits. Additionally, the levels of branched-chain amino acids, α1-
glycoprotein, lactate, and urea were elevated in acquired obesity and associated with 
hyperinsulinemia. The activation of the complement system associated to low-grade 
inflammation in subcutaneous (sc) adipose tissue (AT). In acquired obesity, the expression 
of several complement system related genes in sc AT was altered and plasma concentration 
of C3a was increased. Measures of coagulation, lipoproteins, NMR metabolite profile, and 
complement-system activity were similar between the obesity-concordant twin pairs. 
 
Conclusions Widespread derangements in metabolism emerge predisposing to the 
increased risk for morbidity in young healthy adults in acquired obesity. The fatty liver is 
a key player behind alterations in lipoprotein metabolism. Increased adiposity alone does 
not define the metabolic risk; it is important to assess the risk by determining the fat 
distribution together with biomarker analyses. In this thesis, several new potentially useful 
biomarkers are presented to further characterise and define the metabolic risk in obese 
individuals. These biomarkers relate to blood coagulation, metabolism, and inflammation. 
Complement system activation associates to low-grade inflammation in AT, and may be 
important in protecting AT viability around the sites of necrotic cells. The results show that 
despite genetic predisposition, the individual’s unique lifestyle significantly contributes to 







Tausta Viime vuosikymmeninä lihavuus on yleistynyt huolestuttavasti ja on merkittävä 
kansanterveydellinen uhka. Lihavuus lisää riskiä sairastua diabetekseen ja 
valtimonkovettumatautiin. Lihavuus altistaa myös verenpainetaudille, ei-alkoholiperäisen 
rasvamaksan ja tätä kautta maksatulehduksen kehittymiselle ja veritulpan 
muodostumiselle. Lisäksi lihavuus liitetään useiden eri syöpäsairauksien ilmaantuvuuteen. 
Useat eri geenit säätelevät painoa ja lihavuuteen liittyvien aineenvaihdunnan häiriöiden 
kehittymistä. Sekä liitännäissairauksien että lihavuuden kehittymiselle altistavia 
perintötekijöitä on tunnistettu. Koska ympäristötekijät voivat säädellä geenien toimintaa, 
elämäntavat voivat vaikuttaa sairastumisriskiin. Väestöpohjaisessa aineistossa ei voida 
erottaa geenien ja ympäristön osuutta aineenvaihduntahäiriön taustalla. Koska 
samanmunaisilla (monotsygoottiset, MZ) kaksosilla on sama geeniperimä, eripainoisia 
MZ-kaksosia vertailemalla voidaan vakioida perimän vaikutus ja kuvata hankitun 
lihavuuden merkitystä aineenvaihduntamuutosten taustalla. Lihavuuteen liittyvien 
aineenvaihdunnan häiriöiden mekanismit ovat monimutkaisia, ja nämä vaikuttavat monien 
patofysiologisten kokonaisuuksien ja elinjärjestelmien kautta. Rasvakudoksen sijainnin ja 
ominaisuuksien merkitys aineenvaihduntahäiriöiden taustalla on keskeinen ja osittain vielä 
puutteellisesti tunnettu, joten näitä seikkoja on syytä tutkia lisää. 
 
Tavoitteet Tutkimme eripainoisilla identtisillä kaksospareilla biomarkkereita apuna 
käyttäen 1) muutoksia veren hyytymistä ja liukoisuutta säätelevissä tekijöissä; 2) minkä 
verran muutoksia nähdään veren rasvojen ja lipoproteiinien määrässä ja koostumuksessa; 
3) perimän ja ympäristön osuutta erikseen vyötärölihavuuden ja aineenvaihdunnan 
muutosten taustalla; 4) komplementtijärjestelmän aktivaatiota ja järjestelmän 
osakomponenttien geenien ilmentymistä ihonalaisrasvakudoksessa. 
 
Materiaali ja menetelmät Tutkimusaineisto pohjautuu FinnTwin12 ja FinnTwin16 –
väestökohortteihin. TwinFat- aineisto sisältää yhteensä 286 MZ- ja DZ-kaksosta. TwinFat-
aineistosta kutsuttiin kattaviin aineenvaihduntatutkimukseen eripainoisia (painoindeksin 
(BMI) ero parien välillä > 3kg/m2) MZ kaksospareja (n=14-26 paria, ikä 23–36 vuotta) ja 
heidän vertailuryhmänään oli samanpainoisia (BMI-ero < 3kg/m2) MZ kaksospareja (n=9-
14 paria). Tutkittaessa geenien ja ympäristön välistä vuorovaikutusta vyötärölihavuuteen 
liittyvän aineenvaihduntamuutosten taustalla, hyödynnettiin laajempaa kaksosaineistoa 
(n=1358), jossa mukana oli myös ei-identtisiä kaksospareja. Kehon rasvan määrä ja 
jakauma määritettiin kuvantamismenetelmin (DEXA, magneettikuvaus, 
magneettispektroskopia). Aineenvaihduntamarkkereita (sokeri- ja rasva-aineenvaihdunta, 
inflammaatio, komplementtijärjestelmän aktiivisuus) määritettiin paastoverinäytteestä. 
Ihonalaisrasvasta otetusta kudosbiopsiasta määritettiin komplementtijärjestelmään 
liittyvien geenien ilmentymistä. Kyselylomakkeilla kerättiin tietoa kaksosparien liikunta- 
ja ravitsemustottumuksista. 
 
Tulokset Hankittu lihavuus toi esiin merkittäviä verisuonitukokselle, 
valtimokovettumataudin sekä diabeteksen kehittymiselle altistavia 
aineenvaihduntamuutoksia. Lihavilla kaksosparikeilla plasman fibrinogeenin pitoisuus 
lisääntyy sekä veren hyytymistekijöistä faktori (F) IX :n, XI:n, XII:n ja veritulpan 
liukenemiseen liittyvän PAI-1:n aktiivisuus kohoaa. Lihavuudessa veren 
lipoproteiinipartikkeleista erityisesti aterogeenisten LDL-partikkeleiden ja 
triglyseridipitoisten VLDL-partikkeleiden määrä lisääntyy ja HDL-partikkeleiden ja –




lihavuudessa. Valtimokovettumataudille altistavia muutoksia lipoproteiinipitoisuuksissa 
havaittiin vain, mikäli lihavuuteen liittyi maksan rasvoittumista. Sekä perimä että 
ympäristötekijät vaikuttavat osaltaan terveydelle epäedullisen NMR-metaboliittiprofiilin ja 
vyötärölihavuuden väliseen yhteyteen. Näiden piirteiden ilmeneminen on osittain samojen 
geenien säätelemää. Hankitun lihavuuden vaikutuksesta haaraketjuisten aminohappojen, 
laktaatin, urean ja a1-glykoproteiinin pitoisuus nousee. Merkkinä 
komplementtijärjestelmän aktivaatiosta lihavuudessa järjestelmään liittyvien geenien 
ilmentyminen ihonalaisrasvakudoksessa muuttuu ja plasman C3a-komponentin pitoisuus 
lisääntyy. Kehonkoostumuksessa, aineenvaihduntaa kuvaavien biomarkkereiden 
pitoisuuksissa tai komplementtijärjestelmän aktivaatiossa ei havaittu eroja 
samanpainoisten MZ kaksosparikkien välillä. 
 
Yhteenveto Hankittu lihavuus toi esiin useita sairauksille altistavia 
aineenvaihduntamuutoksia jo varhain nuorilla terveillä kaksosilla. Maksan rasvoittumisella 
on keskeinen merkitys erityisesti rasva-aineenvaihdunnan häiriön synnyssä. 
Aineenvaihduntahäiriöiden riski lihavuudessa on yksilöllinen ja tähän vaikuttaa oleellisesti 
kehon rasvan jakauma. Väitöskirjassani nousee esille uusia veren hyytymisaktiivisuutta, 
aineenvaihduntaa ja inflammaatiota kuvaavia biomarkkereita, joita voidaan mahdollisesti 
käyttää arvioitaessa lisääntynyttä sairastuvuusriskiä lihavuudessa. 
Komplementtijärjestelmän aktivaatio liittyy matala-asteiseen tulehdukseen 
rasvakudoksessa, mutta tämä voi myös olla keskeinen tekijä suojaamaan nekroottisten 
alueiden ympäristöä kudostuholta. Väitöskirjatutkimuksen tulokset osoittavat, että 
perimästä riippumatta elintavoilla on merkitystä aineenvaihduntamuutosten synnyssä. 




The prevalence of obesity has almost doubled since 1980, and obesity is now considered 
to be a global epidemic. According to the World Health Organization (WHO), over 39% 
of adults are overweight (Body Mass Index (BMI) > 25kg/m2), and over 13% of adults are 
obese (BMI > 30kg/m2) (1). In Finland, the prevalence of obesity follows global trends. 
The incidence of obesity temporarily plateaued among adults in early 21st century, but the 
current rate of obesity is still increasing (2)(3)(4). Obesity is common in both adults and 
children (5)(6), and this may limit children’s future health and life expectancy as adults (7). 
Overweight and obesity associate with increased risk of mortality and morbidity in 
adulthood creating a burden to the global economy. An estimated 7.7% of all deaths in the 
European Union in 1997 were attributable to obesity: 70% of those were due to 
cardiovascular disease (CVD) and 20% due to cancers (8). Even after taking into 
consideration the hazardous effect of smoking, excess weight contributes significantly to 
the risk of death in middle age subjects (9)(10). Therefore, one of the key global public 
health targets is the prevention of obesity. 
Following the growing rate of obese subjects, the number of the patients with type 2 
diabetes (T2D), characterised by chronically elevated plasma glucose levels, has globally 
escalated from 108 million to 422 million since 1980 (11). The risk of developing diabetes 
is 30% higher in overweight, and up to 90% higher in very obese, compared to normal 
weight subjects (9). Diabetes contributes significantly to the shorter life expectancy in 
obesity: the overall mortality in diabetes is higher compared to the healthy population 
(12)(13). Like in obesity, CVD is the predominant cause of death in diabetes. 
Dyslipidemia is a key pillar in the pathogenesis of CVD. Overweight and obese subjects, 
as well as the patients with metabolic syndrome, often present pro-atherogenic lipid profile 
predisposing to CVD (14)(15)(16). As the prevalence of the diabetes correlates strongly 
and positively to degree of the obesity, the prevalence of dyslipidemia in obese subjects 
varies. The pro-atherogenic lipid profile associates particularly to abdominal obesity 
(17)(18). Therefore, not only the body size, but the body composition, is an important 
measure when assessing the excess risk for CVD (19). Proatherogenicity typically 
associates with abdominal obesity and fatty liver. In obesity, the clustering of the CVD risk 
factors is common. Derangements in glucose and lipid metabolism combined with arterial 
stiffness and hypertension is a common co-morbidity characterising metabolic syndrome 
(MetS) (Figure 1). In addition, obesity increases the risk of venous thrombosis (20), 
gastrointestinal tract diseases including non-alcoholic fatty liver disease (NAFLD) (21), 
and certain cancers (22). Obstructive sleep apnea, a mechanical obstruction of upper 
airways predisposing to hypoxic periods during sleep associates with metabolic stress, and 
may further increase cardiovascular risk in obesity (23). Excess weight puts mechanical 
load on joints in the lower back and limbs, and degenerative osteoarthritis is higher in obese 
than normal-weight subjects (24). It is noteworthy that wellbeing and quality of life, may 
be prematurely compromised in obesity (25). The link between depression and obesity is 
reciprocal (26). 
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Figure 1 Medical complications in obesity 
Approximately 40–70% of variation in body mass index (BMI) is attributable to genetic 
factors (27)(28)(29). At the individual level, the monogenic form of obesity is more severe, 
the genetic contribution to body weight at the population level is predominantly 
multifactorial (27). Clustering of obesity related co-morbidities suggests that the genetic 
pathways may be pleiotropic, thus the same set of genes regulate both the weight, and 
glucose and lipid metabolism (30). Certain subjects develop obesity-related metabolic 
derangements earlier than others, potentially due to genetic predisposition. There is 
evidence that environmental influences can modify the outcome or the severity of 
phenotype (31)(32). For example, type 2 diabetes is heritable (30)(33), but as described 
earlier, obesity correlates strongly with the prevalence of diabetes. Environmental factors, 
such as eating habits leading to positive energy balance and obesity in subjects genetically 
vulnerable to develop diabetes, are extremely disadvantageous and may lead to the earlier 
development or more rapid progression of the clinical disease. 
Population-based epidemiological studies on obesity cannot answer the question of how 
much of the known association between obesity and metabolic derangements is due to the 
genetic factors, and how much of the variation is due to the unique environment. Twin 
studies are the key when dissecting the effect of the genetic factors from the effects of the 
environment. A rare cohort of Finnish obesity-discordant monozygotic (MZ) twins has 
elucidated these questions (34)(35)(36)(37). The case-control comparison of MZ co-twins 
discordant on weight is ideal to reveal the magnitude of the unique environmental factors, 
as their genetic background is shared. This thesis focuses on describing the impacts that 
acquired obesity and differences in body composition have on metabolism. The results 
complement the efforts of 15 years of data collection and earlier studies in the same cohort 
(36). The results disclose previously uncharacterised similarities and differences in blood 
coagulation and fibrinolysis, lipoprotein metabolism and the complement-system activity 




manifestation of clinical diseases, the results provide new insights into the role of the 
adipose tissue (AT) at the molecular level in the pathogenesis of obesity-related co-
morbidity. 
 
2. THE REVIEW OF THE LITERATURE 
 
2.1 Body composition  
 
Subcutaneous (sc) fat is the largest adipose tissue (AT) depot. Lesser amounts of AT 
localise viscerally (visceral adipose tissue, VAT) in the intra-abdominal (ia) cavity 
surrounding large vessels and organs (38). Sc fat that is distributed to the pelvic or thigh 
area is also referred to as ‘gynoid fat’, whereas AT localised proximally in the trunk, waist, 
or thoracic area is called ‘android fat’ (38)(39). Gender (40)(41), age (42), and ethnicity 
(43)(44) are important determinants of body fat distribution. Women have more fat mass 
than men who have a higher proportion of lean mass on total body mass due to higher 
muscle mass (45). The gynoid fat distribution is typical for premenopausal women. In 
comparison to men, women have a lower VAT to total-body-fat ratio even when the overall 
total-body-fat percentage has been accounted for (40). Body fat percentage increases 
with age and this is partly due to the loss of muscle mass (sarcopenia) (46) and alterations 
in sex steroids (42). Upon aging, maintenance of muscle mass associates with metabolic 
health. If sarcopenia occurs, obesity metabolism may be compromised in comparison to 
normal-weight individuals with low muscle mass (46). After estrogen levels decrease in 
menopause, the proportion of ia fat also increases in women (47). In men, low testosterone 
levels associate with larger amounts of VAT (48)(49). In addition, the accumulation of ia 
fat is characteristic to pathological endocrine conditions, such as hypercortisolism 
(Cushing’s syndrome) and genetic or acquired lipodystrophies (50). Body mass index 
(BMI, kg/m2) correlates well with overall adiposity, especially in high BMI ranges (42). 
Waist circumference (WC) or waist-to-hip ratio (WHR) correlate well with the amount of 
VAT, thus they complement BMI in the assessment of adiposity and body fat distribution. 
 
2.1.1 Visceral fat distribution associates to the pathophysiology of diabetes and CVD  
 
Body fat distribution is an important predictor of derangements in systemic metabolism. In 
particular, VAT associates with an adverse metabolic phenotype (51). The amount of VAT 
associates strongly positively with alterations in glucose and lipid metabolism, 
hyperglycaemia, and hypertriglyceridemia, as well as elevated blood pressure (51)(52) 
predisposing to the risk of CVD events. The relationship between VAT and metabolic 
status is pivotal, as lower ratio of VAT to total adiposity and sc fat, and larger relative 
amounts of femoral fat, associate with healthier glucose and lipid metabolism (53)(54). In 
development of metabolic derangements, however, the role of sc fat, the largest body fat 
depot, cannot be disregarded. High BMI with excess sc fat mass associates with significant 
co-morbidity. The correlation between the amount of sc fat and metabolic risk measures 
occurs, but it is not linear (55). 
 
2.1.2 Body composition is determined by genes and modifiable environmental factors 
 
Both body size and composition are genetically controlled. The genetic contribution to 
height is as high as 80% (56). The heritability of BMI is 40–70% depending on the cohort. 




obesity is the onset of obesity occurring already in early childhood. It is often syndromic 
associating with comorbidity and developmental deficits (57). Recent advances in 
understanding the human genome from large population-based cohorts have brought new 
insight in obesity research and elucidated the genetic landscape in common obesity. 
Numerous genetic loci associate with BMI suggesting the genetic background of obesity is 
polygenic (58). The impact of genetic variants on weight varies with age, the effect being 
largest during childhood (59). When combining the effects of the known genetic variants 
associating with BMI, it is estimated that the net effect of genes explains over 20% of the 
variation in BMI at the population level. 
 
Bouchard et al (60) showed in a pilot twin study that an increase in the amount of VAT did 
not correlate with gained total fat mass. The variance in gaining VAT was significantly 
higher between the pairs than within MZ twin pairs. Thus, the genetic contribution 
determines the inter-individual variation also in the amount of VAT (60). Recent genome 
studies have supported this finding. Several genetic variants have been associated to 
determine body fat distribution (50) and also the lean mass (61). The genetic loci 
associating to WHR have been shown to present greater effect in women in comparison to 
men (62). 
 
Insight on the impact of diet or exercise on body size and composition derive from 
randomised and controlled lifestyle intervention studies. The imbalance in energy intake in 
relation to overall energy consumption leads to weight gain. Positive energy balance and 
excess calories increase both body lean mass and adiposity, but the nutritional content of 
the diet may also influence the changes in body composition. Sugar-sweetened beverages 
and fructose have been shown to favour ectopic and visceral fat accumulation (63)(64). In 
addition, dietary fatty acid composition modifies body fat distribution as the indigestion of 
saturated fats may associate with VAT accumulation (65), whereas mono-unsaturated fatty 
acids (MUFAs) and polyunsaturated fatty acids (PUFAs) may prevent the gain of VAT and 
associate with lower WC (65)(66). Exercise is an effective way to consume energy and 
control body weight, with positive effects on body composition. Aerobic exercise 
effectively reduces visceral fat regardless of the intensity and the volume of the exercise 
regime (67)(68). Additionally, exercise increases lean mass, bone mass, and mineral 
density (69). Anaerobic resistance training, in particular, associates to increase in muscle 
mass (70). Both anaerobic and aerobic exercise have health benefits and are shown to 
reduce the risk of CVD in high risk individuals (71). 
 
2.1.3 Regulation of appetite  
 
The sense of hunger and satiety facilitate controlling the portion size upon meal time and 
not eating too frequently. Incretin hormones, such as glucagon-like peptide (GLP-1), 
cholecystokinin (CCK), peptide tyrosine-tyrosine (PYY), glucose-dependent insulin 
releasing polypeptide (GIP), and ghrelin from the upper gastrointestinal tract contribute to 
the sensation of satiety or hunger (72). In obesity, the effect of incretins in the regulation 
of food intake is blunted (73). The lack of the function of incretin hormones weakens the 
satiety signals in brain. Increased appetite leads to hyperphagia and a surplus of indigested 
calories (74). This leads to positive energy balance if the energy expenditure does not 
increase following increased calorie intake.  
 
AT is the largest endocrine organ secreting adipokines, adipose tissue derived hormones. 




monitoring satiety signals (75). The plasma levels of leptin correlate with the amount of 
AT and the levels raise in obesity (76)(77). However, in obesity, leptin signalling in the 
brain is defective and the appetite is not adequately suppressed. Similarly with ghrelin, in 
obesity the ghrelin levels are not suppressed after a meal and flattened levels may contribute 
to the tendency of snacking (72). In conclusion, in obesity, rather than increased absorption 
of nutrients, hyperphagia contributes to weight gain. 
 
2.2 Adipose tissue morphology 
 
White adipocytes containing triglyceride droplets are the largest cells in AT. The turnover 
of mature adipocytes is 8–10% per year in humans, and new cells are recruited from 
precursors to replace the dying adipocytes (78)(79). Adipose tissue stroma is cell rich and 
comprises extracellular matrix and immune cells. Adipocytes in AT are surrounded by 
vasculature that supplies oxygen, nutrients, and other blood components (80). When energy 
balance is positive, AT needs to expand to store energy. The cell size of the adipocytes 
grows and concomitantly, new adipocytes are recruited from precursors for storing excess 
energy (80). Thus, AT expansion is due to both cell hyperplasia and hypertrophy. AT 
vessels contribute to adipose tissue expansion providing adipocyte progenitor cells from 
blood flow (81). In healthy AT, the vasculature grows allowing the expansion and 
remodelling of AT (78)(82). 
 
Certain adipocytes have distinct features in energy dispersion. Mitochondria-rich 
adipocytes have a brown appearance. Brown adipocytes are distinguishable from white 
adipocytes expressing uncoupling-protein-1 (UCP-1)(80). Brown AT typically localises in 
paracervical and suprascapular regions in adults (83). Characteristic to brown AT is the 
dispersion of energy as heat. Beige adipocytes are cells are predominantly comparable to 
white adipocytes but by beta-adrenergic stimulation they express UCP-1 and functional 
characteristics resemble those of brown adipocytes (84). 
 
Like body size, AT morphology is also under genetic control. Sc AT cellularity within MZ 
co-twins is similar (85)(86). Similarly, weight loss does not have a significant effect on 
overall cellularity in obese subjects (80)(87). In acquired obesity, sc AT is hypoplastic and 
adipocytes are hypertrophic. AT adipocytes grow in size, but adipocyte number does not 
increase (86). Obesity-discordant MZ co-twin comparison confirmed that these alterations 
emerge independent of genetic contribution (86). Obese subjects with hypoplastic sc AT 
presented features of unhealthy metabolism characterised by hyperinsulinemia, 
hyperglycaemia, and pro-atherogenic lipid profile (86). 
 
2.3 Characteristic of healthy adipose tissue 
 
In functional and healthy AT, in a state of overnutrition, energy metabolism favours de 
novo lipogenesis and lipid storage in adipocytes (88). De novo lipogenesis (DNL) is a 
physiological way to dispose glucose in AT. Free fatty acids (FFAs) deriving from diet or 
via de novo lipogenesis from glucose are esterified into triglycerides (TGs), then processed 
in the endoplasmic reticulum to form lipid droplets within adipocytes (78). In AT, insulin 
promotes glucose and lipid uptake and suppresses lipolysis, the net effect is the promotion 
of nutrient storage. The nutrient storage in sc AT adipocytes associates with the 
maintenance of normoglycemic plasma glucose levels and systemic insulin sensitivity 
(89)(90). Adipocytes release energy from TG droplets in demand. The effect of 




demand. In lipolysis, the hormone sensitive lipase (HSL) hydrolyses TGs back to glycerol 
and FFAs. Insulin inhibits HSL and thereby AT lipolysis. 
 
Functional insulin signalling is essential for storing nutrients efficiently in AT and 
maintaining tissue integrity (78). Peroxisome proliferator-activated receptor gamma 
(PPARγ) is a strong insulin-sensitizer in AT (91) (92). It induces the expression of 
transmembranic GLUT4 receptors thereby facilitates glucose uptake and providing 
substrate for DNL (93). Fatty acid transport proteins facilitate fatty acid storage as well as 
controlling lipolysis (94). Carbohydrate-responsive-element-binding protein (ChREBP) is 
a regulator of lipogenic and glycolytic genes (89)(95). It regulates PPARγ activity and 
advances glucose disposal in AT by increasing DNL (95)(89). Lipoprotein lipase (LPL) 
activity is crucial for TG storage in AT. The enzymatic activity of LPL is insulin-dependent 
(96). The high activity of LPL is protective against metabolic derangements in obesity (97). 
Pivotally, in obesity and insulin resistance (IR), the suppressed LPL activity in adipose 
tissue may impair TG storing (97)(98). 
 
2.3.1 AT mitochondria 
 
Glucose disposal and fatty acid storage require energy and the mitochondria in adipocytes 
are responsible for oxidative energy supply in AT (99). The beta-oxidation of FFAs takes 
place in adipocyte mitochondria when FFAs are oxidised to acetyl-co-enzyme-A, and 
subsequently to adenosine di-phosphate (ADP) and reduced to nicotinamide adenine 
diphosphate (NADH) providing energy for metabolism (78). Ketone bodies are the end 
products of beta-oxidation transporting energy to other tissues from AT(100). AT can 
increase its energy production capacity during adipocyte differentiation by recruiting new 
adipocytes and thus increase the total number of adipocytes. Concomitantly, the biogenesis 
of mitochondria and subsequent increase in beta-oxidation capacity are characteristic to 
healthy AT and tissue remodelling in overnutrition (78). If mitochondrial oxidative 
phosphorylation capacity is compromised, the resultant metabolic effects are widespread. 
Diminished oxidative capacity leads to increase in intracellular stress and upregulation of 
proinflammatory signals, eventually leading to cell death. Areas of dying cells generate 
proinflammatory milieu and impair insulin signalling in AT. Mitochondrial dysfunction 
associates with the development of systemic insulin resistance and diabetes (101) and also 
precedes the manifestation of clinical disease (102)(103)(104). The reduced mitochondrial 
DNA copy number and the down-regulation of the mitochondrial gene-expression in AT 
has been demonstrated in acquired obesity (104). 
 
2.4 The role of subcutaneous AT in development of the insulin resistance and 
lipotoxicity 
 
In IR obesity, fatty acid storage and glucose uptake in AT are defective (Figure 2). The 
function of the key enzymes of these processes, including GLUT4, are suppressed 
(89)(105). Concomitantly, when insulin fails to suppress lipolysis, FFAs spill from AT, in 
hyperglycaemic and IR conditions HSL levels increase accelerating lipolysis (106). The 
lipolysis in sc AT, which is the largest adipose depot, contributes significantly to the 
circulating FFA levels (107). The AT lipolysis plays an important role in the pathogenesis 
of insulin resistance as surplus of FFAs leads to accumulation of TG droplets to ectopic 
tissues, such as to the liver, the heart, or muscle. Release of FFAs from AT and lipid 
accumulation ectopically eventually impair insulin sensitivity systemically. Thus, the 




of VAT and abdominal obesity correlate with ectopic lipid accumulation (109). Therapeutic 
obesity intervention by bariatric surgery increases the activity of the key enzymes of DNL 
facilitating energy storage in sc AT(89). 
 
The IR obesity is characterised by impaired glucose tolerance as higher insulin levels are 
needed for glucose uptake to the tissues to maintain normoglycaemia. Glucose absorption 
is accelerated postprandially in obese subjects. As a physiological response to indigested 
glucose, insulin levels rise rapidly. In obesity, insulin secretion is delayed due to reduced 
secretion of incretin hormones from the upper gastrointestinal tract (74). Incretins normally 
suppress glucagon secretion, but in obesity they fail to do so, and glucagon levels rise. As 
a result, hyperglucagonaemia contributes to the pathophysiology of hyperglycaemia by 
releasing more glucose from glycogen storage (110). Muscle glycogen synthesis and 
glucose oxidation for energy production normally accounts for most postprandial glucose 
disposal. In obesity, intramuscular IR resulting from intramuscular TG accumulation 
inhibits glucose uptake into myocytes and contributes to the pathophysiology of 
hyperglycaemia (111)(112). Adiponectin is a potent insulin-sensitising adipokine and its 
receptors are expressed in all tissues but predominantly in muscle and in liver (113). It 
ameliorates insulin resistance and has favourable effects on body weight (114). 
Adiponectin levels decrease in obesity and with age (113)(115). In obesity, pro-
inflammatory adipokines, such as tumour necrosis alpha and interleukins, modify glucose 
tolerance and lipid metabolism. Low-grade inflammation links AT to the pathophysiology 




Figure 2 Features of unhealthy adipose tissue 
 
In conclusion, to be able to expand, AT needs functional mitochondria for its energy 
production. If there is lack of oxidative capacity in the AT mitochondria and the recruitment 
of new adipocytes from precursor cells fail, AT is not able to store nutrients in sc AT depots. 
The accumulation of lipids in VAT and in ectopic tissues intracellular associates with IR. 
In obesity, the levels of insulin sensitising adipokines are reduced. Ectopic fat interacts with 
surrounding tissues in endocrine and paracrine manner. In the pancreas, TGs contribute to 




associates to coronary calcification, myocardial steatosis, and diastolic dysfunction in the 
absence of obstructive coronary artery disease (120).Thus, AT dysfunction leads to 
lipotoxicity due to TG accumulation in ectopic tissues and impaired insulin sensitivity. 
Ectopic fat and systemic low-grade inflammation are key contributors to the 
pathophysiological mechanisms of metabolic co-morbidity. 
 
2.5 Non-alcoholic fatty liver disease (NAFLD) – a manifestation of ectopic adipose 
tissue 
 
In obesity, the risk of developing non-alcoholic fatty liver disease (NAFLD) is 3.5-times 
higher compared to normal weight individuals (121). The global prevalence of NAFLD is 
estimated to be 25% (122) but it varies considerably, from 15% in paediatric up to 90% in 
the severely obese population (123). Elevated alanine transferase levels (ALT) > 30 U/L in 
men, and > 20 U/L in women associate with increased intrahepatic TG accumulation (124). 
In NAFLD, intrahepatic TG content exceeds 5% (124). The liver biopsy is a gold standard 
in NALFD diagnostics, but radiological screening has gained advantage being non-
invasive. The ultrasound screens fatty liver with a sensitivity of 60–94% and specificity of 
66–95% (125). Liver proton magnetic spectroscopy offers higher reproducibility compared 
to ultrasound, and its reliability has been validated against liver biopsies (125). 
 
NAFLD is a manifestation of metabolic syndrome (MetS). The patients with MetS with 
NAFLD show a worse endothelium-dependent vasodilation compared with patients with 
MetS without NAFLD (126). NAFLD with liver IR leads to the failure of insulin to 
suppress gluconeogenesis in the liver resulting hyperglycaemia (127). Over 20% of the 
patients with NAFLD have T2D (122), and more than 2/3 of NAFLD patients are 
dyslipidemic (122)(128). Fatty liver promotes the progression of liver injury and increases 
the risk for non-alcoholic steatohepatitis (NASH) (129). Altered intracellular cholesterol 
homeostasis is involved in pathophysiological mechanisms in NASH (129). Chronic 
inflammation characterises NASH, and patients are at risk of progression of liver disease 
to fibrosis and liver cirrhosis, and irreversible loss of organ function (130). NASH also 
predisposes the development of hepatocellular carcinoma. In prospective studies, NAFLD 
also associates to higher mortality. The risk of death increases with advancing stages of 
fibrosis (128)(131). 
 
Fatty liver has detrimental effects on lipid and glucose metabolism. Lipolysis from AT 
leads to increased FFA flow to the liver via splanchnic circulation, leading to ectopic TG 
accumulation in hepatocytes. Increased liver TG content correlates strongly with systemic 
IR. However, the causality from intrahepatic TG accumulation to IR remains elusive. 
Diacylglycerol (DAG) is a TG metabolite, and DAG levels elevate in obesity due to 
unsuppressed lipolysis. DAG correlates negatively with insulin-mediated suppression of 
hepatic glucose production in obese humans (r=−0.609; p=0.012) (132). Thus, DAG 
accumulation in hepatocytes is a plausible mechanism linking hepatic IR, impaired insulin 
signalling, and elevated TG content. Yet, the association is not observed in all studies (133). 
In fasting state, the liver regulates plasma glucose concentration via gluconeogenesis from 
glycerol, glycogenic amino acids, lactate, and pyruvate, or via glycogenolysis. Liver IR 
contributes to the failure to suppress glucose production in liver contributing to 
hyperglycaemia (127)(134). FFAs accelerate the synthesis of TG-rich lipoprotein particles 
in liver. Very-low density lipoprotein (VLDL) particles are responsible for TG export from 
liver. However, in NAFLD, is increased VLDL particle production is insufficient to lower 




accumulation of free cholesterol (FC) in hepatocytes, even though absorption remains 
intact in NALFD (136). Simultaneously, the fatty liver induces the activation of cholesterol 
biosynthesis (136), it increases the de-esterification and cholesterol efflux from hepatocytes 
is compromised. FC accumulation into hepatocytes aggravates intracellular stress leading 
to apoptosis and cell death. FC in hepatocytes also activates inflammatory pathways 
promoting fibrogenesis (130). 
 
Hepatic steatosis and fibrosis are heritable traits correlating more strongly within MZ than 
DZ twin pairs (137). The well-known genetic loci associating with increased liver fat 
content are variants of patatin-like phospholipase-domain containing (PNALP3) and 
transmembrane 6 superfamily member 2 protein (TM6SF2) genes (138). Lipid 
accumulation to the liver leads to variable clinical outcomes (139)(140). Interestingly, 
variants of TM6SF2 and PNALP3 genes associate with preserved insulin sensitivity and 
lower circulating triglyceride levels in NAFLD (139)(141). In contrast – accumulation of 
hepatic ceramides associate to IR (139). The unique environmental factors when lifestyle, 
exercise habits or dietary factors, differing between individuals can lead to within-pair 
discordance in liver fat, even when genetic factors are fully adjusted as documented within 
weight-discordant MZ twins (37). The differences in the intake of polyunsaturated and 
saturated fats associate with increased liver fat (65). Furthermore, the intake of fructose 
stimulates hepatic de-novo lipogenesis (DNL) (142). Weight loss and exercise are first line 
therapies for NASH, but even more modest weight loss efficiently reduces intrahepatic TG 
(143)(144). 
 
2.6 Obesity and pro-atherogenic derangements of lipoprotein metabolism 
 
Pancreatic lipase hydrolyses dietary fat TGs into fatty acids (FAs) which are then absorbed 
by enterocytes in the intestinal lumen. If absorbed FAs are not oxidised to produce energy 
or used as substrate for cholesterol (C) synthesis in the gastrointestinal tract, they are re-
esterified to TGs and incorporated together with apolipoproteins and form soluble 
chylomicron particles, which enter the blood stream via lymphatic vessels. Lipoprotein 
particles are mainly synthesised in the liver. The lipoproteins comprise surface 
apolipoprotein, thin phospholipid layer and core lipids (TGs and cholesterol esters). The 
higher the protein content, the denser and smaller is the lipoprotein particle. The lipid 
content is highest in very low-density lipoproteins (VLDL). The lipids gradually decrease, 
and the proportion of proteins increases from intermediate density lipoproteins (IDL) to 
low density lipoproteins (LDL). High-density lipoprotein (HDL) particles have the highest 
protein content of 25–50% (Figure 3). TG-rich chylomicrons and VLDL particles provide 
the main FA sources for peripheral tissues for their energy demand. Overproduction of TG 
rich (non-HDL) lipoprotein particles and low HDL-C are characteristic to derangements in 







Figure 3 Lipoprotein classes according their size 
 
2.6.1 Hypertriglyceridemia reflects elevated number of large VLDL particles	  
 
In obesity, hypertriglyceridaemia mainly reflects elevated TG content in chylomicrons and 
VLDL particles. Hyperinsulinemia contributes to increased VLDL particle size and number 
(146)(147). FFA flux from AT due to uncontrolled lipolysis and increased production of 
apolipoprotein B (ApoB) in fatty liver provide substrates for VLDL assembly. Indeed, in 
obese subjects with hypertriglyceridaemia, VLDL secretion rate is increased and clearance 
is impaired, whereas VLDL kinetics is normal in normotriglyceridaemic obese subjects 
(148). VLDL particles and hypertriglyceridemia has been proposed to be an independent 
risk factor for CVD beyond LDL-C (149). 
 
Several genetic loci associate with hypertriglyceridaemia and other pro-atherogenic lipid 
traits (150). As these loci explain an estimated 10-12% of inter-individual variation in TG 
levels (150), modifiable environmental factors have a significant role contributing to TG 
levels. A protein-rich diet in relation to carbohydrates or fats has been shown to have to 
lowering TGs when the overall energy of the diet was adjusted (151). As 
hypertriglyceridemia can also be reversible after bariatric surgery (152), in spite of the 
genetic determination, acquired obesity aggravates derangements in lipid metabolism. 
 
2.6.2 Small oxidised LDL-particles promote atherosclerosis 
 
Low-density-lipoprotein (LDL) particles carry the majority of circulating cholesterol (153). 
Prevalence of hypercholesterolemia is higher in overweight compared with normal weight 
subjects but it does not increase linearly with BMI (17). Hyperinsulinemia and NAFLD 
correlate strongly and positively with the LDL-C concentrations and also LDL particle 
number (146). In metabolically unhealthy obesity, LDL particles undergo qualitative 
changes that promote atherosclerosis. Increased VLDL TGs are predictive for small LDL 
size (154). Cholesterol transfer between lipoprotein particles and TG hydrolysis from LDL 
result in the formation of small and dense LDL particles (154). The small LDL particles 
are susceptible to oxidation which promotes their atherogeneity (155). Oxidised small LDL 
(oxLDL) particles accumulate within macrophages, resulting in the formation of foam 
cells. The lipid-engorged macrophages release pro-inflammatory cytokines contributing to 
inflammation of the arterial wall, and inhibits nitric oxide release and vasodilation (155). 
The catabolism of LDL is suppressed. In particular, the clearance of small LDL particles 
by hepatic LDL receptors is reduced (155). Thus, the formation of small and dense LDL 




cardiovascular risk in obesity (155)(156). Longitudinal studies have shown vascular 
atherosclerotic lesions manifest decades before the clinical disease in obese subjects (157). 
 
2.6.3 Decreased number and diminished size of HDL particles 
 
High-density lipoprotein particles (HDL) are responsible for reverse cholesterol transport 
from peripheral vessels to liver for cholesterol secretion to bowel for disposal. HDL 
associates with anti-inflammatory and anti-atherogenic properties correlating negatively 
with insulin resistance and risk of CVD (158). HDL particles are heterogeneous and can be 
divided into subclasses with varying function and size (159). The largest particles have the 
highest capacity for cholesterol transport. In obesity, HDL-C concentration (17) and HDL 
particle number are reduced, and particle size diminished (160). The net effect is reduced 
capacity for reversed cholesterol transport. The prevalence of low HDL-C yields up to 30–
40% in obese subjects (17) and is a highly heritable trait (160).  
 
AT distribution (ia and ectopic preponderance) and its function in obesity contributes to 
proatherogenic dyslipidemia. AT is a major source of free cholesterol and the adipocytes 
transfer cholesterol to HDL particles (161). Additionally, hyperglycaemia, IR, and 
abundance of FFAs inhibit ApoA1 synthesis in liver (158). AT contributes to lipidation of 
apolipoprotein A1 (ApoA1), the main surface protein in HDL. The cholesterol transfer 
from AT to new HDL particles is reduced in adipose tissue inflammation (161). The plasma 
cholesteryl ester transfer protein levels are increased in obese subjects making this a 
plausible mechanism for the reduction of serum HDL-C levels in obesity (162). 
 
The overproduction of large VLDL particles, especially when liver is fatty, initiates a 
sequence of events that results in the atherogenic lipid profile with low HDL-C (145). 
Hypertriglyceridemia alters HDL functional properties by impairing anti-inflammatory and 
vasoactive capacity against oxLDL-induced vasoconstriction (163). Low HDL-C can also 
be secondary to elevated serum levels of inflammatory cytokine levels without concomitant 
hypertriglyceridemia (158)(164). In metabolically unhealthy obesity, AT releases 
inflammatory adipokines such as tumour necrosis factor alpha (TNF-α) that influence both 
on the loss of anti-inflammatory properties and decreased HDL particle number (164).  
 
The genetic factors explain a considerable amount of the variation of the levels and 
the composition of plasma lipoproteins but the contribution of acquired 
environmental factors remains important. The data describing the magnitude of 
environmental contribution of lipoprotein metabolism lacks the genetic control 
effect. Earlier studies describe the quantitative measures well, in addition to 
alternations in the cholesterol and lipoprotein particle concentrations in obesity. 
Whether the composition of lipoprotein particles in different particle classes 
changes with acquired obesity is previously uncharacterised. Interestingly, some 
obese individuals remain free from atherogenic lipid derangements. As described 
above, the fatty liver induces alternations in lipoprotein metabolism. However, not 
all subjects develop NAFLD. To complement the current data, a twin study is useful 
to assess the magnitude of the contribution of the environmental factors on 
lipoprotein metabolism in acquired obesity. Taking account for the clustering of 
abdominal obesity and dyslipidemia, twin studies can answer questions on the 





2.7 Prothrombotic state in obesity 
 
The formation of a blood clot is a key event in the pathogenesis of arterial and venous 
thrombotic complications. Blood coagulation is a cascade where activated coagulation 
factors (F) and platelets together form a fibrin clot. In the clot lysis, plasminogen is 
converted to active plasmin by tissue plasminogen activator and urokinase, resulting in 
fibrin degradation products (Figure 4). The clot formation and lysis are dynamic events. In 
obesity, NAFLD associates with the excess production of coagulation factors in liver 
(165)(166). Additionally, synthesis of coagulation factors occurs also in AT (167)(168). 
The low-grade inflammation in AT promotes the release of pro-inflammatory adipokines 
and cytokines. Subsequently, inflammation fuels the production of coagulation factors 
promoting the pro-thrombotic state in obesity. The adiposity associates to the defective 




Figure 4 Blood coagulation cascade and fibrinolysis 
 
Figure modified from Pallister CJ, Watson MS (2010). Haematology, Scion Publishing pp 336-47. 
VII- XIII, blood coagulation factors; a, activated from; PAI-1, plasminogen activator inhibitor-1; 
TF, tissue factor; PL, platelet membrane phospholipid; Ca++, calcium ion 
 
2.7.1 Platelet hyperaggregation 
 
In formation of thrombus, activated platelets aggregate on fibrin net. Unhealthy obesity 
associates with platelet hyper-responsiveness, promoting platelet aggregation with fibrin. 
The underlying molecular mechanisms are complex, including altered platelet size and the 
enhanced turnover rate, increased biosynthesis of thromboxane, as well as platelet surface 
adhesion molecules and their ligands. Platelets’ resistance to pro-thrombotic signals depend 









Obesity modifies the activity of the coagulation cascade and alters the levels of several 
coagulation factors (167). Fibrinogen, as well as von Willebrand factor (vWF), FVII and 
FVIII levels rise in obesity (168)(172)(173). Fibrinogen is an acute phase protein and 
elevated fibrinogen levels associate with low-grade inflammation and pro-inflammatory 
cytokines produced by AT macrophages (174). vWF is mainly synthesised by vascular 
endothelium (175). It stabilises FVIII re-enforcing its pro-coagulative capacity. Indeed, the 
levels of these two coagulation factors are typically linked (168). FVII levels correlate 
positively with hypertriglyceridemia (176), and dietary fat intake has been shown to elevate 
VII activity postprandially (168)(177). Adipokines leptin, visfatin, and resistin contribute 
to procoagulative state (167)(178). Leptin and leptin-receptor-deficient mice are protected 
from arterial thrombosis, the role of leptin in prothrombotic state may be causal (179). 
 
The levels of coagulation factors are heritable, suggesting strong genetic control (180). 
However, the results from weight loss (181)(178)(182) and dietary intervention studies 
(167) indicate the pro-coagulative state is modifiable. Upon weight loss, the levels and 
activity of coagulation factors decrease (182)(183). The levels of coagulation factors 
associate positively with insulin resistance and low-grade inflammation, suggesting that 
the genetic regulation of the levels of coagulation factors may be pleiotropic. The function 
of the same gene may influence both metabolic traits and the coagulation factors (184). The 
FXIII-A gene is an interesting novel finding and it expresses in the sc AT (185). The FXIII 
gene polymorphism has been proposed to one of novel candidate genes in the in 
development of obesity. FXIII-A is a negative regulator of adipogenesis. Located on the 
surface of preadipocytes, FXIII-A has an inhibitory effect on preadipocyte differentiation 
(186). 
 
2.7.3 Impaired fibrinolysis 
 
Impaired fibrinolysis characterises metabolically unhealthy obesity. Plasminogen activator 
inhibitor-1 (PAI-1) inhibits the activity of the tissue plasminogen activator and urokinase, 
and thereby inhibits the conversion of plasminogen to clot-lysing plasmin. Adipocytes 
(168) and AT stromal cells, including macrophages, produce PAI-1 (187) and the 
circulating levels of PAI-1 rise in obesity (188). The levels of PAI-1 correlate strongly with 
the amount of VAT (187) and therefore PAI-1 is a surrogate marker for ectopic fat 
deposition. VAT, more than sc or femoral fat, contributes to PAI-1 levels (189)(190). 
Locally in AT, PAI-1 is involved with adipose tissue differentiation, which prevents 
angiogenesis and predisposes to hypertrophic adipogenesis, increased adipose tissue stroma 
cellularity, and faster weight gain (191). In contrast, PAI-1 levels drop during caloric 
restriction (192). The circulating levels of PAI-1 drop as an immediate response to obesity 
surgery (193) before a significant drop in body weight. Thus, it is not only the reduction of 
fat mass explaining such an acute change, but other factors besides adiposity play a role. 
The genetic polymorphism of PAI-1 has clinical importance as certain gene variants of 
PAI-1 contribute to development and severity of cardiovascular disease (194).  
 
The previous data on hypercoagulable state in obesity does not fully cover the entire 




FVIII, and fibrinolytic marker PAI-1, while many other factors remain less 
characterised. The heritability of coagulation factors is high. When validating the 
results of the obesity-induced alterations in coagulation and fibrinolysis in MZ twin 
cohorts, results can reveal new associations and pathways to the common genetic 
basis. The genes regulating the coagulation cascade may be pleiotropic, and the 
same genes may regulate the levels of several coagulation factors simultaneously. 
The BMI-discordant MZ twin comparison permits the control of several 
confounders, including genetic factors. 
 
2.8 Systemic low-grade inflammation in obesity 
 
Systemic low-grade inflammation accompanies the metabolic derangements of MetS, 
cardiovascular disease and diabetes. Underlying pathophysiologic mechanisms include 
impairment of insulin signalling and deterioration of glucose uptake in insulin-sensitive 
tissues (195). Additionally, inflammation also impairs the reverse cholesterol transport 
pathway. The change in lipoprotein profile favours atherogenesis and cholesterol plaque 
instability. The levels of pro-inflammatory cytokines such as TNF- α, interleukin-6 (IL-6), 
and hsCRP elevate in obesity. AT contributes to pro-inflammatory milieu by secreting 
numerous cytokines (196). 
 
Leptin is a regulatory hormone with multiple roles in the immune system. It activates the 
immune system, enhances its function, and induces immune cell proliferation (197). In 
contrast, the role of adiponectin contradicts the anti-inflammatory switch in AT 
macrophages and suppresses their pro-inflammatory cytokine release (198). TNF- α 
inhibits adiponectin synthesis (199). Oxidative stress, potentially due to mitochondria 
dysfunction in obese AT, associates with low-grade inflammation. In dysfunctional AT, 
the vasculature surrounding hyperplastic adipocytes is underdeveloped and this may lead 
to diminished blood flow inducing hypoxia (200)(201). Yet, the role of AT hypoxia in 
human obesity is complex and not fully understood.  
 
2.8.1 Macrophages pro-inflammatory characteristics associate to adipocytes’ 
apoptosis in AT 
 
Infiltration of immune cells is characteristic of obese AT. The number of macrophages 
correlates with the overall adiposity (202). The number of macrophages increases when 
maximum lipid storing capacity in AT adipocytes is reached (203). Indeed, the adipocyte 
hypertrophy promotes macrophage recruitment and the number of macrophages can 
increase by up to 50% of all AT cells (204). Macrophages cluster together and surround 
dying adipocytes forming crown-like structures (CLS). The lifespan and the turnover rate 
of adipocytes in obese adipose tissue is similar to lean state (205). However, the overall 
adipocyte number is higher in obesity, therefore dying adipocytes are more frequent (205). 
The role of macrophages is to clear the cell and lipid debris, such as triglycerides 
phospholipid membrane derivatives (204). The number of macrophages diminishes after 
weight loss as shown post-operatively in patients that have undergone gastric bypass (206). 
 
Macrophage infiltration does not trigger the systemic immune response in obesity. 
Macrophage surface markers differ between healthy and unhealthy subjects, and pro-
inflammatory markers are more abundant in unhealthy AT (207)(208). Lean AT immune 
cells are predominantly macrophages polarised to M2 state, so called ‘alternatively 




inflammatory immune response (209). In obesity, low adiponectin levels and adipocyte 
hypertrophy promote macrophage polarisation to pro-inflammatory M1 state (209)(210). 
The expression of stress-markers on surfaces of hypertrophic adipocytes may influence the 
switch in polarisation (195)(209). 
 
In CLS, macrophages are predominantly polarised to M1 state, and secrete pro-
inflammatory cytokines attracting more immune cells to the area (210). Inadequate 
clearance of necrotic cell material is a strong pro-inflammatory signal fuelling AT 
inflammation. Furthermore, lipid-filled macrophages act as a buffer preventing lipid spill 
from AT to ectopic tissues (204). In conclusion, the shift in macrophage polarisation is 
crucial in the development of low-grade inflammation that associates to metabolic 
complications in obesity (195)(204). 
 
2.8.2 Cytokines and intracellular inflammatory signalling 
 
The cytokines released from adipocytes, AT immune cells, and stroma mediate the insulin 
signalling in AT (211). TNF-α, IL-1β, and IL-6 impair insulin signalling in AT and 
correlate with insulin resistance (212)(213). In contrast, IL-10 is a potent insulin sensitiser 
(214). Hyperglycaemia and free fatty acids induce the production of pro-inflammatory 
cytokines activating the inflammasome, the intracellular inflammatory signalling pathways 
(195). Molecular mechanisms between inflammation and insulin sensitivity are complex. 
The cytokines activate intracellular inflammatory signalling pathways via ligands and 
receptors on the cytoplasmic membrane (211). Inflammatory signalling pathways interact 
and inhibit phosphorylation of proteins in the early insulin signalling route. They also 
contribute to the generation of reactive oxygen species in mitochondria intensifying 
endoplasmic reticulum stress and activating nuclear transcription of pro-inflammatory and 
cytokine genes maintaining the inflammatory state (215). Eventually, altered nuclear gene 
transcript responses locally in AT broaden to systemic pro-inflammatory signals. 
 
Some twin studies suggest genetic factors contribute to variation in the immune response 
(216)(217). In contrast, the role of lifestyle factors is evident, as weight loss associates with 
decreased levels of pro-inflammatory cytokines and improved insulin sensitivity (212). 
Additionally, the immune response is modifiable by diet (211)(218)(219).  
 
2.8.3 The multiple roles of the complement system in AT  
 
The level of the immune response requires constant monitoring. Imbalance in immune 
system activation may lead to an inappropriate level of inflammation and tissue damage, 
manifestations of autoimmune diseases, or immune deficiencies. The complement system 
clears tissue debris and monitors low-grade- inflammation in AT, mainlining the tissue 
integrity. The complement system consists of membrane-bound or soluble circulating 
proteins. Hepatocytes synthesise most complement components, but AT adipocytes and 
stroma also play an important role in their production. In fact, complement factor D, also 
known as adipsin, is a well-known adipokine (220). Interestingly, the complement 
components C1q and mannose-binding lectin (MBL) are structural homologues to 
adiponectin (221). 
 
The complement system is enzymatically activated via three routes, the classical, the 
alternative, and the lectin pathways (Figure 5). All three pathways combine and lead to the 




(MAC). Characteristic to MAC attack is the rupture of cell membranes, and consequently 
the cell dies. MAC attack is typical at the sites of bacterial infections. Additionally, the 
complement proteins prime antigens for opsonisation, and take part in humoral immune 
defense, chemotaxis, and leucocyte recruitment (222)(223). 
 
Complement system activation has systemic effects also outside AT. Complement 
component 3 (C3) is the most abundant protein in human sera and its levels elevate in 
obesity (224). C3 is a biomarker for unhealthy metabolism and together with other 
complement proteins acts as a biomarker for NAFLD (225)(226). The activation of the 
complement system correlates positively with the components of the MetS and CVD. 
Together with complement factor H (CFH) and factor B (CFB), C3 associates positively 
with BMI, waist circumference, triglycerides, and inflammatory parameters, and negatively 
with insulin sensitivity and HDL cholesterol (227)(228). Additionally, the elevated levels 
of C3 and C4b independently predict future type 2 diabetes (229). The complement 
activation pathways intertwine with those of the blood coagulation cascade and the 
formation of thrombus. Interactions between the immune system and blood clotting are 
dynamic. Coagulation factors XIa, Xa, and IXa, and plasmin, act as natural C3 and C5 
convertases cleaving C3 and C5 (230). In contrast, the complement components C3, C5, 
and C5AR1 activate the coagulation cascade and tissue factor (231). These interactions 
seem clinically relevant – as described earlier, the obesity associates with prothrombotic 
state. 
 
In AT, instead of MAC activation and cell lysis, the complement system is a key player in 
the protection of healthy cells from pro-inflammatory immune response from dying and 
necrotic adipocytes (222)(223). The complement system, as well as adiponectin, clear 
foreign material by recognising patterns of immune complexes or carbohydrate structures 
(221). Interestingly, the acylation stimulating protein (ASP, C3a desArg), a biomarker of 
complement activation, stimulates glucose and free fatty acid uptake in AT enhancing 
energy storage (232)(233). 
 
 
Figure 5 Complement system pathway and its receptors and regulators 
 





Low-grade inflammation in obesity predisposes to diabetes and CVD disrupts the 
glucose and lipid metabolism. The complement system is an important regulator of 
immune response and its role in AT preceding the manifest clinical disease is not 
completely understood. It is important to assess how acquired obesity alters the 
expression of the genes regulating the complement system activation in AT. Since 
immune cells are abundant in AT stroma, it is intriguing whether hypertrophic 
adipocytes have independent role in induction of alterations in obesity- induced 
complement gene-expression transcripts. When comparing the sc AT gene-expression 
profiles of obesity-discordant MZ twins with well-characterized clinical phenotypes 
this will give insight on the role of lifestyle in the regulation of innate immune 
responses. 
 
2.9 The role of the twin studies in the obesity research 
 
2.9.1 Classic twin study design 
 
Twin pregnancies comprise 1.5 % of all pregnancies (234) Finland. Dizygotic (DZ) twins 
are born when two eggs are fertilized by two different sperms. Therefore, they share 50% 
of their genes being as similar as any siblings. Monozygotic (MZ) twin pregnancies 
comprise of 30% of all twin pregnancies (235). MZ twins share 100% of the genes, 
therefore often are considered “identical”, and resemble each other more than DZ pairs. 
Some phenotypic traits, such as eye colour, are determined by genes. In contrast, some 
traits are more complex, such as height or body weight, are affected by several genes or 
interplay of genes and environment. Different alleles, the genes that code the same trait, 
determine the variance of genetic effect. MZ and DZ twins are often raised together. 
Therefore, the twin pairs share many environmental factors, such as socio-economic class, 
upbringing or nutrition. MZ twins’ unique environmental factors such as individual habits 
and lifestyle eventually influence on genetic variance and the penetration of a phenotypic 
trait. 
 
2.9.2 Discordance within monozygotic twin pairs arise from differences in unique 
environments 
 
By comparing similarities of MZ and DZ twin pairs, it is possible estimate the heritability 
of different traits. The heritability estimates elucidate how much of the variance of certain 
trait is due to genetic effects among individuals. Heritability of BMI is overall high 
indicating the body size is strongly genetically controlled (29). The heritability estimates 
of BMI show variation depending on study design and population selection. The influence 
of the genetic factors is greatest influence during childhood and declines with age 
(29)(28).  High heritability and genetic dominance of a trait does not mean that lifestyle or 
other environmental factors would not have impact on phenotype. As an example, the 
polymorphism in FTO-gene is known to increase body weight and the risk of obesity. 
However, with successful lifestyle intervention, the carriers of risk allele were able to lose 
weight (236). 
 
The heritability is typically higher when little variation occurs in environmental factors 
(237). In Finnish twin cohort, BMI heritability estimates ranged from 0.58 to 0.69 among 
11-17 years old (238). The effect of common environmental effects weakened with the age 
as the effects of unique lifestyles became more prominent (238). Similar observation was 




(239). Even if the co-twins were discordant at birth, then the growth appeared similar 
during childhood. Divergence in growth started re-emerging at the age of 18 leading to 
significant discordance (within –pair difference in BMI > 3 kg/m2) in adulthood (239). 
 
Discordance in birth weight is common among twin pregnancies (240) and this suggests 
twin’s unique intra-uterine condition contribute to the expression of genes. The differences 
within co-twins may emerge as early as during embryogenesis or during intra-uterine 
growth due to unequal nutrient distribution or placental vasculature (241). In rare cases de 
novo genetic mosaicism, chromosomal re-arrangements and mutations have led to 
discordance of the phenotype (241). However, the differences within adult MZ twin pairs 
usually arise from their own non-shared habits and environmental factors such as smoking, 
physical exercise or diet. 
 
Differences of the epigenome, the methylation of non-coding DNA and histone acetylation 
in chromatin, mediate the relationship between genotype and unique environmental factors. 
The epigenetic differences have impact on the expression of the coding genes (242). 
Phenotypic differences arising from epigenetic changes seem to augment over the lifespan 
and lead to heritable differences in gene transcripts within ageing MZ twin pairs (243). Yet, 
the causality of epigenetic mechanisms as a driver on outcome of complex metabolic traits 
remains unclear. The discordance in methylation profiles is not established as concluded in 
obesity-discordant twin study by Souren (244). Interestingly, DNA methylation profile in 
BMI-discordant twin pairs was similar in healthy obesity without metabolic complications, 
but differed when obesity associated with metabolic disturbances (245). The evidence from 
environmental contribution to the outcome of a disease is highly informative for lifestyle 
intervention and primary prevention of metabolic complications in obesity. 
 
Several studies have addresses the questions whether lifestyle patterns could be genetic. A 
twin studies showed the genetic variation explain 40% of unhealthy eating patterns as well 
as contributed to the initiation of smoking (246). Additionally, the genetic variance may 
explain the intensity of smoking and the amount of cigarettes smoked (246). Data collected 
from questionnaires on the food-frequency and participation on competitive sports imply 
the eating and exercise habits are genetic controlled (247). 
 
2.9.3 Obesity-discordance within MZ twin pairs is rare 
 
In MZ twin studies, it is possible to analyse gene-environment contributions by twin-twin 
comparison of observed phenotypic differences. The comparison MZ co-twins allows the 
analyses of discordance of a disease or trait in unique case-control setting. Insights on the 
metabolic consequences of acquired obesity have gathered from carefully characterized 
sample of population based cohort of BMI-discordant twins from Finland (36). Similar twin 
cohorts have also been described elsewhere (248)(249). As discordance within MZ twins 
is rare, the explanation arises from a longitudinal follow-up study showing  BMI-
discordance in MZ twins is only temporary: only 2,4% of pairs remained discordant over 
in average 6.4yrs follow-up (248). 
 
Differently expressing genes within MZ co-twins offer a powerful tool to detect possible 
genetic causality. After detection of a suggestive genetic contribution on a trait, it is 
possible to continue research to genotyping specific loci on chromosomes and further 
search for candidate genes. Clustering of the metabolic traits, such as hypertriglyceridemia, 




pleiotropic action of the same genes on these traits. In multivariate model exploring 
aetiology of the coherence of the components of MetS in middle-aged men only adiposity 
was genetically and environmentally related to all of the metabolic traits (250). This result 
suggests candidate gene studies on metabolic dysfunction should be aimed towards the 
genes regulating AT distribution and function. 
 
It is evident that the phenotypes (insulin resistance and metabolic syndrome) are influenced 
by lifestyle and environmental factors which need to be considered when exploring the 
underlying genetic architecture of these traits. The classic twin study design however, does 
not allow the researcher to consider the effects of both shared environment and gene-
environment interaction simultaneously. More complex twin analytical models such as 
Cholesky (251)(252) are used decomposing genetic and environmental correlations 
between two or more traits. 
 
The prevalence of the obesity-related metabolic diseases has rapidly increased in past 
decades, yet, the human genome has not changed with the same timeframe. The eating 
habits may have earlier been considered merely due to unique lifestyle and individual 
preferences. Now we know that the same genes not actually only regulate the body size 
but also appear to regulating appetite and satiety. The environmental factors 
undoubtedly contribute to the function of the genes regulating metabolic pathways and 
cannot be disregarded. Therefore, this thesis is aimed to complement current evidence 







The objective of this thesis was to explore, in a unique setting of young adult obesity-
discordant MZ-twins with identical genes, phenotypic (environmentally determined) 
changes brought by acquired obesity in blood coagulation, serum lipids/lipoproteins, and 
complement system. Specifically, in this thesis the following key points were 
investigated: 
I: Changes in blood coagulation factors, measures of fibrinolysis, and the susceptibility to 
thrombosis in acquired obesity 
II: Early changes in lipid metabolism, serum lipoprotein particle quantity, and quality in 
acquired obesity 
III: The magnitude of environmental and genetic contributions to the association between 
the abdominal obesity and serum metabolites assessed by NMR 
IV: Changes in the circulating levels of complement-system proteins and complement 









The Finnish Population Registration Centre was the provider of the data of all Finnish twins 
from five consecutive birth cohorts (253). The twins for obesity-studies were recruited from 
two population-based longitudinal studies, FinnTwin16 (FT16) and FinnTwin12 (FT12). 
The twins were invited for interview and to fill questionnaires about their behavioural and 
health habits. In FT16, twins born 1975–1979 (n=5601 at baseline), were followed up by 
questionnaires at 16, 17, 18.5, and 22–27 years of age (response rates 83–97%). For the 
FT12 cohort (n=5184 at baseline), twins born 1983–1987 were sent questionnaires at 11–
12, 14, and 17.5 years (response rates 74–92%). Monozygosity was confirmed by 
genotyping 10 informative genetic markers (254) and later by genome-wide association 
study (GWAS) platform. 
 
Figure 6 presents the descriptive flow chart of twin cohorts. The TwinFat sample was 
enrolled from the FT12 and FT16 cohorts based on the reported BMIs in the fourth wave 
of the data collection. Twins were selected aiming to cover a full BMI range, of both 
normal-weight and obese subjects, and a full range of within-pair differences in BMI. In 
addition, 100 twin individuals were chosen randomly with respect to their BMIs, and they 
were included in the quantitative gene analyses. The TwinFat subsample comprised 286 
subjects (136 MZ subjects; 150 same sex DZ subjects; age range: 22.8-36.2; 52.9% female). 
Altogether 33 MZ twin pairs were discordant for BMI (ΔBMI ≥3 kg/m2; age range: 22.8-
36.1; 64% female). The BMI-discordance in MZ twins is extremely rare, and these pairs 
represent the top 5% of the most discordant pairs of FT12 and FT16 birth cohorts.  
 
Quantitative genetic analyses (Study III) included a larger population of FT12 and FT16 
subjects (n=1368; FT12: n=725, FT16: n=543 and TwinFat: n=100; MZ: 531, DZ: n= 837; 
age range: 21.0-31.5; 52.5% female). The intensive cohort from TwinFat subsample 
comprised 81 MZ twin individuals (aged 22–36, 54% women). Within the intensive cohort, 
26 full pairs discordant for BMI (ΔBMI > 3kg/m2) were carefully examined 2002-2011. A 
total of 14 full pairs concordant for BMI (ΔBMI <3kg/m2) were randomly selected for their 
controls. Over the year, all pairs had not remained BMI-discordant longitudinally. The data 
from repeated clinical examinations were analysed as concordant control pairs. 
 
All twin pairs were Caucasian and normotensive, none were pregnant or lactating, and oral 
contraceptive use was documented. One obese co-twin had T2DM and used metformin and 
insulin, and one twin had inactive ulcerative colitis and used mesalazine and azathioprine. 
These individuals came to clinical examination only after 2008, therefore they are not 
included in study I as the data for analyses was collected earlier. All twins were medically 
examined affirming their physical and psychiatric health status. The twins’ weight had been 
stable for at least 3 months prior to the examination. The study protocol was designed and 
performed according to the principles of the Helsinki Declaration and was approved by the 






Figure 6 The flow chart of twin cohorts 
 
4.2 Body composition measures and clinical chemistry (I-IV) 
 
A summary of the available clinical and anthropometric measures in Studies I-IV is 
available in Appendix Table 1. Briefly, weight and height were measured after a 12-hour 
overnight fast in order to calculate BMI (body mass (kg)/height(m)2). Body composition 
was measured using whole-body dual x-ray absorptiometry (DXA) scans (Lunar Prodigy, 
Madison, WI, software version 8.8). A standardised procedure at least 4 hours after a light 
meal with empty bladder was used to avoid differences in the hydration status. Whole body 
fat percentage was calculated as 100x fat mass/(fat mass + lean mass + bone mineral 
content). The total body and android and gynoid fat mass and fat percentage were 
determined from a total body scan as described by Wiklund et al (255). 
 
MRI measurements were performed on a clinical 1.5 Tesla imager (Avanto, Siemens, 
Germany, Erlangen). To allow measurement of abdominal fat distribution, a T1-weighted 
axial image stack of 16 slices with a thickness of 10 mm and gap of 0 mm was centred at 
L4/L5 intervertebral disk. Selective fat excitation was used to obtain Images with a standard 
body coil. MR images were analysed using SliceOmatic v4.3 segmentation software 
(Tomovision, Montreal, Canada). The areas of sc and ia fat tissue were measured for each 
slice using a region-growing routine. The results were expressed as total volumes of sc fat 
and ia fat. 
 
For liver fat analyses, point resolved spectroscopy (PRESS) localisation technique with 




Orthogonal three plane images were used for localisation of the cubic 8 -27 cm3 voxel of 
interest within the right lobe of the liver avoiding signal contamination from vascular 
structures, gallbladder and adipose tissue. The MRS data was collected using a flex surface 
coil in combination with spine coils. The liver spectra were analysed with jMRUI v3.0 
software (256) by using the AMARES algorithm (257). Areas of water signal at 4.7 parts 
per million (ppm) and methylene signal from intracellular triglycerides at 1.3 ppm were 
determined using a line-fitting procedure. Spectroscopic intracellular triglyceride content 
was expressed as methylene/(water+methylene) signal area x 100 and values were further 
converted to mass fractions as earlier described by Kotronen et al. (258). 
 
Blood samples were collected from antecubital veins at 8:00-8:30 am after fasting 10-12 
hours overnight. Plasma and serum were separated by centrifugation for 15 min at 2000 g 
at 4 ºC. The separated plasma and serum were frozen in aliquots at -70 ºC until assayed. In 
studies I-IV, the serum insulin was analysed with time-resolved immunofluorometric assay 
(Perkin Elmer, Waltham, MA, USA) and high sensitivity C-reactive protein (hsCRP) 
(Cobas CRP (Latex) HS, Roche Diagnostics). Other laboratory analyses from 
plasma/serum are listed in Appendix Table 2. 
 
4.3 Euglycaemic hyperinsulinaemic clamp (Study I) 
 
In Study I, insulin sensitivity was determined by the euglycaemic hyperinsulinaemic clamp 
technique (259). Two 18-gauge catheters (Venflon; Viggo-Spectramed, Helsingborg, 
Sweden) were inserted: one to an antecubital vein to be used for infusion of insulin and 
glucose; a second inserted retrograde in a warmed hand vein to obtain arterialised venous 
blood for measurement of plasma glucose concentrations (every 5 min) and serum free 
insulin concentration (every 30 min). The rate of the continuous regular human insulin 
(Insulin Actrapid; Novo Nordisk, Denmark) infusion was 40 mU/m2·min (1 mU/kg×min) 
for 120 min. Normoglycaemia was maintained by adjusting the rate of a 20% glucose 
infusion based on plasma glucose measurements from arterialised venous blood. Insulin 
sensitivity was determined from the glucose infusion rate needed to maintain 
normoglycaemia after correction for changes in the glucose pool size (259). The M-value 
was expressed as mg glucose/kg fat-free mass per minute and considers that glucose uptake 
occurs mainly to muscle. Because hepatic glucose production is maximally suppressed in 
non-diabetic subjects already at an insulin concentration achieved during infusion of insulin 
at a rate of 0.5 mU/kg×min (260), the M-value reflects the glucose uptake. For study III, 
HOMA-IR was calculated as fasting plasma glucose*serum insulin/22.5 (261). 
 
4.4. Serum metabolites (Study III) 
 
All serum samples were analysed using the same high-throughput NMR metabolomics 
platform. Altogether 56 metabolites were selected to provide quantitative information on 
lipoprotein subclass and particle concentrations, and serum FAs, including omega-3 and 
omega-6 FAs and low molecular-weight metabolites such as nine amino acids, 3-
hydroxybutyrate, and α1-glycoprotein. Altogether 56 metabolites were selected and 
analysed in the current study. The sample preparation and NMR spectroscopy methods 








4.5 Lifestyle questionnaires, diet, smoking, and physical activity (Study II) 
Energy and macronutrient intakes were assessed from three-day food records and analysed 
by Diet32, established on a national Finnish database for food composition (264). Habitual 
alcohol intake, smoking, and physical activity habits were assessed using questionnaires. 
The non-smokers comprised never smokers and former smokers, and the current smokers 
comprised those who were daily or occasional smokers. Baecke physical activity scores 
comprise an index for physical activity in total (total index) and separate indices for 
physical activity at work (work index), sports activities during leisure time (sport index), 
and physical activity during leisure time excluding sports (leisure time index (265). 
4.6 Adipose tissue biopsies (Study IV) 
 
Adipose tissue (AT) biopsies were obtained from periumbilical sc fat using a surgical 
technique. RNA was prepared from frozen fat. The diameter of fat cells was measured 
under a light microscope from fresh biopsies treated with collagenase. From biopsy 
samples, the transcriptomics experiments were performed with Affymetrix U133 Plus 2.0 
chips. Raw gene expression data were preprocessed with the GeneChip robust multiarray 
averaging (GCRMA) algorithm using BioConductor in R (266)  and by using Brainarray 
custom cdf for probe annotations (267), and were validated with qPCR as in the study by 
Naukkarinen et al (37). 
 
4.7 Statistical methods 
 
Statistical analyses were performed using the Stata statistical software (releases 9.0-11.0; 
Stata Corporation, College Station, Texas). Survey data procedures were used to correct for 
clustered sampling of co-twins within pairs. Log- and rank transformations were used to 
normalise the distribution of non-normally distributed data. Wald and Mann-Whitney tests 
for independent samples (=t-tests adapted for clustered twin data) were used to compare 
groups between samples. Pearson correlations, with correction for clustering, were 
calculated to determine the relationships between clinical and biochemical and gene-
expression parameters in individual twins (I-IV). The co-twins were compared by 
Wilcoxon’s signed ranks test (I-IV). Male and female pairs were combined because MZ 
co-twins are matched for gender by definition. Spearman correlations of within-pair 
differences in body composition, inflammation and metabolic measures were used to test 
the effects of the extent of adiposity discordance (I-IV). Because MZ twins are identical at 
the sequence level and share all their segregating genes, the associations within MZ pairs 
are fully adjusted for genetic effects. Twin similarity was assessed using intra-class 
correlations (ICC)(I-II). Multiple regression analyses were performed to detect independent 
predictors of observed differences within twin pairs. 
 
4.7.1 Quantitative genetic model fitting (III) 
 
The classical twin study design considers two types of genetic and two types of 
environmental influences. The additive genetic influences (A) result from the cumulative 
effects of genes. The dominant genetic effects (D) result from interactions between alleles 
at the same locus (dominance) or different loci (epistasis). The common environmental 
influences (C) make the twin pair similar for the trait, and the unique environmental effects 
(E) include all environmental factors and experiences that make the twin pair dissimilar. 




D, whereas DZ pairs correlate 1/2 and 1/4 for these components, respectively. Both MZ 
and DZ pairs correlate 1 for C. E is uncorrelated for both types of twins by definition. 
Different combinations of these components (e.g. ACE, ADE, AE and CE) can be 
hypothesised to account for the pattern of variation and covariation in twin data. Dividing 
each of these components by the total variance yields the different standardised components 
of variance, such as heritability, which is defined as the proportion of the total variance 
attributable to genetic variation. 
 
In Study III, the quantitative genetic model fitting was performed to assess the contributions 
of genetic and environmental factors to the co-variation of abdominal obesity (expressed 
her as WC) with circulating serum metabolites. In brief, twin methodology makes use of 
the fact that MZ twins share 100% of their segregating genes, whereas DZ twins share an 
average of 50% by descent. Given the significant associations between abdominal obesity 
and most serum metabolites, a bivariate Cholesky decomposition model (Figure 7) was 
used to examine the genetic and environmental contributions to the covariance between 
WC and 56 serum metabolites. The first factor (A1, E1) contributes to both variables (i.e. 
WC and the metabolite), and the second factor (A2, E2) reflects influences specific to the 
second variable, thus the metabolite (251). Whether the best-fitting bivariate model was 
ACE, ADE, AE or CE for WC and for the metabolites was determined by considering both 
goodness-of-fit and parsimony in explaining the data. Mx, a structural equation modelling 




Figure 7 Schematic presentation of Cholesky decomposition model to assess the genetic 
and environmental contributions to the covariance between WC and metabolites profile 
 





The focus of the analyses in studies I–IV was to characterise and compare phenotypes of 
BMI-discordant MZ twin pairs. Their clinical characteristics are summarised in Table 1.  
5.1 High overall within-pair similarity of BMI-concordant MZ twin pairs (Studies I–
II) 
In studies I–II, within pair intra-class correlations (ICC) were calculated in order to quantify 
the degree of the resemblance of the MZ co-twins with in their phenotypic measures of 
coagulation factors and lipid parameters. Figure 8 demonstrates ICCs of selected 
biomarkers. The coagulation factors and lipoprotein particles appeared to be under strong 
familial influence in both concordant and discordant MZ twin pairs (r=0.48–0.97, p<0.05). 
However, with BMI-discordance, the magnitude of the familial influence was weaker. The 
correlation estimates (r) for total cholesterol were more significant within concordant 
(r=0.88, p<0.001) than discordant pairs (r=0.58, p<0.01). For Factor IX (FIX) the ICC 
within discordant pairs was non-significant (r= 0.34, p=ns) whereas within the concordant 
pairs the ICC was highly significant (r=0.86, p<0.001). The ICCs for all measured 
lipoprotein parameters of the concordant pairs were high and statistically significant (0.70–
0.85, p<0.01). However, in BMI-discordant pairs, ICCs for VLDL, ApoB, VLDL-C, LDL-
C, HDL2a%, and total TG concentration were low (r=0.11–0.35, p=ns) and no significant 
familial resemblance occurred. 
Figure 8 Intraclass correlations within MZ twin pairs either concordant or discordant on 
obesity 












5.2 Acquired obesity associates with hypercoagulable state (Study I) 
 
The objective in the study I was to quantify the magnitude of changes in blood coagulation 
factors and the markers of fibrinolysis in acquired obesity. Despite the strong familial 
control of the overall activity of the markers of coagulation and fibrinolysis, several 
differences emerged within BMI-discordant co-twins. The obese co-twins of BMI-
discordant pairs had higher levels of fibrinogen, and the activities of factors IX, XI, and 
XII, as well as PAI-1, were increased (Figure 9). The differences were significant, even the 
effect of potential confounders, gender, smoking, and the use of oral contraceptives, were 
adjusted. There were no differences in markers of coagulation, PAI-1, or D-dimer between 





Figure 9 Increased activity of markers of blood coagulation and fibrinolysis in acquired 
obesity 
 
Figure modified from Pallister CJ, Watson MS (2010). Haematology, Scion Publishing pp 336-47 
VII- XIII, blood coagulation factors; a, activated from; PAI-1, plasminogen activator inhibitor-1, 
TF, tissue factor; PL platelet membrane phospholipid; Ca++, calcium ion 
 
In univariate analyses of twin individuals, the body fat distribution, the amount of sc and 
ia fat and liver fat, as well as inflammation (hsCRP) associated positively with 
hypercoagulable state (r=0.36–0.73, p<0.05 for all). In contrast, the correlations between 
FIX% and FXI% and insulin sensitivity (M-value) were negative (r=-0.40 and -0.54 
respectively, p<0.01 for both). 
 
To control the genetic effects behind the differences observed within MZ twin pairs, the 
correlation analyses were repeated and Spearman correlation analyses were performed 
between the intra-pair differences (Δ) in the anthropometric and metabolic parameters (Δsc 
fat, Δia fat, Δliver fat, Δinsulin, ΔM-value and ΔhsCRP) and the Δmarkers of the 
coagulation and the fibrinolysis. ΔFibrinogen levels and ΔPAI-1 activity correlated 
positively and significantly (r=0.42–0.70 and r=0.52–0.58 respectively, p<0.05) with 
Δadiposity markers, Δinsulin, and ΔhsCRP. Therefore, the acquired adiposity contributes 





5.3 Atherogenic lipoprotein profile in acquired obesity (Studies II–III) 
 
In study II, the quantity and the quality of the fasting serum lipoprotein profile was assessed 
by ultracentrifugation, gradient gel-electrophoresis, and colorimetric enzymatic methods. 
In study III, the analyses of lipoprotein subfractions were replicated with NMR. The aim 
was to determine how excess body fat and its distribution in obesity reflects the 
proatherogenicity in lipoprotein measures. The correlations between overall obesity, body 
fat distribution and the measures of insulin resistance (fasting insulin, glucose and HOMA-
IR) and lipoprotein particle profile was analysed. Additionally, the data from 3-day food 
diaries and questionnaires on physical activity (Study II) was available after 
complementing the assessment of the role of the lifestyle factors. 
 
5.3.1 Increase in proatherogenic lipoprotein particles (Studies II–III) 
 
The heavier co-twins of BMI-discordant pairs had more atherogenic lipoprotein profile 
compared with their leaner co-twins. They had significantly higher concentrations of ApoB 
as well as total, IDL- and LDL-C. The total IDL and LDL particle mass was higher in obese 
subjects. Obesity induced alterations in HDL-subfractions. The concentrations of HDL-C 
and HDL2-C and proportion of HDL2b were lower and HDL mean particle size was 
smaller (Study II). Obese co-twins had a higher proportion of small HDL3c particles in 
comparison to leaner co-twins. 
 
In the heavier co-twins of BMI-discordant pairs, the corresponding pro-atherogenic 
lipoprotein subfraction profile emerged in NMR (Study III). The heavier co-twins had 
higher concentrations of VLDL and LDL particles, therefore more ApoB, triglycerides, and 
cholesterol than their leaner counterparts. The concentrations of HDL particles and HDL-
C were lower and HDL diameter was smaller. HDL-to-LDL-ration was lower, and the 
ApoB-to-ApoA1 was higher in the heavier co-twins. 
 
NMR measurements allowed the estimation of fatty acid profiles. The ratio of poly-
unsaturated fatty acid (PUFA) to total FAs was lower in the obese than lean co-twins. All 
lipid and lipoprotein measures were similar within BMI-concordant co-twins, independent 
of the method being used in the analyses. 
 
5.3.2 Unaltered lipoprotein particle composition (Study II) 
 
Figure 10 describes the composition of lipoprotein particles in the heavier co-twins of the 
BMI-discordant pairs. The particle composition of the leaner co-twin resembles the one 
seen in heavier co-twins (data is not shown). Only subtle changes in the particle 
composition were seen in obesity: percentage of IDL free cholesterol (7.7% vs. 7.0%, 
p=0.05) and IDL cholesterol esters (10.6% vs. 9.0%, p=0.05) were elevated. Additionally, 







Figure 10 Lipoprotein particle compositions in the heavier co-twins of the BMI-discordant 
pairs 
 
Taken together, of the alterations in the lipoprotein measures in studies II–III, the 
lipoprotein particle composition does not change but the number of non-HDL lipoprotein 
particles increases, and the capacity of HDL particles to carry cholesterol is compromised. 
 
5.3.3 Abdominal body fat distribution associates to atherogenic lipoprotein profile 
(Studies II–III) 
 
In Spearman correlation analyses within MZ twin pairs the Δatherogenic lipid and 
lipoprotein parameters correlated significantly ΔBMI (Figure 11). Similar correlations 
were observed with other Δmeasures of obesity: the Δamount of sc, ia, and liver fat after 




Figure 11 Partial correlates between within-pair difference (Δ) in BMI and lipoprotein 
profile in monozygotic twins (Study II) 
 
The positive correlations between Δia fat, Δliver fat, and ΔNMR lipoprotein measures 
associated with atherogenecity (ΔLDL particle concentrations, ΔLDL-C, ΔApoB, ΔApoB-
to-ApoA1 -ratio, ΔHDL diameter) were indeed stronger than the correlations between 
atherogenic of lipid variables and ia and liver fat when twin subjects were analysed as 




pairs allows the full control of genetic factors and this indicates that acquired obesity indeed 
induces pro-atherogenic alterations in lipoproteins independent of genetic background. 
 
The gynoid distribution of body fat associated with anti-atherogenic lipid and lipoprotein 
measures (Study III). Unlike other fat distribution measures, gynoid fat failed to correlate 
with atherogenic lipid measures. The positive correlation was strongest between gynoid fat 
and HDL diameter (r=0.41), negative correlation with medium and small VLDL particles 
and triglycerides (r=-0.43–0.48). The contribution of lifestyle factors on lipoprotein 
measures was assessed in study II. The correlation between Δphysical activity and 
Δatherogenic lipid profile was inverse. 
 
The measures of adiposity are highly inter-correlated: BMI, sc and ia fat more strongly with 
each other than liver fat. Therefore, in Study II multivariate regression analyses were used 
to assess if any component of body fat distribution independently explained the within-pair 
differences in the pro-atherogenic lipid profiles. When entering ∆sc fat, ∆ia fat, ∆liver fat, 
sex, ∆smoking status, and ∆physical activity as independent variables in the models, ∆liver 
fat was the only variable independently explaining the variation in ∆ApoB (β=2.2±1.0, 
p=0.05; whole model adjusted R2=0.45, p=0.01), ∆TC (β=3.6±1.4, p=0.02; R2=0.37, 
p=0.04), ∆LDL-C (β=2.9±1.3, p=0.04; R2=0.56, p=0.003), ∆HDL3-C (β=0.7 ± 0.3, p=0.04; 
R2=0.08, p=0.32;) and also marginally ∆LDL mass (β=5.7±2.9, p=0.07; R2=0.48, p=0.01). 
∆Physical activity remained significant in models explaining ∆LDL-C (β=-10.4±2.8, 
p=0.002; R2=0.56, p=0.003), ∆LDL mass (β=-16.7 ± 6.2, p=0.016; R2=0.48, p=0.01) and 
marginally ∆HDL3b (β=-1.5 ± 0.7, p=0.06; R2=0.28, p=0.088). 
 
5.3.4 The role of fatty liver (Study II) 
 
The results from the analyses within pairs indicate the excess adiposity and the fat 
distribution modifies the concentrations of lipoproteins towards proatherogenicity. Despite 
marked differences in weight within pairs (mean ∆weight 17kg) the data showed that not 
all obese co-twin subjects accumulate liver fat. Seven BMI-discordant pairs who did not 
differ in their liver fat content were identified (Study II). Interestingly, within these liver 
fat-concordant pairs, all lipid and lipoprotein measures between leaner and heavier co-twins 
were similar. In contrast, the heavier co-twins with concomitant increase in liver fat (∆liver 
fat > 2%) had higher levels of ApoB, TC, LDL-C, IDL-C, and HDL3c, higher LDL mass, 
and lower levels of HDL-C, smaller HDL mean particle size (p<0.05) and marginally 
higher TG concentrations (p=0.07) than their leaner counterparts. In conclusion, 
proatherogenic lipid derangements emerge only when obesity was accompanied with 
ectopic fat in the liver. 
 
5.3.5 The insulin resistance (IR) and NMR lipoprotein subfractions (Study III) 
 
In twin individuals, the measures of IR (fasting plasma insulin and HOMA-IR) correlated 
positively with pro-atherogenic NMR lipoprotein subclasses. Inverse correlations were 
seen between IR and LDL, and HDL particle diameters, and the ratio of HDL-to-LDL-C. 
Within MZ twin pairs, Δinsulin resistance correlated positively with ΔTGs and ΔVLDL 
particle concentrations, Δmedium and Δsmall LDL particles, and ΔApoB. The Spearman 
correlations between ΔIR and Δlipid measures within pairs were lower compared to the 
univariate correlation analyses in twin individuals. This is indicative of the genetic control 





5.4 Fatty acids and other NMR metabolites as biomarkers in acquired obesity (Study 
III) 
 
From NMR small circulating metabolites, the concentrations of branched-chain amino-
acids (BCAAs) leucine, isoleucine and valine, as well as lactate, glycerol, urea and 
inflammatory marker α1-glycoprotein were higher in the heavier co-twins vs leaner co-
twins. 
 
BCAAs and α1-glycoprotein correlated positively and with measures of obesity and insulin 
resistance and negatively with gynoid fat in twin individuals. The correlation between the 
measures of adiposity and IR and the ratios of PUFAs and omega-6 FAs to total FAs was 
negative. Within MZ twin pairs, positive correlation was seen between Δα1-glycoprotein, 
Δisoleucine, and Δinsulin resistance. The correlations between other ΔNMR measures with 
Δobesity measures and Δinsulin resistance failed to reach statistical significance. This 
analysis confirms that α1-glycoprotein and BCAAs are plausible candidates for biomarkers 
of metabolic complications in obesity. The acquired insulin resistance modifies the levels 
of these NMR metabolites. 
 
5.5 Genetic and environmental correlations between abdominal obesity and 
circulating NMR metabolic profile (Study III) 
 
The observed phenotypic correlations between abdominal obesity and NMR metabolites 
were decomposed into their genetic (rg) and environmental (re) components with bivariate 
modelling (Study III, see Methods, Figure 7). WC correlated with 50 out of 56 NMR 
metabolites. In most cases, the contribution of genetic and unique environmental 
component to overall correlations between abdominal obesity and NMR metabolites were 
similar. 
 
The genetic correlations between abdominal obesity and NMR metabolites were most 
significant for HDL-C and HDL particle diameter, serum TGs, the ratio of ApoB to ApoA1, 
BCAAs, phenylalanine, and α1-glycoprotein. Therefore, the effect of the same genes may 
contribute to the phenotypic traits of abdominal obesity and NMR profile. The 
environmental correlations were highest for LDL particle diameter, glycerol, and 
glutamine. Thus, differences in individual unique lifestyles may modify the concentrations 
of these measures. 
 
5.6 Up-regulation of early complement system pathways in acquired obesity (Study 
IV) 
 
To investigate the role of complement-system activity during low-grade inflammation in 
obese AT, the transcriptome array of the complement-system-related genes from AT and 
isolated adipocytes was analysed. The complement components in AT biopsy samples was 
localised with immunohistochemical stain. 
 
The expression levels of the classical and the alternative-pathway related genes correlated 
significantly and positively (r=0.26–0.69) to obesity measures (sc and ia fat volumes, liver 
fat) and hsCRP, whereas the correlation between the terminal pathway and the obesity 
measures and inflammation was negative in twin individuals. Altogether 23 out of 46 




adipocytes, differed between BMI-discordant co-twins (Figure 11). The expression levels 
of the genes of the classical, the lectin, and the alternative pathway were up-regulated and 
the terminal-pathway-related genes down-regulated in obese co-twins. The up-regulated 
genes included the genes of several complement regulatory proteins and receptors. The 
plasma levels of C3a were elevated in obese co-twins, whereas the levels of soluble sC5b-




Figure 12 Alterations in complement-system-related genes expressed in sc fat within BMI-
discordant co-twins 
 
Modified from Kaye et al. Front Immunol. 2017; 8: 545. doi:10.3389/fimmu.2017.00545 
 
5.6.1 Immunohistochemical stain (Study IV) 
 
Crown-like structures (CLS) represent the dying areas of dying adipocytes. The CLS were 
more frequent in AT of the heavier co-twins. Two complement components were stained: 
C1q indicating the initiation of the classical complement pathway; and C3d, a remnant of 
C3b deposition on cell surface typically observed in prolonged inflammation. C3d stained 
faintly, and C1q strongly, in adipocyte cell membranes and intracellularly around CLS. 
Thus, the complement activation is in proximity with the areas enriched with AT immune 
cells. 
 
5.6.2 Complement gene expression in subcutaneous fat (Study IV) 
 
As the heavier co-twins of BMI-discordant pairs were hyperinsulinemic in comparison to 
their leaner counterparts (Table 1)  we analyzed how the complement gene transcriptome 
associates with gene expressions of insulin-signalling-pathway related genes. 
Hyperinsulinemia associated positively with the expression of 9 (out of 15) classical-
pathway-related genes in AT (r=0.28–0.46, p<0.03) and 9/15 genes related to alternative 
pathway (r=0.29–0.52, p<0.02). Hyperinsulinemia and the gene expression of C1QTNF7 
(r=-0.36, p=0.004) and the terminal pathway components correlated inversely (C5 r=-0.40 




correlated positively to hyperinsulineamia (r=0.44 and 0.66 respectively) in AT. A 
significant negative correlation emerged between alternative and classical pathway genes 
and the expression of insulin-signalling-route-related genes in AT. 
 
Correlations between plasma insulin levels and the complement gene expression were not 
significant for adipocyte transcripts. A significant and negative correlation emerged 
between the expression of 8/15 classical and 10/15 the alternative pathway related genes 







6.1 The summary of the main results and their interpretation 
 
This thesis arises from twin cohorts in the Finnish population-based registry; one of the 
largest and most carefully documented twin samples worldwide. The comparison of BMI-
discordant young MZ co-twins provides an ideal case-control study setting, fully matching 
the effect of the genetic background; whereas the adjustment of the genetic background in 
larger populations is impossible. The results of this thesis complement earlier studies of 
this Finnish BMI-discordant MZ twin cohort (34)(36)(86)(103)(104) and reveal previously 
uncharacterised phenotypic differences between obese and lean co-twins. 
 
The MZ twin pairs were already discordant at birth, the heavier co-twin being circa 221g 
per BMI units (p=0.066 weight in grams, p=0.01 for BMI-unit) heavier in comparison to 
their leaner counterparts. However, differences in birth weight had disappeared at the age 
of 6 months but re-emerged after  puberty (254). In this study, the acquired obesity was 
hypothesised to induce differences in metabolism within twin pairs. All metabolic measures 
were similar within the co-twins of BMI-concordant pairs, indicating strong genetic control 
of the metabolism. However, obesity-discordant twins differed in their biomarkers of blood 
coagulation and fibrinolysis, lipoprotein metabolism, and inflammation. Several of these 
measures have previously been associated with increased risk of thrombosis, 
cardiovascular disease, and diabetes. Additionally, the obese co-twins were more insulin-
resistant and presented more features of low-grade inflammation in comparison to their 
leaner counterparts. These results conclude the acquired obesity predisposes to 
hypercoagulable state, increased levels of pro-atherogenic lipoproteins, and activates the 
complement system in AT. These derangements in metabolism occur already in young 
otherwise healthy twin subjects without clinical disease. These studies provide new 
potentially useful biomarkers for characterising an unhealthy metabolic profile in obesity. 










In this thesis, the BMI-discordance was defined as within-pair difference (D) over 3kg/m2. 
A similar definition has been used in other studies (248)(268). To understand the 
contribution of adipose tissue distribution, the body composition was assessed with DEXA 
and MRI. These modalities enabled the dissection of fat distribution between the gynoid 
and android regions, and further division of the abdominal obesity into sc and ia fat 
compartments. Additionally, proton magnetic spectroscopy was performed to assess liver 
fat content. Only in study III, including larger number of twin subjects (n=1368), BMI-
calculations and waist circumference were collected from the self-reported measurements 
without imaging. The heavier co-twins of BMI-discordant pairs had substantially higher 
amounts of body fat. Indeed, the heavier co-twins had nearly 100% more ia fat and up to 
280% liver fat compared to their leaner counterparts. 
 
In this study, sc and ia fat correlated the strongest with the derangements of coagulation 
factors, hyperinsulinemia, pro-atherogenic lipids, and inflammation. The liver fat varied 
within obese subjects: despite significant within pair differences in body weight within 
BMI-discordant pairs, not all obese subjects had accumulated liver fat. Fatty liver was 
shown to be the key driver towards pro-atherogenic lipoprotein profile. The association 
between unhealthy serum NMR metabolite profile and abdominal obesity was strong. We 
dissected the correlations between waist circumference and serum metabolite profile into 
genetic and environmental components. The results demonstrated that both components 
contribute to the observed associations. Bivariate correlation analyses in the twin cohort 
revealed that these associations are partly due to shared genetic factors: the same genes 
control both the waist circumference and the levels of branched-chain amino-acids. 
 
The complement system activation in acquired obesity is present both locally in sc AT and 
systemically. The gene expression of the early complement pathway was up-regulated and 
the terminal pathway down-regulated in sc fat microarray. Circulating levels of plasma C3a 
are higher in obesity. In sc AT biopsies, the complement protein deposits surrounded the 
apoptotic adipocytes when assessed by immunohistochemical stain. 
 
6.1.1 Overproduction of coagulation factors (Study I) 
 
The genetic factors account for 41–75% of the variation in the levels of coagulation factors 
(269). As an indication of strong genetic control, the activities of the coagulation factors 
were similar and highly correlated within BMI-concordant MZ twin pairs. In acquired 
obesity, the activities of FIX, FXI, FXII, and PAI-1 and the levels of fibrinogen were 
elevated. As the increase in PAI-1 activity impairs endogenous fibrinolysis, the 
hypercoagulable state in obesity is due to both increased production of coagulation factors 
and diminished clot lysis. It is possible that the gender (270), smoking (271), or the use of 
oral contraceptives (271) may be drivers behind observed changes in coagulation and 
fibrinolysis. These potential confounders were accounted for by adjusting in the correlation 
analyses. The effect of leptin, that may promote thrombosis, was not analysed (188). This 
was the first study showing the magnitude of the effect of acquired obesity on FIX, FXI, 
and FXII activities. This study affirms that the hypercoagulable and hypofibrinolytic state 
is an important mechanism behind increased cardiovascular risk in acquired obesity. 
 
Several haemostatic markers are produced in the liver. The fatty liver associates with the 
overproduction of the coagulation factors (272). The adipocytes secrete pro-inflammatory 
cytokines that are shown to increase fibrinogen and PAI-1 production in hepatocytes in 




the fatty liver does not fuel the pro-coagulative state (272). In this study within MZ pairs, 
DBMI, Dhyperinsulinemia, and Dinflammation correlated positively with Dfibrinogen and 
DPAI-1 activities. This indicates the independent effect of obesity on coagulation and 
fibrinolysis. PAI-1 activity is directly correlated to AT mass and its gene-expression is 
upregulated in VAT (273). The effect of adiposity on blood coagulation appears stable over 
time as Dfibrinogen levels persist within co-twins in pairs who remain BMI-discordant over 
time (248). 
 
The results from weight loss studies support the role of acquired obesity on haemostasis. 
The activity of PAI-1 and fibrinogen levels decrease after weight loss by lifestyle 
intervention (274). Similarly, the levels of coagulation parameters decreased after bariatric 
surgery (275). Additionally, as shown in longitudinal follow-up of the MZ twin cohort, 
before the BMI-discordance within co-twins emerged, fibrinogen levels were similar (248). 
These findings indicate that adverse changes in blood coagulation are induced by increased 
adiposity and the pro-thrombotic state alleviates with weight loss. 
 
The adipose tissue adipokines, including leptin, resistin, and visfatin, modulate the pro-
thrombotic state (178)(276)(277). The proposed mechanism for adipokine effects is 
enhanced activation of the expression of pro-thrombotic adhesion molecules in vascular 
endothelium as demonstrated by resistin and visfatin (178). In contrast, adiponectin and 
apelin have anti-thrombotic effects (117)(278). As the serum adiponectin levels in the 
obese twins were decreased vs. leaner co-twins, this may aggravate the pro-thrombotic state 
in acquired obesity. Additional studies on endothelial function would complement the 
current data. As the  pro-inflammatory environment in obesity can significantly contribute 
to plasma PAI-1 levels (189) it would be interesting to analyse the role of innate immunity 
and its association of fibrinolytic measures in acquired obesity. 
 
6.1.2 The role of fatty liver-overproduction of lipoproteins (Study II) 
 
Abdominal obesity and metabolic syndrome are characterised by increased TG-rich 
lipoprotein particles, formation of small atherogenic LDL-particles, and low concentrations 
and diminished size of HDL lipoproteins, as well as lower levels of HDL-C. As expected, 
the obese co-twins in this thesis study had pro-atherogenic lipoprotein profiles, and this 
was affirmed both with ultracentrifugation (Study II) and later with NMR (Study III). The 
leaner co-twins presented a healthier lipid and lipoprotein profile. The BMI-concordant MZ 
twin pairs presenting similar lipid profiles confirm the strong genetic control of lipoprotein 
metabolism. This is the first study to document that acquired obesity does not significantly 
alter the lipoprotein particle composition, including surface phospholipids, protein 
component, and core lipids. Indeed, the derangements in lipoprotein metabolism in 
acquired obesity are due to changes in the particle numbers. 
 
Unique to this study, two distinctive groups were identified within the heavier co-twins of 
BMI-discordant pairs. In the other sub-group, acquired obesity was accompanied by a 
concomitant increase in liver fat, whereas in another subgroup, no difference in liver fat 
emerged despite a 17kg weight discordance. Liver fat content correlates more significantly 
within MZ than DZ twin pairs, and the heritability of hepatic steatosis is high (137)(279). 
The genetic factors may explain how in this study some, but not all, heavier co-twins had 
elevated liver-fat content despite similar Dweight. Several genetic variants, including those 
of PNPLA3 and TM6SF2 genes, predict the development of fatty liver in adults (280)(281). 




these unique environmental factors may trigger liver fat accumulation in genetically 
vulnerable individuals. 
  
We discovered that the lipoprotein measurements differed within BMI-discordant pairs 
only when they were also liver-fat discordant. In unhealthy obesity, the enlarged ia fat 
volume is likely contribute to derangements of lipoprotein metabolism. However, in this 
study, out of body fat depots, in multivariate regression analyses, the contribution of liver 
fat remained significant towards proatherogenic lipid profile. Obese co-twins with fatty 
liver had elevated TGs, higher ApoB, and LDL-C. This represents the overproduction of 
TG-rich VLDL particles. Without increase in liver fat, these signs of proatherogenicity did 
not occur in acquired obesity. ApoB is an essential protein required for assembly and 
secretion of VLDL from the liver. The elevated ApoB in obese co-twins represents the 
increased number of both VLDL as well as LDL particles. Consequently, this data showed 
the VLDL and LDL particle masses were elevated in obesity. Impaired clearance of TG-
rich lipoproteins and the complex lipid exchange between lipoprotein particles induces the 
formation of small particularly atherogenic LDL-particles (146). In acquired obesity, the 
simultaneous decrease in HDL-particle size and HDL-C associates with impaired reverse 
cholesterol transport capacity to the liver. This contributes to the formation of cholesterol 
plaques in vessels and the risk of atherosclerotic vascular disease. This data affirms that 
these proatherogenic alterations occur before the manifestation of clinical disease in young 
adults. 
 
Recently, a twin study by Cui et al (282) revealed shared genetic factors behind hepatic 
steatosis, elevated TGs, and low HDL. Furthermore, insulin resistance and hyperglycaemia 
shared common genetic pathways with fatty liver. In line with Cui, in this study data Dpro-
atherogenic lipoprotein measures associated significantly to the Dmeasures of systemic 
insulin resistance within MZ twin pairs. It is well-known that IR and dyslipidaemia cluster 
in the metabolic syndrome and the data supports the underlying common genetic pathways 
behind phenotypic traits. 
 
The dysfunctional AT with limited capacity to expand is contributing to liver fat 
accumulation and pro-atherogenic lipoprotein profile. Limited expansion in adipocyte cell 
volume and the compromised recruitment of new adipocytes for lipid storage leads to 
ectopic fat distribution outside AT, also into the hepatocytes. Heinonen et al. (86) reported 
that the sc AT morphology was altered in acquired obesity. The AT of obese co-twins was 
indeed hypertrophic and hypoplastic in comparison to their leaner counterparts. In obese 
AT, the adipocyte hypertrophy, instead of adipocyte hyperplasia, associated with impaired 
insulin signalling and AT insulin resistance (86). The impaired insulin action leads to 
uncontrollable lipolysis from AT. The fatty acid flux from lipolytic AT provides substrate 
for hepatic TG accumulation contributing to increased concentrations of plasma TG-rich 
lipoproteins as demonstrated in these studies. Therefore, the compromised capacity of sc 
AT capacity to expand and store lipids is one plausible mechanism behind pro- atherogenic 
lipoprotein metabolism documented in this study. 
 
The overconsumption of calories, high intake of simple sugars (283) or saturated fats can 
increase the hepatic fat content (284). In contrast, the exercise training reduces the liver fat 
also independent of diet (67)(285). As underlying genetic factors may also contribute to the 
response of body composition following physical activity (286), the combination of diet 
and exercise is useful to control both the fat accumulation to the liver and plasma lipid 




for healthy lipid profile. It is reasonable to assume that exercise improved the insulin 
sensitivity in physically active twins. Consequently, the improved insulin action controls 
sc AT lipolysis and lipid spill to ectopic tissues, including the liver. Further studies on twin 
pairs discordant in regard to physical activity would provide insight into the potential 
underlying mechanisms of exercise on lipoprotein metabolism. 
 
A subgroup of obese subjects does not seem to develop obesity-related metabolic 
complications, at least in the early phase of obesity. The key characteristics of metabolically 
healthy obesity (MHO) are the lack of features of MetS, low liver fat content, high insulin 
sensitivity and aerobic fitness, preserved mitochondrial function and low systemic 
inflammation despite high BMI (37)(288)(289). The prevalence of MHO varies depending 
on definition of MHO and cohort. In the Finnish population cohort, the prevalence was 
23% (290). However, the lack of a uniform definition of MHO is a limitation for 
characterisation of the subjects in practice. Age, sex, cardiorespiratory fitness, diet, and 
ethnicity are known contributors to metabolic status but often they are not taken account of 
in the assessment of metabolic health (291). Longitudinally, the conversion towards 
obesity-associated metabolic complications implicates also that MHO is not a stable 
condition. After 5 years of follow-up, 35% of originally MHO individuals had developed 
metabolic derangements and only 10% were still metabolically healthy after 20 years (292). 
Thus, cross-sectional studies do not predict the future health risk in MHO. 
 
The VAT accumulation, adipose tissue morphology and function contribute to obese, but 
metabolically healthy phenotype (291). In BMI-discordant (within pair difference ∆18kg) 
MZ twin pairs, the excess liver fat dichotomised metabolically healthy and unhealthy 
groups (37). Low inflammation gene transcripts and preserved mitochondrial function 
characterised the sc fat of the MHO co-twins (37). These features potentially reflect better 
fat storing capacity in sc AT and protection from ectopic fat accumulation viscerally and 
in the liver. MHO subjects seemingly adapt to overnutrition and surplus of energy. They 
present similar glucose and insulin responses after high-calorie meals as lean individuals 
(293). After a meal, preserved postprandial incretin response associates to healthy obesity 
and may reflect better beta-cell function and the capacity to increase insulin secretion from 
beta-cells (294). 
 
6.1.3 Serum metabolomics (Study III) 
 
New risk markers have been identified from serum metabolomic profiles for prediction of 
CVD (295) and insulin resistance (296) and even all-cause mortality in obese subjects 
(297). In the present study, the levels of BCAAs, as well as pro-atherogenic lipids and α1-
glycoprotein, were elevated in acquired obesity. No differences in NMR metabolite panel 
within BMI-concordant pairs emerged. In a study utilising Mendelian randomisation, 
adiposity was shown to directly alter the levels of multiple cardiometabolic risk markers in 
young adults (298). 
 
In the correlation analyses in twin individuals, we found out that the android/abdominal fat 
distribution associated with high-risk metabolites, whereas the association of the gynoid fat 
distribution with metabolomics signature was more favourable. The abdominal fat 
distribution correlated strongly and positively with pro-atherogenic lipid profile, increased 
levels of BCAAs, and a1-glycoprotein, and negatively with glutamine. Both environmental 
and genetic factors contribute to the observed correlations. For ApoA1, BCAA, and 




respectively) was significant and stronger than the contribution of unique environmental 
factors to the co-occurrence of the abdominal obesity and metabolite profile. This study 
data suggests that shared genes determine both phenotypes: abdominal obesity and serum 
levels of metabolites. 
 
BCAAs are catabolised in mitochondria and their oxidative capacity determines the rate of 
this process. In the BMI-discordant twin cohort, as well as in other studies, the 
mitochondrial number in sc AT is reduced and their functional capacity is impaired in 
acquired obesity (103)(299)(300). Thus, mitochondrial dysfunction in sc AT may explain 
the observed differences in BCAA metabolism in acquired obesity, even though the role of 
abundant mitochondria in muscle or BCAA catabolism liver were not analysed. BCAA 
metabolism may have a causal role in the development of type 2 diabetes in insulin-resistant 
obesity (301)(302).Yet, all studies do not support this hypothesis (303)(304) and more 
research is needed. The link between mitochondrial function and IR appears to be 
bidirectional (300). The reactive oxygen species and inflammatory response contribute to 
the underlying metabolic pathways and cannot be disregarded (300). 
 
6.1.4 The complement system in obesity (Study IV) 
 
The active role of AT and adipocytes in cross-talk with the immune system is notable. This 
study indicates the interplay of complement system activity and AT, and contributes to the 
AT dysfunction in obesity. Highlighting the role of gene-environment interactions and the 
heritability of the complement component levels (305), this study elucidates the 
contribution of the unique lifestyle on complement system activity. The differences within 
MZ co-twins emerged only if they were discordant on obesity. In agreement with the earlier 
twin study of di Franco et al showing C4 and factor B levels are modifiable by 
environmental exposures (306), this study’s co-twin comparison of obesity-discordance 
showed obesity does induce differences in the activity of the complement system. The 
abdominal obesity in particular associated with the activation of complement system and a 
similar conclusion has been made in other studies (307)(308). 
 
The activation of the complement system occurs both locally in sc AT systemically as 
plasma levels of C3a and adipsin increase. The complement component C3 is a well-known 
biomarker for the risk of CVD (222). Indeed, C3 and its metabolites are present in plasma 
thrombus and have anti-fibrinolytic properties (309)(310). Local complement activation 
was seen in sc fat as early complement pathway gene expression was up-regulated in AT 
and adipocyte gene transcripts. In accordance with these results, the expression of 
complement-system-related genes by adipocytes has been documented elsewhere (222). In 
obesity, the gene expression of the terminal pathway was suppressed in sc fat. This 
indicates that rather than being involved in cell destruction and tissue damage, the role of 
complement is the opsonisation clearance of debris in AT. The role of complement 
regulators controlling the activation of the terminal pathway is crucial maintaining the 
tissue integrity. Indeed, the gene-expression of clusterin, an inhibitor of the terminal 
pathway significantly up-regulated in obese co-twins of the BMI-discordant pairs and 
correlated strongly with all obesity measures. The results are in line with Won et al 
describing the role of clusterin in AT inflammation (311). 
 
Adipocyte hyperplasia is linked to increased rate of apoptosis (312). Apoptotic cell death 
and subsequent macrophage infiltration in AT is a link to detrimental metabolic sequalae, 




components were localised in sc AT biopsies in macrophage-rich areas surrounding dying 
apoptotic cells. In adipocytes, functional insulin signalling allows the regulation of glucose 
and FA uptake. In obese sc AT, the up-regulation of complement gene expression in 
adipocytes negatively associated with the expression of the genes related to the insulin 
signalling route. Therefore, the complement system may play a role in the development of 
the AT IR. The mechanisms that initiate the apoptosis are not yet understood. Concomitant 
mitochondrial dysfunction and lack of capacity to produce energy for metabolic needs may 




BMI-discordance in MZ twins is extremely rare. Only 26 healthy pairs were identified from 
10 Finnish yearly population-based birth cohorts. No other case-control study setting has 
facilitated as careful a match for genetic and other shared environmental factors. Despite a 
relatively low number of subjects, these studies still capture meaningful differences in 
metabolism in acquired obesity. Twin studies have a key role in determining the magnitude 
of genetic and environmental contribution to individual differences for obesity-related 
metabolic derangements. Combining twin registries adds power to studies in future obesity-
discordant twin studies (314). 
 
In study III, only self-reported obesity measures were collected from the larger twin cohort. 
The intensively studied, obesity-discordant twin pairs and their controls were exposed to 
physical examinations, numerous biochemical analyses, radiological examination, and 
invasive AT biopsies. The demanding study protocol may have limited the number of 
consenting participants. The data on BMI-discordant pairs declining the invitation for these 
studies was not available when summarising this thesis. The unique differences on the 
physical activity and diet were documented in food and exercise diaries from participants 
but only in the study II this data was analysed. The magnitude of the effect of the differences 
in these lifestyle factors on metabolism was beyond the scope of this thesis. 
 
Study III reports only the selected metabolites (n=56) from NMR. The results from the full 
NMR metabolomic panel are reported in other studies (315). For study IV, total RNA was 
extracted from whole-adipose tissue biopsies and transcriptomics analyses of fat were 
performed by microarray. Microarray probe design limits the identification of complement-
protein related genes in sc AT biopsies. Currently, more developed high-throughput 
sequencing techniques enable quantifying the transcriptomes with more precision (316). 
 
The setting of studies I-IV is cross-sectional and describes the nature of the metabolic 
derangements ‘here and now’. As discordance in MZ twins is rare and may be only 
temporary (248), the differences in metabolism may not persist over time. Additionally, as 
the observed differences in metabolism within discordant pairs are subtle, the clinical 
relevance of acquired obesity in young adulthood over individuals’ lifespan is unknown. 
Even if obese co-twins presented with an unhealthy metabolism at the time of the data 
collection for studies I-IV, the increase in morbidity cannot be predicted without 






7. CONCLUSIONS AND FUTURE PROSPECTS 
 
Obesity-related metabolic disturbances arise from complex gene-environment interplay. 
Overall similarity within MZ pairs indicates the strong genetic control of metabolism. Yet, 
the differences in metabolism between obesity-discordant co-twins arises from the 
differences in unique lifestyles. This thesis describes how acquired obesity associates with 
unhealthy metabolism. The derangements of metabolism are subtle but widespread and 
correspond to several metabolic pathways predisposing to CVD. Indeed, the risk factors 
for atherosclerosis, thrombosis, and diabetes cluster in acquired obesity irrespective of 
genetic background. The signature of unhealthy metabolism manifests already early in 
young adulthood, which emphasises the importance of adopting healthy lifestyle and 
balanced energy intake already at an early age. 
 
It is important to note that the metabolic risk varies even within the same obesity class. 
Body fat distribution and adipose tissue function determine individual metabolic 
responses and healthier features, including low levels of proatherogenic lipids, 
coagulation factors, and inflammation, associated with lower levels of liver and ia fat. 
The metabolic risk should always be assessed individually. A combined measure of BMI 
and a radiological measure of ia or ectopic fat would help to distinguish the individuals 
with the highest risk. Based on the analyses in this thesis, liver fat associates with 
derangements in lipid metabolism. This implies new therapeutic targets towards 
dyslipidemia may arise from molecules that modify liver fat content. As hypercoagulable 
state and the complement activation co-occur in obesity, the complement system may 
provide new therapeutic targets for atherothrombosis and controlling the low-grade 
inflammation in obese subjects. When lipids are stored in sc AT adipocytes, the lipolysis 
is controlled, AT can expand, and the liver and other organs are protected from ectopic 
lipid accumulation. Better understanding of the adipocyte biology, characteristics of energy 
storing, and dispersion properties may eventually offer a measure of the energy deposition 
threshold in AT before lipid spillover occurs.  
 
The high prevalence of obesity-related morbidity is a burden and challenging the global 
health care resources. Overall obesity increases morbidity and even mortality. With 
current understanding, defining the healthy level of overweight or obesity is impossible. 
Obese individuals carrying the highest metabolic risk need support and resources for 
lifestyle and pharmacological interventions, whereas when metabolism remains healthy, 
less intensive monitoring is needed. Nevertheless, for all individuals, regardless of their 
obesity status, it is important to support the efforts of preserving healthy lifestyle to 
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Appendix Table 2 Summary of the laboratory analyses from plasma/serum 
 
 Laboratory measure Assay Kit/Method Manufacturer 
Plasma Coagulation Factors (Study I) 
 PT  NycotestÒ PT reagent Axis-Shield PoC AS, Oslo, 
Norway 
APTT ActinÒ FSL reagent Siemens Healthcare Diagnostics 
 Fibrinogen Multifibren®  
VWF ristocetin cofactor 
(VWF:RCo) 
BCÒ von Willebrand Reagent 
FVII Dade® Innovin® and 
Coagulation Factor VII 
Deficient Plasma 
FVIII, FIX, FXI, FXII Pathromtin SLÒ, and specific 
coagulation factor deficient 
plasma 
FXIII BerichromÒ 
D-dimer Tina-quant D-Dimer®, 




Biopool International, Umeå, 
Sweden 
Serum Lipoprotein Measures (Study II) 
 Total Cholesterol Enzymatic method, 
Konelab 60i analyzer  
  
Thermo Fisher Scientific Oy 
 Triglycerides 
ApoA1 Immunoturbidometry  
 
Wako Chemicals GmbH, Neuss, 
Germany 
ApoB Orion Diagnostica, Espoo, 
Finland 
ApoC3 ELISA Ref (317) 
VLDL, IDL, LDL, 
HDL2 and HDL3 




Konelab 60i analyzer 
Thermo Fisher Scientific Oy 
HDL 2b, 2a, 3a, 3b, and 
3c subspecies and HDL 
mean particle size 
Gradient gel electrophoresis Ref (319)(320) 
Mean HDL particle size calculation from the area under 
the densitometric scan 
Mean LDL particle size  Ref (321) 
Serum adipokines (Study IV) 
 Adiponectin, Adipsin DuoSet ELISA R&D Systems Europe Ltd, 
Abindgon, UK 
Metabolomics (Study III) 
 NMR metabolites NMR Spectroscopy Ref (263), (262) 
Complement components (Study IV) 
 C3a Enzyme-linked immunosorbent 
assay, MicroVue C3a Plus 
Quidel Corporation, San Diego, 
CA, USA 
Soluble C5b-9 terminal 
pathway complex 
C5b-9 Plus enzyme 
immunoassay (EIA) 
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IntroductIon
Obesity is characterized by multiple hemostatic disturbances 
in blood coagulation, including enhanced platelet activa-
tion (1), increased concentrations, and enhanced activities of 
plasma coagulation factors (2–4) as well as impaired fibrinoly-
sis in form of increased production of plasminogen activator 
inhibitor-1 (PAI-1) (5). Several other mechanisms, such as 
systemic inflammation (6), endothelial dysfunction, distur-
bances of lipid and glucose metabolism, and insulin resistance 
also contribute to the hypercoagulable state in obesity (7).
Both environmental (8,9) and genetic factors account for the 
altered coagulation profile in obese individuals. Genetic fac-
tors contribute to the interindividual variation of blood coagu-
lation protein levels (10–12). Inherited genetic polymorphisms 
influence the hemostatic profile and increased risk of vascular 
events (13). Pleiotropically acting genes may contribute to the 
clustering of procoagulant and metabolic risk factors in obese 
individuals (10,14,15).
In study settings investigating the relationship between 
obesity and coagulation, it is difficult to disentangle the influ-
ence of the genetic background from the effects of acquired 
obesity per se. Monozygotic (MZ) twin pairs discordant for 
obesity offer a unique opportunity in humans to study the 
effect of obesity on coagulation and fibrinolysis while con-
trolling the genetic background. The aim of our study was 
to investigate how obesity, independent of genetic factors, 
influences markers of coagulation and fibrinolysis. We chose 
a set of coagulation tests which reflect established risk factors 
for thrombosis and analyzed their possible links with various 
markers of adiposity, inflammation, and insulin sensitivity.
Obesity-Related Derangements of Coagulation 
and Fibrinolysis: a Study of Obesity-Discordant 
Monozygotic Twin Pairs
Sanna M. Kaye1, Kirsi H. Pietiläinen1–3, Anna Kotronen4, Lotta Joutsi-Korhonen5, Jaakko Kaprio2,3,6, 
Hannele Yki-Järvinen4, Angela Silveira7, Anders Hamsten7, Riitta Lassila5 and Aila Rissanen1
Coagulation and fibrinolytic activities are under strong genetic control. We studied the effects of acquired obesity, 
independent of genetic factors on coagulation and fibrinolysis activities in obesity-discordant healthy monozygotic 
(MZ) twin pairs. Fourteen obesity-discordant (BMI within-pair difference >3 kg/m2) and 10 concordant (BMI difference 
<2 kg/m2) MZ twin pairs were identified from the nationwide FinnTwin16 study. Body composition (dual-energy 
x-ray absorptiometry), abdominal fat distribution (magnetic resonance imaging), liver fat (magnetic resonance 
spectroscopy), high sensitivity C-reactive protein, insulin sensitivity (euglycemic hyperinsulinemic clamp), and a panel 
of different markers of blood coagulation and fibrinolysis in the fasting state were measured. Strong resemblance was 
observed in most coagulation factors within all twin pairs, with the intraclass correlations ranging from 0.73 to 0.97, 
P < 0.03. However, the activities of fibrinogen and FIX, FXI, and FXII, and plasminogen activator inhibitor-1 (PAI-1) 
activities were increased in the obese co-twins (P < 0.05) and strongly correlated with the measures of adiposity, 
inflammation, and insulin resistance (r = 0.32–0.73, P < 0.05) among the twin individuals. Intrapair differences in 
fibrinogen and PAI-1 correlated with those in BMI, adiposity, and fasting insulin levels (r = 0.40–0.58, P < 0.05) 
indicating the independent effect of obesity. Derangements of blood coagulation and fibrinolysis are present already 
in early adulthood in obese subjects. Acquired obesity, independent of genetic factors, increases the activities of 
fibrinogen and activities of FIX, FXI, FXII, and PAI-1. This study confirms the mechanisms of simultaneous activities of 
intrinsic coagulation factors and impaired fibrinolysis predisposing obese subjects to thrombosis.
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The participants belong to the FinnTwin16 cohort, a population-based, 
longitudinal study of five consecutive birth cohorts (1975–1979) of 
twins, their siblings and parents (16). Twin pairs were recruited to the 
current study based on their responses to questions on weight and 
height in a questionnaire (response rate 88%) at the age of 23–27 years 
(17–19). After screening all MZ twin pairs (n = 658), we identified 18 
pairs with a reported BMI difference of at least 4 kg/m2 (MZ discord-
ant pairs), such that one co-twin was nonobese (mean BMI ≈25 kg/m2), 
whereas the other was obese (mean BMI ≈30 kg/m2) without having 
associated comorbidities. Fourteen of these pairs (eight male and six 
female pairs) participated. In addition to these weight-discordant pairs, 
we studied 10 concordant MZ pairs (five male and five female pairs) 
with an intrapair BMI difference of less than 2 kg/m2.
The subjects were healthy, normotensive and did not use any medica-
tions, except for oral contraceptives (n = 8 of 22 women). Their weight 
had been stable for at least 3 months before the study. Females were 
scheduled to attend during the follicular phase of their menstrual cycle. 
Only four of the 48 participants were currently smokers. Two pairs had a 
family history of type 2 diabetes. Monozygosity was confirmed by geno-
typing 10 informative genetic markers (18). The subjects provided written 
informed consent. The protocol was designed and performed according 
to the principles of the Helsinki Declaration and was approved by the 
ethics committee of the Helsinki University Central Hospital. Detailed 
description of the MZ twin material has been published earlier (17,20).
clinical assessment
Body composition was measured by dual-energy x-ray absorptio metry 
(Lunar Prodigy, software version 2.15; GE Healthcare, Madison, WI) 
(21). Subcutaneous and intra-abdominal fat were determined by mag-
netic resonance imaging of 16 transaxial scans reaching from 8 cm above 
to 8 cm below the fourth and fifth lumbar interspace (17). Liver fat con-
tent was measured by proton magnetic resonance spectroscopy (22). 
This measurement has been validated against histologically determined 
lipid content in our laboratory (23) and against estimates of fatty degen-
eration or infiltration by X-ray computer-assisted tomography (22). All 
spectra were analyzed by a physicist in a blinded fashion. The reproduc-
ibility of repeated measurements of liver fat in nondiabetic subjects was 
11% when studied on two occasions in our laboratory (24).
Insulin sensitivity
Whole body insulin sensitivity was determined by the euglycemic 
hyperinsulinemic clamp technique (25). Two 18-gauge catheters 
(Venflon; Viggo-Spectramed, Helsingborg, Sweden) were inserted, one 
in an antecubital vein for infusion of insulin and glucose, and another 
retrogradely in a warmed hand vein to obtain arterialized venous blood 
for measurement of plasma glucose concentrations every 5 min and 
serum free insulin concentration every 30 min. Regular human insulin 
(Insulin Actrapid; Novo Nordisk, Bagsvaerd, Denmark) was infused in 
a primed-continuous fashion. The rate of the continuous insulin infu-
sion was 40 mU/m2/min (1 mU/kg/min) for 120 min. Normoglycemia 
was maintained by adjusting the rate of a 20% glucose infusion based 
on plasma glucose measurements from arterialized venous blood every 
5 min. Whole body insulin sensitivity (the M-value, expressed as mg/
kg fat-free mass/min) was determined from the glucose infusion rate 
needed to maintain normoglycemia after correction for changes in the 
glucose pool size (25). Because hepatic glucose production is maximally 
suppressed in nondiabetic subjects already at an insulin concentration 
achieved during infusion of insulin at a rate of 0.5 mU/kg/min (26), the 
M-value reflects the glucose uptake.
clinical chemistry
Blood samples were collected from antecubital veins at 8:00–8:30 am 
after a 10–12 h overnight fast. Plasma and serum were separated by cen-
trifugation for 15 min at 2,000g at 4 °C. The separated plasma and serum 
were frozen in aliquots at −70 °C until assayed. Samples from tubes con-
taining 0.109 mol trisodium citrate were analyzed for prothrombin time 
(PT), activated partial thromboplastin time (APTT), fibrinogen, and 
for activities of von Willebrand factor (VWF), FVII, FVIII, FIX, FXI, 
FXII, and FXIII by using the BCS XP coagulation analyser (Siemens 
Healthcare Diagnostics, Marburg, Germany) at the coagulation labora-
tory of the Helsinki University Hospital (HUSLAB). PT was measured 
by using Nycotest PT reagent (Axis-Shield, Oslo, Norway), APTT by 
Actin FSL reagent (Siemens Healthcare Diagnostics), and fibrinogen 
with a modification of the Clauss method (Multifibren U; Siemens 
Healthcare Diagnostics). D-dimer was assessed with the immunoturbi-
dimetric assay (Tina-quant D-Dimer; Roche Diagnostics, Mannheim, 
Germany). For activities of VWF ristocetin cofactor (VWF:RCo), 
we used the BC von Willebrand reagent, for FVII Dade Innovin and 
coagulation factor VII deficient plasma and for FXIII Berichrom FXIII, 
all the reagents from Siemens Healthcare Diagnostics. For one-stage 
FVIII, FIX, FXI, and FXII activity measurements we used Pathromtin 
SL and the specific coagulation factor deficient plasma, respectively (all 
from Siemens Healthcare Diagnostics). The local reference ranges for 
the coagulation variables were as follows: PT 70–130%, APTT 23–33 s, 
fibrinogen 1.7–4.0 g/l, D-dimer <0.5 mg/l, VWF:RCo 44–183%, FVII 
76–170%, FVIII 52–148%, FIX 67–135%, FXI 60–120%, FXII 60–150%, 
and FXIII 76–156%.
Serum high sensitivity C-reactive protein (hsCRP) was measured 
using the double antibody sandwich enzyme-linked immunosorb-
ent assay with rabbit antihuman CRP and peroxidase-conjugated rab-
bit antihuman CRP. The assay was linear up to 5 mg/l and logarithmic 
thereafter. Plasma PAI-1 activity was assayed with commercially available 
kits (Asserachrom PAI-1; Diagnostica Stago, Gennevilliers,France and 
Chromolize PAI-1; Biopool International, Umeå, Sweden respectively). 
The local reference values for PAI-1 activity were 7 (3–17) IU/ml (median 
(interquartile range)). One unit of PAI-1 activity is defined as the amount 
of PAI-1 that inhibits one international unit of human single chain tissue 
plasminogen activator as calibrated against the International Standard for 
tissue plasminogen activator, lot 86/670 distributed by National Institute 
for Biological Standards and Control, Holly Hill, England. PAI-1 activity 
was measured in 32 MZ individuals, 16 full pairs and hsCRP in 40 indi-
viduals, 19 full pairs. Overall, the inter-assay and intra-assay coefficients 
of variation were 10% or less across the measurements of all variables.
statistical analyses
The statistical analyses were performed using the Stata statistical soft-
ware (release 9.0; Stata, College Station, Texas). Survey data proce-
dures were used to correct for clustered sampling of co-twins within 
pairs (27). Log-transformation was used to normalize the distribution 
of non-normally distributed data. Wald tests for independent sam-
ples (=t-tests adapted for clustered twin data) were used to compare 
men vs. women, users vs. nonusers of contraceptives, and smokers vs. 
nonsmokers. Pearson correlations, with correction for clustering (27), 
were calculated to determine the relationships between clinical and bio-
chemical parameters in individual twins. The co-twins were compared 
by Wilcoxon’s signed ranks test. Male and female pairs were combined 
because by definition, MZ co-twins are matched for gender. Spearman 
correlations of within-pair differences in body composition and meta-
bolic measures were used to test the effects of the extent of adiposity 
discordance on coagulation. Because MZ twins are identical at the 
sequence level and share all their segregating genes, the associations 
within MZ pairs are fully adjusted for genetic effects. Twin similarity 
was assessed using intraclass correlations.
results
Body composition and insulin resistance in twin pairs
The characteristics of MZ twins examined in the present study 
are summarized in Table 1. The intrapair differences of BMI 
ranged from 0.0–2.3 kg/m2 in the weight-concordant pairs and 
from 3.8–10.1 kg/m2 in the discordant pairs. Concordant MZ 
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co-twins did not differ in measures of fat distribution (mag-
netic resonance imaging), insulin sensitivity (M-value, fasting 
glucose or insulin) or inflammation (hsCRP). In the discordant 
pairs, the heavier co-twins had 1.8 times the amount of abdom-
inal subcutaneous fat, 2.0 times the amount of intra-abdominal 
fat, and 2.9 times the amount of liver fat compared with their 
leaner counterparts. The heavier co-twins also had lower insu-
lin sensitivity and higher fasting insulin levels compared with 
the leaner co-twins. hsCRP values were over twofold higher in 
the heavier than in the leaner discordant co-twins.
Measures of coagulation factors and fibrinolysis  
in twin pairs
Each coagulation factor was first tested with respect to differ-
ences between genders, users and nonusers of contraceptives, 
and between smokers and nonsmokers. Men had lower lev-
els of fibrinogen (2.9 vs. 4.0 g/l, P = 0.0006), D-dimer (0.08 vs. 
0.11 mg/l, P = 0.025), lower activities of FVII (106 vs. 123%, 
P = 0.028), and FXIII (77 vs. 95%, P = 0.0006) than women. 
Women using oral contraceptives had higher activities of FVII 
(135 vs.109%, P = 0.003), FIX (110 vs. 96%, P = 0.006), FXI 
(106 vs. 95%, P = 0.047), and FXII (131 vs.94%, P = 0.0003) 
than women not using contraceptives. However, all these values 
were in reference ranges. Activities of PT (132 vs. 114%, P = 
0.0008), FVII (123 vs. 113%, P = 0.045), FXI (113 vs. 96%, P = 
0.006), and PAI-1 (32 vs. 9%, P = 0.0004) were increased and 
APTT was shorter (28 vs. 31 s, P = 0.0004) in smokers. Again, 
all these values fell to the normal range. We adjusted gender, 
use of contraceptives, and smoking status in all analyses.
The results of coagulation tests in the co-twins are shown 
in Table 1. Compared with the leaner co-twins, the heavier 
co-twins of the obesity discordant pairs tended to have higher 
levels of most coagulation factors. This difference was most 
striking for FIX, FXI, FXII and PAI-1 activities, and fibrino-
gen concentrations. In the MZ concordant group, the coagula-
tion markers were similar in the lean and the slightly heavier 
co-twins.
relationships between obesity and metabolic measures, 
coagulation factors, and measures of fibrinolysis
Univariate associations in individual twins. Most coagulation 
factors were strongly associated with BMI and other adipos-
ity measures including the amount of subcutaneous, intra-
abdominal, and liver fat. Especially, fibrinogen, PT(%), and 
FIX, FXI and PAI-1 activities associated strongly with the 
markers of obesity (Table 2). The amount of liver fat correlated 
table 1 Physical characteristics and levels of coagulation factors and variables measuring fibrinolytic activity in monozygotic 
(MZ) twins
MZ concordant n = 10 pairs MZ discordant n = 14 pairs
Leaner Heavier Leaner Heavier
BMI (kg/m2) 26.3 ± 2.3 27.3 ± 2.3** 25.3 ± 0.5 30.5 ± 0.5***
Body fat % 25.2 ± 3.9 27.5 ± 4.0* 29.7 ± 2.4 40.2 ± 2.1***
Subcutaneous fat (dm3) 2.7 (1.4–3.8) 2.9 (1.6–4.2) 2.7 (2.4–4.0) 4.8 (4.4–5.8)***
Intra-abdominal fat (dm3) 0.6 (0.4–0.9) 0.6 (0.4–1.3) 0.5 (0.4–0.7) 1.0 (0.8–1.2)***
Liver fat (%) 1.5 (1–7.5) 1 (1–9) 1.25 (1–2.5) 3.6 (2–11)***
M-value (mg/kg fat-free 
mass/min)
7.4 ± 0.9 7.5 ± 1.0 9.2 ± 0.9 6.3 ± 0.6**
Insulin (mU/l) 6 (5–9) 6.5 (4–10) 5 (3–8) 9 (6–11)*
hsCRPa (mg/l) 0.5 (0.1–1.4) 0.5 (0.2–4.0) 0.9 (0.2–1.1) 2.0 (0.9–3.4)**
Fibrinogen (g/l) 3.2 (2.7–3.7) 2.9 (2.6–4.0) 3.2 (2.4–3.5) 3.4 (2.8–4)**
FVII (%) 110 ± 7.8 106 ± 5.4 118 ± 5.8 117 ± 5.6
FVIII (%) 94 ± 9.8 93 ± 11.4 97 ± 6.5 101 ± 6.7
FIX (%) 95 ± 4.7 96 ± 6.2 95 ± 3.8 105 ± 3.8*
FXI (%) 91 ± 4.4 93 ± 5.6 96 ± 3.8 105 ± 4.8*
FXII (%) 96 ± 6.9 95 ± 6.4 100 ± 6.5 108 ± 7.0**
FXIII (%) 87 ± 5.0 86 ± 4.9 83 ± 5.4 86 ± 5.3
VWF:RCo (%) 70 (57–102) 64 (57–84) 89 (81–128) 93 (63–101)
PAI-1b (%) 1.1 (0.0–4.0) 1.4 (0.7–5.8) 4.1 (3.4–21.2) 17.5 (8.3–25.1)**
D-dimer (mg/l) 0.05 (0.05–0.1) 0.05 (0.05–0.1) 0.05 (0.05–0.1) 0.05 (0.05–0.1)
Data are mean ± s.e., or for non-normally distributed variables and median followed by the 25th and 75th percentiles. Wilcoxon’s test for paired samples, leaner vs. 
heavier co-twin, P values adjusted for sex, smoking, and use of oral contraceptives.
F, coagulation factor; hsCRP, high sensitivity C-reactive protein; MZ, monozygotic; PAI-1, plasminogen activator inhibitor-1; VWF:RCo, von Willebrand factor ristocetin 
cofactor activity.
a11 MZ discordant pairs, 9 MZ concordant pairs. b9 MZ discordant pairs, 7 MZ concordant pairs.
*P < 0.05; **P < 0.01; ***P < 0.001.
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positively with FIX and PAI-1 activities and negatively with 
APTT, whereas BMI and the amount of intra-abdominal fat 
correlated directly with FXII and FXIII activities.
The degree of insulin resistance and inflammation correlated 
with most markers of coagulation. High fasting insulin levels 
and low M-value, as well as elevated hsCRP, associated with 
hypercoagulable state (Table 2).
Univariate associations within twin pairs. In intrapair analyses 
within twin pairs, i.e., in analyses controlling for genetic effects 
within MZ twin pairs, all measures of adiposity and insulin 
resistance were related to fibrinogen levels and PAI-1 activ-
ity. Intrapair differences (∆) in fibrinogen and PAI-1 activity 
both correlated positively with intrapair differences in BMI 
 (Figure 1). ∆Fibrinogen associated with ∆subcutaneous fat (r = 
0.42, P = 0.04), ∆hsCRP (r = 0.70, P = 0.0008), and ∆fasting 
insulin levels (r = 0.55, P = 0.005). Equally, ∆PAI-1 associated 
with ∆subcutaneous fat (r = 0.54, P = 0.03), ∆intra-abdominal 
fat (r = 0.52, P = 0.04), and ∆fasting insulin levels (r = 0.58, P = 
0.018). Intrapair differences in FIX and FXI activities correlated 
with that in  fasting insulin (r = 0.45, P = 0.03 and r = 0.40, P = 
0.05 respectively). ΔD-dimer correlated negatively with Δinsulin 
sensitivity (r = −0.43, P = 0.04).
Multivariate associations within MZ twin pairs. Multivariate analy-
ses were performed using intrapair differences in MZ pairs to 
assess which of the previously mentioned covariates indepen-
dently explained the perturbed coagulation and fibrinolytic 
variables of D-dimer and PAI-1 in obese co-twins. We entered 
differences in body fat distribution (∆subcutaneous fat, ∆intra-
abdominal fat, and ∆liver fat), ∆fasting insulin, ∆hsCRP, gender, 
smoking status, and use of oral contraceptives as independent 
variables in the models. ∆Fibrinogen was independently related 
to ∆hsCRP (β = 0.35 ± 0.15, P = 0.04; adjusted whole model R2 
= 0.29, P = 0.18). ∆FXII was independently influenced by use 
of oral contraceptives (β = 24.5 ± 9.9, P = 0.04; adjusted whole 
model R2 = 0.59, P = 0.03). Within pairs, no other measures 
of adiposity or metabolism were related to the coagulation or 
fibrinolysis markers in the multivariate analyses.
Within twin-pair similarity of measures of coagulation and fibrin-
olysis. Finally, we calculated within-pair intraclass correlations 
in order to quantify the degree to which twins resembled each 
other in their measures of coagulation and fibrinolysis. FVII, 
FVIII, FXI, FXII, FXIII, and VWF activities, fibrinogen, PT, and 
APTT all appeared to be under strong familial influence in both 
concordant (r = 0.86–0.97, P < 0.003) and discordant (r = 0.73–
0.92, P < 0.03) MZ twin pairs. Yet, FXI, FXII and PAI-1 activi-
ties, and fibrinogen concentrations were significantly increased 
in the obese MZ co-twins (Table 1). The intraclass correlation 
for FIX activity was strong in weight-concordant MZ twins (r = 
0.95, P = 0.001) but weaker in MZ discordant twins (r = 0.63, 
P = 0.14).
table 2 univariate correlations between adiposity measures, high sensitivity c-reactive protein (hscrP), insulin sensitivity, and 
coagulation factors in individual MZ twins (n = 48)
BMI Sc fat Ia fat Liver fat hsCRPa M-value Insulin
PT (%) 0.48*** 0.52*** 0.36** 0.17 0.60*** −0.16 0.39***
APTT (s) −0.30 −0.18 −0.29 −0.33* −0.01 0.40** −0.45**
Fibrinogen (g/l) 0.60** 0.37** 0.55** 0.11 0.37** −0.28 0.35*
FVII (%) 0.38 0.37* 0.32* 0.03 0.38* −0.03 0.15
FVIII (%) 0.31 0.20 0.17 0.10 0.21 −0.22 0.37*
FIX (%) 0.73*** 0.60*** 0.60*** 0.41* 0.56*** −0.54*** 0.56**
FXI (%) 0.63** 0.52*** 0.51*** 0.31 0.47** −0.43** 0.53***
FXII (%) 0.42* 0.32 0.50** 0.36 0.18 −0.32 0.43**
FXIII (%) 0.42* 0.25 0.39* −0.06 0.13 0.06 0.12
VWF:RCo (%) 0.09 −0.06 0.05 −0.03 −0.02 0.02 0.23
PAI-1b (%) 0.73*** 0.69** 0.59*** 0.53** 0.62*** −0.34 0.61***
D-dimer (mg/l) −0.11 −0.20 0.03 0.05 −0.18 0.08 0.16
Sc fat = subcutaneous fat in dm3. Ia fat = intra-abdominal fat in dm3.
APTT, activated partial thromboplastin time; F, coagulation factor; hsCRP, high sensitivity C-reactive protein; MZ, monozygotic; PAI-1, plasminogen activator inhibitor-1; 
PT, prothrombin time; VWF:RCo, von Willebrand factor ristocetin cofactor activity.
an = 40 individuals. bn = 32 individuals.


































Figure 1 Associations between intrapair differences (∆) in BMI and 
∆PAI-1 (n = 16 pairs) and fibrinogen (n = 24 pairs) in monozygotic 
twins. P values adjusted for gender, smoking status, and use of oral 
contraceptives. PAI-1, plasminogen activator inhibitor-1.




In this study, we analyzed how obesity influences variables 
of blood coagulation and fibrinolysis in a unique genetically 
controlled sample of obesity-discordant MZ twin pairs. Their 
obesity was of a recent nature as the obese co-twins aged 23–27 
at the time of the study had become obese only after puberty 
(18). We demonstrated a consistent increase in several mark-
ers of coagulation and fibrinolysis in obesity in these healthy 
young adults. The activities of FIX, FXI, and FXII, fibrinogen 
and PAI-1 were enhanced most in obese co-twins.
In addition to these influences of acquired obesity, we found 
that most of the coagulation factor activities (FVII, FVIII, 
FIX, FXII, FXIII, VWF, PT, and APTT) and fibrinogen were 
extremely similar especially within weight-concordant MZ co-
twins, suggesting a tight genetic regulation of the individual 
coagulation factors. Thus, two main observations on the obes-
ity-related prothrombotic state can be made in our study: (i) it 
arises early in still otherwise healthy young adults, soon after 
the development of obesity, and (ii) its origin is a complex mix-
ture of each individual genetic background and lifestyle.
Controlling for genetic background, within-pair differences 
in fibrinogen and PAI-1, the two crossroad factors of blood 
coagulation and regulation of fibrinolysis, related to the differ-
ences in measures of obesity (BMI, subcutaneous, and intra-
abdominal fat). Previous studies have shown that increased 
PAI-1 activity is compatible with widely documented obesity-
linked derangement of fibrinolysis (4,5). Elevated fibrinogen 
levels predicted with future cardiovascular events in a large 
meta-analysis (28,29). In return, weight loss and exercise have 
been documented to decrease the activity of PAI-1 (9). Again, 
decrease in fibrinogen levels occurred after weight loss upon 
bariatric surgery in morbidly obese patients (30).
The activity of PAI-1 showed wide variation. We took this in 
consideration by log-transformation since the data was non-
normally distributed. The highest PAI-1 levels were observed 
in smokers. As there were four current smokers in the group 
of weight-discordant twins (two in the leaner and two in the 
heavier co-twins) and none in the group of weight-concordant 
pairs, smoking may explain part of the increased PAI-1 lev-
els in the weight-discordant pairs. Thus, the effect of smoking 
was adjusted in our analyses. However, smoking did not fully 
explain why the discordant pairs would have higher PAI-1 lev-
els than the concordant pairs. Without the smokers, leaner vs. 
heavier PAI-1 levels were 8.0% vs. 20.4% in the discordant and 
3.9% vs. 3.9 % in the concordant pairs.
Increased FVII, FVIII, and VWF levels are associated with 
obesity, the presence of premature atherosclerotic disease and 
insulin resistance (31–33). However, obesity did not associate 
with increased FVIII or VWF activity in our study. The dis-
crepancy with some earlier observations that obesity generally 
raises levels of VWF (4) may arise from the young age of our 
subjects. Increased VWF refers to endothelial dysfunction (4) 
which may not occur in young individuals having yet fairly 
modest metabolic sequelae of obesity.
Elevated FIX, FXI, FXII, and FXIII are all risk markers 
for thrombosis (34–37) and this study revealed how obesity 
modulates their activities. Earlier evidence of increased activi-
ties of these clotting factors in obesity originates from studies 
of closely related metabolic disorders. For example, FIX is ele-
vated in type 2 diabetes and in conditions with increased cir-
culating interleukin-6 concentrations (38–40). FXII has been 
shown to correlate with BMI (41), compatible with our results. 
The FXIII gene was identified as an obesity gene in a genome-
wide association study by Naukkarinen et al. (42), constituting 
a new link between obesity and increased risk of thrombosis.
In our study, obese co-twins displayed lower insulin sensi-
tivity and hyperinsulinemia compared with their leaner coun-
terparts, independent of the genetic background. In individual 
twins, fasting insulin concentrations correlated positively with 
fibrinogen, PT, FVIII, FIX, FXI, FXII, and PAI-1 and nega-
tively with APTT. FIX, FXI, and D-dimer were associated with 
the insulin resistant state independent of genetic factors within 
pairs. Therefore our results imply that the prothrombotic and 
hypofibrinolytic milieu in acquired obesity concurs with insu-
lin resistance. Of note, phenotypic correlations between insu-
lin resistance and hemostatic factors have been reported in 
earlier twin studies (32) and their coexistence may also arise 
from pleiotropically acting genes (32).
hsCRP correlated with fibrinogen, PT, FVII, FIX, FXI, and 
PAI-1 activities (Table 2). In this study, the heavier MZ co-twins 
had higher hsCRP concentrations than their leaner counter-
parts and this difference independently predicted variation of 
fibrinogen in multivariate analysis in twin pairs. These results 
are in line with earlier reports on the associations between a pro-
thrombotic state and inflammation (6,38,43,44). Sakkinen et al. 
suggested that fibrinogen to a larger extent reflects inflamma-
tion rather than procoagulation in obesity (45). Inflammatory 
cytokines, such as interleukin-1, interleukin-6, and tumor necro-
sis factor-α, produced by adipose tissue stimulate hepatocytes 
to produce PAI-1 and acute phase reactants, some of which are 
procoagulants (43,44,46). The extent of inflammation associates 
with adipose tissue mass and decreases upon weight loss (47).
We observed a particularly strong familial link for the lev-
els of most coagulation factors. Intraclass correlation analyses 
showed high-degree of resemblance between the MZ co-twins 
despite of acquired weight differences with ensuing differences 
in the levels of coagulation factors. Interestingly, however, the 
within-pair correlation of FIX weakened with weight-discord-
ance, suggesting that obesity modifies the pathways responsi-
ble for the production of FIX. Significant genetic influences on 
fibrinogen, FVII, and VWF have been reported in earlier twin 
studies (11,48,49). A similar genetic resemblance between MZ 
twins was reported for FVIII, FXIII, and PAI-1 (11). In our 
study, intraclass correlation point estimates were higher than 
in these other studies including older subjects. This implies 
that the relative contribution of environmental influences over 
genes is likely to increase with age.
Adiposity may functionally alter the function of several genes 
in the coagulation cascade. One such gene is hepatocyte nuclear 
factor-4α, a transcription factor which regulates the synthesis 
of FVII, FIX, FXI, FXII, and FXIIIB in liver (50,51). The activi-
ties of some of these coagulation factors (FIX, FXI, FXII) were 
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elevated in the obese co-twins and correlated with adiposity 
markers in our study. Another regulator of coagulation and fibri-
nolysis is CCAAT/enhancing binding protein-α, a transcription 
factor protein expressed both in liver and in adipose tissue (52). 
Enhanced expression of CCAAT/enhancing binding protein-α 
augments the levels of FIX (52), and its binding site is also present 
in the PAI-1 gene (53). Accordingly, both FIX and PAI-1 activi-
ties were increased in obese co-twins and correlated strongly 
with intra-abdominal and subcutaneous fat in our data. Finally, 
the observed prothrombotic state observed in our study may also 
arise from disturbed clearance of coagulation factors in liver. The 
low-density lipoprotein receptor-related protein-1 is expressed 
in hepatocytes and mediates intracellular degradation of several 
molecules including FVIII, FIX, D-dimer, and PAI-1 (54,55).
Weight—discordance in monozygotic twins is extremely rare 
and we were only able to find 14 discordant pairs for this study. 
The small number of study subjects may set limitations in the 
interpretation of the results of our study but our results are in line 
with earlier reports showing that obesity is a procoagulant state. 
We showed that the measures of coagulation and fibrinolysis are 
extremely similar in MZ co-twins, implying that genetic factors 
may confound studies comparing obese and nonobese subjects 
from studies of individuals. Therefore, it is an important advan-
tage that we here were able to control for the genetic effects by 
using the MZ obesity-discordant design and showed that despite 
significant heritable components, acquired obesity impairs most 
coagulation factors. As a limitation, we would also like to note 
that several markers of fibrinolysis–tissue plasminogen activa-
tor, urokinase-type plasminogen activator, plasminogen, and 
antiplasmin–measuring the global fibrinolytic activity were not 
included in our analyses. This study demonstrated that derange-
ments of coagulation and fibrinolysis are present already in early 
adulthood in obese but otherwise healthy subjects. The levels of 
coagulation factors are under strong genetic control, but obesity 
in parallel with insulin resistance and inflammation influence 
the activity of most measures of coagulation and fibrinolysis in a 
complex manner requiring further mechanistic studies.
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Acquired Liver Fat Is A Key Determinant of
Serum Lipid Alterations in Healthy
Monozygotic Twins
S.M. Kaye1, M. Maranghi2,3, L.H. Bogl4, J. Kaprio4,5,6, A. Hakkarainen7, J. Lundbom7,
N. Lundbom7, A. Rissanen8, M.-R. Taskinen2 and K.H. Pietil€ainen1,5
Objective: The effects of acquired obesity on lipid profile and lipoprotein composition in rare BMI-
discordant monozygotic (MZ) twin pairs were studied.
Design and Methods: Abdominal fat distribution, liver fat (magnetic resonance imaging and
spectroscopy), fasting serum lipid profile (ultracentrifugation, gradient gel-electrophoresis, and
colorimetric enzymatic methods), and lifestyle factors (questionnaires and diaries) were assessed in 15
BMI-discordant (within-pair difference [D] in BMI >3 kg/m2) and nin concordant (DBMI <3 kg/m2) MZ
twin pairs, identified from two nationwide cohorts of Finnish twins.
Results: Despite a strong similarity of MZ twins in lipid parameters (intra-class correlations 0.42-0.90, P
< 0.05), concentrations of apolipoprotein B (ApoB), intermediate-density lipoprotein cholesterol, low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein 3a% (HDL3a%), and HDL3c% were
higher (P < 0.05) and those of HDL cholesterol, HDL2-C, and HDL2b% were lower (P < 0.01) in the
heavier co-twins of BMI-discordant pairs. The composition of lipoprotein particles was similar in the co-
twins. When BMI-discordant pairs were further divided into liver fat-discordant and concordant (based on
median for Dliver fat, 2.6%), the adverse lipid profile was only seen in those heavy co-twins who also
had high liver fat. Conversely, BMI-discordant pairs concordant for liver fat did not differ significantly in
lipid parameters. In multivariate analyses controlling for Dsubcutaneous, Dintra-abdominal fat, sex,
Dsmoking and Dphysical activity, Dliver fat was the only independent variable explaining the variation in
DApoB, Dtotal cholesterol, and DLDL-C concentration.
Conclusions: Several pro-atherogenic changes in the amounts of lipids but not in the composition of
lipoprotein particles were observed in acquired obesity. In particular, accumulation of liver fat was
associated with lipid disturbances, independent of genetic effects.
Obesity (2013) 21, 1815-1822. doi:10.1002/oby.20228
Introduction
Obesity-associated derangements of plasma lipid profile are a widely
documented risk factor for cardiovascular disease (1). Body fat
depots differ in their contribution to lipid metabolism. Intra-abdomi-
nal (ia) fat rather than subcutaneous (sc) or gynoid body fat is asso-
ciated with an atherogenic lipid profile and increased cardiovascular
risk (2,3). Ectopic fat in liver contributes significantly both to serum
triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C)
levels (4). The derangement of lipoprotein composition due to liver
steatosis is already seen in children presenting higher amounts of
large very low-density lipoprotein (VLDL), small dense low-density
lipoprotein (LDL), and smaller HDL particles (5). Characterizing the
individuals at highest cardiovascular risk is a challenge. Not all
obese individuals present the same harmful metabolic sequelae prob-
ably due to a different predisposition to accumulation of ectopic fat
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(6,7). A subgroup of obese individuals remains insulin sensitive and
presents with normal TG and HDL-C concentrations (8). Detailed
lipid concentrations and compositions and their relationships to body
fat distribution in obesity are poorly characterized.
Derangements in the lipid profile are determined by complex combi-
nations of genetic and lifestyle factors (9). In our previous studies,
we provided evidence for large genetic influences on variations in
LDL-C (79%), HDL-C (73%), and TGs (64%), as has been previ-
ously reported elsewhere (10). In large genome-wide association stud-
ies, several single nucleotide polymorphisms associate with lipid lev-
els in humans (11). Moderate heritability estimates were observed for
LDL peak particle size (49%) and HDL mean particle size (56%) and
HDL subspecies (46-63%) (10), confirming that substantial environ-
mental influences also exist. The sources of those environmental
influences are variable and may be difficult to distinguish from
genetic and environmental influences. Obesity and regional fat distri-
bution have a substantial heritability (12) and many genes underlying
obesity have been identified (13). BMI-discordant monozygotic (MZ)
twins offer a unique model where the influence of acquired obesity
on lipid profile can be disentangled from genetic factors, as in this
design the lean and heavy subjects are completely matched for any
variations in the genetic background (DNA sequence) (14).
We aimed to determine the associations between acquired obesity
and serum lipid profile with a special emphasis on fat distribution,
sc, ia, and liver fat in rare MZ twin pairs discordant for BMI. In
addition, we tested the similarity of lipoprotein particle quantity and
quality in MZ twins, to evaluate the genetic similarity within the
twin pairs. We also aimed to carefully adjust the confounding
effects of lifestyle factors on lipid profile in our analyses.
Methods
Subjects
The twins included in this study were recruited from two population-
based, longitudinal studies, FinnTwin16 (FT16) and FinnTwin12 (FT12),
each consisting of five consecutive birth cohorts of Finnish twins (15). In
FT16, twins born between 1975 and 1979 were followed up by question-
naires at 16, 17, 18.5, and 22-27 years of age (response rates 83–97%, n
¼ 5,601 at baseline). In FT12, twins born between 1983 and 1987 were
sent questionnaires at 11-12, 14, and 17.5 years (response rates 74-92%,
n ¼ 5,184 at baseline). This study included an intensive subsample from
the last follow-ups of both FT12 and FT16 studies including 15 pairs (6
male and 9 female pairs) discordant for BMI (within-pair difference in
BMI3 kg/m2 and 10-30 kg in weight) and 9 pairs (5 male and 4 female
pairs) concordant for BMI (within-pair difference in BMI <3 kg/m2).
Within-pair difference of 3 kg/m2 represents the top 5% most discord-
ant pairs in the cohorts. All pairs were of Caucasian origin with a mean
age of 28.1 years (range 22.8-33.1 years). Except for one obese co-twin
who had recently developed type 2 diabetes and was on insulin therapy
and another obese co-twin having an inactive ulcerative colitis and being
on mesalazine and azathioprine treatment, the subjects were healthy and
did not take any medications. The twins’ weights had been stable for at
least 3 months prior to the study. None of the female subjects were preg-
nant or lactating. One female subject used oral contraceptives. Mono-
zygosity was confirmed by genotyping of 10 informative genetic markers
(16). The study protocols were approved the ethical committee the Hos-
pital District of Helsinki and Uusimaa, Finland. Written informed con-
sent was obtained from all participants.
Diet, smoking, and physical activity
Energy and macronutrient intakes were assessed from 3-day food
records and analyzed by Diet32, which is based on a national Fin-
nish database for food composition (17). Habitual alcohol intake
was assessed by a structured questionnaire. The non-smokers com-
prised never smokers, former and occasional smokers, and the cur-
rent smokers comprised those who were daily smokers (n ¼ 6 indi-
viduals). Physical activity was assessed using the Baecke physical
activity questionnaire, which derives an index for physical activity
in total (total index) and separate indices for physical activity at
work (work index), sports activities during leisure time (sport
index), and physical activity during leisure time excluding sports
(leisure time index) (18).
Body composition
Weight and height were measured after 12-h overnight fast to calcu-
late BMI. Body composition was measured using whole body dual
X-ray absorptiometry (DXA) scans (software version 8.8, Lunar
Prodigy, Madison, WI,USA). A standardized procedure at least 4 h
after a light meal with empty bladder was used to avoid differences
in the hydration status. Whole body fat percentage was calculated as
fat mass/(fat mass þ lean mass þ bone mineral content).
Magnetic resonance experiments
The magnetic resonance (MR) measurements were performed on a
clinical 1.5 T imager (Avanto, Siemens, Germany, Erlangen). To
allow measurement of abdominal fat distribution, a T1-weighted
axial image stack of 16 slices with thickness of 10 mm and gap of 0
mm was centered at L4/L5 intervertebral disk. Selective fat excita-
tion was used to obtain images with a standard body coil. MR
images were analyzed using SliceOmatic v4.3 segmentation software
(Tomovision, Montreal, Canada). The areas of sc and ia fat tissue
were measured for each slice using a region-growing routine. The
results were expressed as total volumes of sc fat and ia fat.
For liver-fat analyses, point resolved spectroscopy (PRESS) localization
technique with repetition time (TR)/echo time (TE) of 3,000/30 ms
and 16 acquisitions was used to obtain non-suppressed liver spectra.
Orthogonal three plane images were used for localization of the cubic
8-27 cm3 voxel of interest within the right lobe of the liver avoiding
signal contamination from vascular structures, gallbladder, and adipose
tissue. The MRS data were collected using a flex surface coil in com-
bination with spine coils. The liver spectra were analyzed with jMRUI
v3.0 software (19) using the AMARES algorithm (20). Areas of water
signal at 4.7 parts per million (ppm) and methylene signal from intra-
cellular TGs at 1.3 ppm were determined using a line-fitting procedure.
Spectroscopic intracellular TG content was expressed as methylene/
(water þ methylene) signal area  100 and the values were further
converted to mass fractions as described earlier (21).
Biochemical analyses
Venous blood samples from the study subjects were drawn after an
overnight fast and serum and EDTA plasma were separated by cen-
trifugation and stored at -80C until analysis for lipid profile.
Plasma concentrations of apolipoprotein A1 (ApoA1) and apolipo-
protein B (ApoB) were measured by immunoturbidometric methods
(for ApoA1, Wako Chemicals GmbH and for ApoB, Orion Diagnos-
tica, Espoo, Finland). Serum apolipoprotein C3 (ApoC3)
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concentration was quantitated by ELISA (22). Serum total choles-
terol (TC) and TGs were determined using an automated Konelab
60i analyzer (Thermo Fisher Scientific Oy) by enzymatic methods
(Refs. 981812 and 981301).
Fasting serum lipoproteins (VLDL, intermediate-density lipoprotein
[IDL], LDL, HDL2, and HDL3) were separated by sequential flota-
tion ultracentrifugation using a modification of the method of Havel
et al. (23). Lipoprotein compositions were analyzed using enzymatic
methods by Konelab 60i. HDL was separated and isolated by ultra-
centrifugation from 0.5 ml plasma (24). Distribution of HDL2b, 2a,
3a, 3b, and 3c subspecies and HDL mean particle size were deter-
mined by native gradient gel electrophoresis as previously described
with minor modifications (24,25). The molecular size intervals for
HDL subspecies 2b, 2a, 3a, 3b, and 3c were used, and for each sub-
species, the relative area under the densitometric scan was reported.
Mean HDL particle size was calculated by multiplying the mean
size of each HDL subclass by its relative area under the densitomet-
ric scan. LDL peak particle diameters determined using 1 mm 2-
10% linear non-denaturating polyacrylamide gradient gels (26).
Statistical methods
Statistical analyses were performed with Stata statistical software
(release 11.0; Stata Corporation, College Station, TX, USA). Results
are expressed as mean 6 SE unless otherwise specified. Twin similar-
ity was assessed using sex-adjusted intra-class correlations (ICCs).
Mean values of leaner and heavier co-twins are shown unadjusted.
Wilcoxon matched-pairs signed-ranks test was performed to test
whether heavier and leaner co-twins differed significantly from each
other. Within-pair differences (D) were calculated by subtracting the
leaner co-twin’s value from the heavier co-twin’s value and using all
twin pairs in analyses. Mann–Whitney U-test was used to test whether
Dlipids differed in discordant vs. concordant groups. Pearson partial
correlations adjusted for sex were used to calculate correlations
between Ds of different adiposity measures. The effects of acquired
adiposity on serum lipid profiles were calculated using Pearson partial
correlations (Deach adiposity measure vs. Deach lipid value) adjusted
for sex, Dphysical activity (total index), and Dsmoking status. Simi-
larly, the effects of Dphysical activity on Dlipids were tested by Pear-
son correlation adjusted for sex and Dsmoking. Multiple regression
analyses included Deach lipid value against Dsc fat, Dia fat and
Dliver fat, sex, Dphysical activity, and Dsmoking in the same model.
Because further adjustment for Dpercentage of energy from macronu-
trients or alcohol did not substantially change these results, they were
not included in the final models.
Results
Physical characteristics
Physical characteristics and the lipid profiles of MZ twin pairs are
summarized in Table 1. Briefly, within-pair differences (D) in BMI
ranged from 3.1 to 9.4 kg/m2 in discordant pairs and from 0.1 to 2.3
kg/m2 in concordant pairs. The heavier co-twins of BMI-discordant
pairs had on average 1.6 times the amount of sc fat, 2.0 times that
of ia fat, and 5.1 times the amount of liver fat than their leaner
counterparts. These parameters did not differ between the heavier
and leaner co-twins in BMI-concordant twin pairs. To further ana-
lyze the influence of liver fat we divided BMI-discordant twin pairs
into two subgroups based on median for Dliver fat (2.6%) in this
study sample: seven BMI-discordant pairs (Dweight 16 kg) where
both co-twins had low liver fat percentages (from 0.1 to 1.6%) had
no differences in liver fat (Dliver fat 0-0.2%, P ¼ 0.40). The
remaining eight BMI-discordant pairs (Dweight 17 kg) differed sig-
nificantly for liver fat: the heavier co-twins’ liver fat% ranged from
3.8% to 9.4% (Dliver fat 2.6-9.0%, P ¼ 0.012).
Within-pair similarity of lipid profile
At first, sex-adjusted ICC was determined from all twins to assess
familial, probable genetic control over lipoprotein composition. In
pairs concordant for BMI, ICC coefficients ranged from 0.51-0.93
(all P < 0.05) for concentrations of lipids, phospholipids, and pro-
teins in VLDL, LDL, IDL, and HDL particles as well as lipoprotein
particle masses. Equally, ICC analysis revealed high within-pair simi-
larity in apolipoproteins ApoB and ApoC3 (0.70 and 0.81 respec-
tively, both P < 0.05), TC concentration (0.85, P ¼ 0.0004), all HDL
subclasses (0.60-0.77, all P < 0.05), HDL mean particle size (0.80, P
¼ 0.01), and marginal significance in ApoA1 (0.56, P ¼ 0.06).
Within-pair similarity was significant even in BMI-discordant twins
for concentrations of lipids, phospholipids, and proteins in IDL and
HDL2 particles (0.48-0.64, P < 0.05). However, we identified some
notable exceptions. In VLDL, within-pair similarity in particle com-
position weakened with weight-discordance as ICC coefficient range
0.11-0.35 was much lower and statistically non-significant compared
with the marked resemblance in concordant pairs (0.70-0.85, P <
0.01). There was very little within-pair resemblance for ApoB,
VLDL-C, LDL-C, HDL2a%, total TG concentration, and VLDL and
LDL masses in BMI-discordant twin pairs (0.12-0.38, P ¼ 0.07-
0.29). There was no within-pair similarity in LDL peak particle size
and only modest similarity in HDL3 particle in this data.
Differences in heavier vs. leaner co-twins in lipid
profile and lipoprotein composition
The BMI-concordant MZ co-twins did not differ for their lipid pro-
file (Table 1). In BMI-discordant pairs, the heavier co-twins had sig-
nificantly higher levels of ApoB (P ¼ 0.01), TC (P ¼ 0.05), LDL-C
(P ¼ 0.05), IDL-C (P ¼ 0.01), and HDL3c% (P ¼ 0.003), as well
as higher IDL and LDL masses (P ¼ 0.02 and 0.05 respectively).
Levels of HDL-C, HDL2-C, and HDL2b% were lower (P ¼ 0.01
for all) and HDL mean particle size was smaller (P ¼ 0.01) in the
heavier co-twins. There were no differences in concentrations of
ApoA1, ApoC3, VLDL-C and HDL3-C, LDL peak particle size,
VLDL, or HDL masses between the co-twins. Neither total TG (Ta-
ble 1) nor VLDL-TG (54.4 6 5.7 mg/dl vs. 69.2 6 7.7, P ¼ 0.15)
concentration differed between leaner and heavier co-twins.
Acquired obesity associated with only minor changes in the lipopro-
tein particle composition when assessing qualitative composition of
each lipoprotein particle (data not shown). The heavier co-twins of
the discordant pairs had significantly higher percentages of IDL free
cholesterol (7.7 vs. 7.0%, P ¼ 0.05) and cholesterol esters (10.6 vs.
9.0%, P ¼ 0.05) in relation to other components within IDL particle
when compared with their leaner counterparts. HDL2 particles were
enriched with TG’s in the heavier co-twins (6.1 vs. 5.1%, P ¼ 0.02).
Correlations between adiposity, physical activity,
and lipid profile within twin pairs
In analyses controlling for genetic effects within all MZ twin pairs,
Pearson partial correlation coefficients between Dmarkers of
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adiposity, and Dlipid profile adjusted for sex, Dphysical activity, and
Dsmoking are presented in Table 2. DBMI, Dia, Dsc, and Dliver fat
were strong correlates of atherogenic lipid parameters independent
of genetic effects. After further adjusting for Dliver fat, correlations
became weaker for many variables.
In contrast, Dphysical activity adjusted for sex, Dsmoking,
and DBMI associated strongly with a favorable lipid profile:
ApoB: r ¼ 0.53, LDL-C: r ¼ 0.54, HDL-C: r ¼ 0.47, LDL
mass: r ¼ 0.48, HDL mass: r ¼ 0.46, HDL3b: r ¼ 0.45 (P <
0.05 for all).
Most adiposity measures were significantly correlated with each
other. Sex-adjusted partial correlations were as follows: DBMI and
Dsc fat: r ¼ 0.93, P < 0.001, DBMI and Dia fat: r ¼ 0.72, P <
0.001, DBMI and Dliver fat: r ¼ 0.35, P ¼ 0.09, Dia fat and Dsc
fat: r ¼ 0.62, P ¼ 0.002, Dia fat and Dliver fat: r ¼ 0.52, P ¼ 0.01.
Because of the high correlation between the measures of adiposity,
multivariate regression analyses were performed to assess which
component of body fat distribution independently explained pro-
atherogenic changes in lipid profile. We entered within-pair differen-
ces in body fat distribution (Dsc fat, Dia fat, and Dliver fat), sex,
TABLE 1 Physical characteristics and lipid profiles of monozygotic twin pairs
BMI-discordant n ¼ 15 pairs BMI-concordant n ¼ 9 pairs
DBMI >3 kg/m2 DBMI <3 kg/m2
Leaner Heavier Leaner Heavier
Adiposity measures
BMI (kg/m2) 24.8 6 1.0 30.3 6 1.0*** 27.6 6 1.1 29.3 6 1.1**
Body fat % 32.2 6 2.4 40.6 6 2.0*** 31.6 6 3.1 33.0 6 2.6
Sc fat (dm3) 3.4 6 0.4 5.4 6 0.1*** 3.6 6 1.0 3.9 6 0.5
Ia fat (dm3) 0.6 (0.3–0.8) 1.1 (0.7–1.5)*** 1.1 (0.6–1.5) 1.1 (0.6–1.4)
Liver fat (%) 0.6 (0.4–1.1) 3.8 (0.6–6.1)** 1.3 (0.5–1.6) 1.0 (0.5–1.7)
Apolipoproteins
ApoA1 (mg/dl) 128.9 (119.3–172.5) 129.9 (113.0–144.8) 126.4 (112.6–130.5) 127.6 (118.8–142.6)
ApoB (mg/dl) 69.8 6 3.3 81.1 6 4.0** 81.0 6 9.6 81.1 6 7.6
ApoC3 (mg/dl) 9.5 6 0.7 9.4 6 0.7 9.4 6 2.0 9.7 6 1.3
Serum TGs and cholesterol
TG (mg/dl) 93.8 (74.3–115.1) 112.4 (87.6–130.1) 83.2 (63.7–201.8) 98.2 (74.3–104.4)
TC (mg/dl) 174.6 6 5.5 183.7 6 6.2* 173.4 6 14.5 176.6 6 13.4
VLDL-C (mg/dl) 9.4 6 1.0 12.4 6 1.8 14.1 6 4.9 11.3 6 3.2
LDL-C (mg/dl) 98.4 6 5.8 110.4 6 5.6* 104.1 6 11.1 108.4 6 11.5
IDL-C (mg/dl)a 3.8 (2.9–4.3) 5.0 (3.1–6.7)** 3.7(2.5–5.5) 2.6 (2.3–5.4)
HDL-C (mg/dl)a 62.7 6 3.7 51.2(46.0–61.8)** 50.9 6 3.6 52.8 6 3.8
HDL2-C (mg/dl) 31.9 6 3.5 21.3 (15.4–25.0)** 21.1 6 3.9 15.3 (14.8–21.5)
HDL3-C (mg/dl) 30.8 6 1.2 31.4 6 1.2 29.7 6 1.8 32.4 6 1.8
Lipoprotein particle mass and size
VLDL mass (mg/dl) 95.2 6 8.8 121.6 6 14.0 143.2 6 44.3 123.8 6 33.1
LDL mass (mg/dl) 243.6 6 11.4 254.3 (228.0–316.8)* 267.7 6 24.6 276.7 6 26.7
IDL mass (mg/dl) 25.3 6 2.3 29.0 6 2.9* 25.3 6 3.7 24.8 6 3.1
HDL mass (mg/dl) 393.4 6 23.1 362.5 6 22.1 334.5 6 15.4 351.8 6 25.6
LDL size (nm) 26.6 6 0.2 26.3 6 0.2 26.1 6 0.4 25.9 6 0.3
HDL size (nm) 9.6 6 0.1 9.4 6 0.1** 9.2 6 0.2 9.1 6 0.1
HDL subclasses
HDL2a% 27.0 6 1.0 27.2 6 0.8 24.4 6 1.9 25.8 6 1.4
HDL2b% 36.0 6 2.9 28.7 6 3.0** 23.7 6 5.0 20.3 6 3.1
HDL3a% 24.3 6 1.6 27.5 6 2.1 30.5 6 2.1 33.7 6 1.9
HDL3b% 9.2 6 1.1 11.2 6 1.1 15.7 6 3.1 15.0 6 1.9
HDL3c% 3.5 6 0.6 5.4 6 1.1** 5.7 6 1.5 5.2 6 0.8
Data are mean 6 SE, non-normally distributed data are median (25–75% inter-quartile range). Wilcoxon signed ranks test leaner vs. heavier co-twin, *P < 0.05, **P <
0.01, ***P < 0.001. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoC3, apolipoprotein C3; HDL-C, high density lipoprotein cholesterol; ia, intra-abdominal; IDL-C,
intermediate density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; sc, subcutaneous; TC, total cholesterol; TG, triglycerides; VLDL-C, very low density
lipoprotein cholesterol.
aThe within-pair difference significantly different (P < 0.05) in discordant vs. in concordant pairs (Mann-Whitney U-test).
Obesity Liver Fat and Lipid Alterations—A Twin Study Kaye et al.
1818 Obesity | VOLUME 21 | NUMBER 9 | SEPTEMBER 2013 www.obesityjournal.org
Dsmoking status, and Dphysical activity as independent variables in
the models. Out of all body fat depots, Dliver fat was the only one
independently explaining the variation in DApoB (b ¼ 2.2 6 1.0, P
¼ 0.05; whole model adjusted R2 ¼ 0.45, P ¼ 0.01), DTC (b ¼ 3.6
6 1.4, P ¼ 0.02; R2 ¼ 0.37, P ¼ 0.04), DLDL-C (b ¼ 2.9 6 1.3, P
¼ 0.04; R2 ¼ 0.56, P ¼ 0.003), DHDL3-C (b ¼ 0.7 6 0.3, P ¼
0.04; R2 ¼ 0.08, P ¼ 0.32), and also marginally DLDL mass (b ¼
5.7 6 2.9, P ¼ 0.07; R2 ¼ 0.48, P ¼ 0.01). DPhysical activity
remained significant in models explaining DLDL-C (b ¼ 10.4 6
2.8, P ¼ 0.002; R2 ¼ 0.56, P ¼ 0.003), DLDL mass (b ¼ 16.7 6
6.2, P ¼ 0.016; R2 ¼ 0.48, P ¼ 0.01), and marginally DHDL3b (b
¼ -1.5 6 0.7, P ¼ 0.06; R2 ¼ 0.28, P ¼ 0.088).
Influence of liver fat on lipid profile in twins from
BMI-discordant pairs
Division of the BMI-discordant pairs based on their within-pair dif-
ferences for liver fat revealed an interesting splitting of the results.
Despite the marked difference in weight in both groups, only those
obese co-twins who also had high liver fat, showed a pro-atherogenic
lipid profile (Figure 1). In this group, the heavier co-twins had higher
levels of ApoB, TC, LDL-C, IDL-C, LDL mass, HDL3c and lower
levels of HDL-C, smaller HDL mean particle size (P < 0.05), and
marginally higher TG concentrations (P ¼ 0.07) than their leaner
counterparts. ApoA1, ApoC3, VLDL-C, VLDL, IDL and HDL
masses, LDL peak particle size, or other HDL subclasses did not dif-
fer between the co-twins neither in liver fat discordant nor in liver fat
concordant pairs (data not shown). In BMI-discordant but liver fat
concordant pairs, the lipid profiles were very similar between the co-
twins: the only difference noted was a slightly smaller HDL peak par-
ticle size (9.7 vs. 9.5 nm, P ¼ 0.05) in the heavier co-twins.
Discussion
In this study, we were able to demonstrate that acquired obesity is
associated with several pro-atherogenic derangements in the lipopro-
tein metabolism especially when obesity is accompanied with a fatty
liver. In our study, we used a unique sample of MZ twin pairs dis-
cordant for BMI, which allowed us to estimate the effects of
acquired adiposity in heavier and leaner individuals matched for
genetic background. A further advantage of this study was that half
TABLE 2 Pearson partial correlations between within-pair differences (D) in adiposity and Dlipid parameters, adjusted for sex,
Dsmoking, and Dphysical activity in monozygotic twin pairs (n 5 24 pairs)
DLiver fat% DBMI
DBMI adjusted
for DLiver fat DSc fat
DSc fat adjusted




DApoA1 0.06 0.09 0.12 0.18 0.20 0.10 0.14
DApoB 0.56** 0.55* 0.45* 0.44* 0.39 0.49* 0.32
DApoC3 0.09 0.00 0.03 0.15 0.18 0.06 0.02
Serum TGs and cholesterol
DTG 0.47* 0.52* 0.43(*) 0.38 0.32 0.57** 0.46*
DTC 0.53* 0.31 0.17 0.30 0.21 0.23 0.00
DVLDL-C 0.31 0.56* 0.50 0.44* 0.39 0.60** 0.54*
DLDL-C 0.40(*) 0.21 0.08 0.24 0.17 0.12 0.06
DIDL-C 0.40(*) 0.53* 0.46* 0.44* 0.39 0.45* 0.33
DHDL-C 0.12 0.38 0.37 0.37 0.36 0.39(*) 0.38
DHDL2-C 0.32* 0.37 0.29 0.32 0.27 0.41(*) 0.32
DHDL3-C 0.42(*) 0.14 0.33 0.22 0.36 0.07 0.31
Lipoprotein mass and size
DVLDLmass 0.43(*) 0.52* 0.44(*) 0.38 0.32 0.56** 0.45*
DIDLmass 0.11 0.21 0.18 0.17 0.15 0.13 0.09
DLDLmass 0.44* 0.35 0.23 0.36 0.29 0.27 0.09
DHDLmass 0.07 0.10 0.13 0.16 0.19 0.08 0.13
DLDL size 0.08 0.32 0.31 0.28 0.27 0.43(*) 0.44(*)
DHDL size 0.30 0.48* 0.42(*) 0.47* 0.43(*) 0.41(*) 0.33
HDL subclasses
DHDL2a% 0.06 0.05 0.03 0.09 0.07 0.02 0.06
DHDL2b% 0.30 0.46* 0.40(*) 0.45* 0.41(*) 0.42(*) 0.34
DHDL3a% 0.21 0.31 0.26 0.32 0.28 0.24 0.17
DHDL3b% 0.31 0.44* 0.37 0.43(*) 0.38 0.30 0.19
DHDL3c% 0.09 0.18 0.16 0.18 0.17 0.27 0.25
(*)P < 0.08, *P < 0.05, **P < 0.01.
Sc fat, subcutaneous fat in dm3; Ia fat, intra-abdominal fat in dm3.
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of these rare MZ pairs were highly discordant for liver fat, whereas
the other half was composed of co-twins which in spite of large dif-
ferences in body weight had equally low liver fat values in both twin
pair members. Using this unique experiment of nature, we demon-
strated that the heavier co-twins with high liver fat had higher concen-
trations of pro-atherogenic lipoprotein particles and less atheroprotec-
tive qualities in their lipid profile. The heavier co-twins with low liver
fat resembled their lean co-twins more; however, a non-significant
trend for worsening of the lipid profile with overall fatness was
observed in them as well. Our data further showed that the serum lipid
profile is very similar in MZ twins concordant for body weight and
remains highly correlated between co-twins in case of TC, IDL-C,
HDL-C, and HDL subclasses even in the BMI-discordant pairs. How-
ever, TG, ApoB, LDL-C, HDL2a, VLDL, and LDL masses reacted to
obesity as the within-pair similarity was lost in BMI-discordant pairs.
This suggests that the lipoprotein metabolism has a strong genetic
background but there is an interaction with acquired obesity in a com-
plex manner, depending on the distribution of body fat.
FIGURE 1 Lipid profiles in BMI-discordant twins divided into two groups based on the median of within-pair difference
(D) in liver fat 2.6%: (1) concordant (Dlfat <2.6%) or (2) discordant (Dlfat 2.6%) for liver fat. Both groups were
equally discordant for overall obesity (mean Dbody weight 16 and 17 kg). Data are mean 6 SE. P values: leaner vs.
heavier co-twins in Wilcoxon signed ranks tests and liver fat discordant vs. concordant pairs in Mann–Whitney U-
test. Liver fat concordant group, n ¼ 7 pairs. Liver fat discordant group, n ¼ 8 pairs. Lfat, liver fat; ApoB, apolipopro-
tein B; LDL-C, low density lipoprotein cholesterol; IDL-C, intermediate density lipoprotein cholesterol; HDL-C, high
density lipoprotein cholesterol.
Obesity Liver Fat and Lipid Alterations—A Twin Study Kaye et al.
1820 Obesity | VOLUME 21 | NUMBER 9 | SEPTEMBER 2013 www.obesityjournal.org
The heterogeneity in the lipid panel in our BMI-discordant twin
pairs supports previous data on the hypothesis that there might be a
distinctive group of metabolically healthy obese people (27).
Uncomplicated obesity is characterized by low amount of visceral
adipose tissue (28), low inflammatory state (29), and a lower degree
of ectopic fat deposition, in particular in muscle and liver (27).
Because liver fat and ia fat are highly correlated, their independent
roles on the lipid derangements have been difficult to distinguish.
This study suggests that liver fat is the main culprit of the lipid dis-
turbances as it was the only body fat depot that remained significant
in explaining the lipid parameters in the multivariate models. This
finding is in line with the close biological role of the liver as the
factory of lipoprotein particles (30).
Fatty liver leads to overproduction of VLDL particles. In addition to
overproduction of these TG-rich lipoproteins, hypertriglyceridemia
is due to impaired clearance of VLDL particles (7). Overproduction
of VLDL has effects both on HDL and LDL via actions of choles-
terol ester transfer protein (CETP) secreted in liver. CETP mediates
the bidirectional transfer of lipoprotein core lipids between different
particles. When VLDL concentration is high, HDL cholesterol esters
are preferentially transferred by CETP to larger VLDL particles that
become cholesterol rich and thus potentially more atherogenic (31).
In addition, CETP is involved with the formation of small LDL par-
ticles. This most atherogenic subclass of LDL develops when TGs
in LDL are gradually hydrolyzed by hepatic lipase resulting in the
formation of small LDL particles (32). Again, our findings showing
a pro-atherogenic lipid pattern mainly when the liver is fatty, corre-
sponds well with this biology.
Our data with detailed measures of lipoprotein particles, their size
and composition and apolipoproteins have revealed several new
findings beyond the traditional measures of basic lipid values. Both
LDL-C and LDL particle mass were higher in the heavier co-twins
suggesting that the heavier co-twins have an increased number of
LDL particles as reflected by the increase of ApoB concentration. In
general, HDL is divided into HDL2 and HDL3 subspecies based on
their size. While the larger HDL2 has better cholesterol efflux
capacity, the smaller and denser HDL3 has been demonstrated to
protect LDL from oxidation (33). In this study, ApoA1, the predom-
inant protein carried on HDL particles, did not differ between heavy
and lean co-twins. As there was no difference in HDL mass either,
it suggests that HDL particle concentration remains unchanged in
obesity. Low HDL-C in heavier co-twins was due to a reduction of
cholesterol in large HDL2 particles, HDL2b in particular, the sub-
class that is considered the most cardioprotective (34). Subsequently,
HDL particle size was smaller in the heavier co-twins of the BMI-
discordant pairs in our data.
Accumulation of fat in the liver has proven to be in part geneti-
cally controlled: familial clustering of fatty liver has been demon-
strated (35). Approximately 60% of the variability of liver enzymes
is heritable (36), and several novel gene candidates and single nu-
cleotide polymorphisms in DNA have been described for explain-
ing either fatty liver (35,37) or liver enzymes (38). It is therefore
probable that the propensity to accumulate fat in the liver in obe-
sity is also partly genetic. Notably, in our study, the liver was fatty
after development of obesity but not in lean twins, which points to
the importance of obesity as the trigger of the genetic predisposi-
tion. However, despite the fact that PNPLA3 and LYPLAL1 gene
variants are significantly associated with liver fat, they do not
affect serum lipids (37). This suggests that other underlying mecha-
nisms are involved in the lipoprotein derangements. Whether the
same sets of genes explain liver fat and serum lipids remains to be
studied.
It is also possible that environmental factors, such as physical activ-
ity and diet modify the function of relevant genes and explain the
acquired differences in liver fat content and the lipid profile. Exer-
cise training has been proven to reduce intra-hepatic fat content in
adults (39). The associations with exercise and lipid levels are less
consistent. In Sullivan’s trial, no improvement in VLDL-TG or
ApoB100 secretion rates was seen (39). In a meta-analysis of
randomized controlled-trials in adults improvement was seen only
when exercise was combined with diet (40). It is therefore important
that we utilized the information from 3-day food diaries and physi-
cal activity questionnaires to examine the roles of lifestyle factors
on the lipid profile. Low physical activity, together with high liver
fat remained as an independent predictor of high LDL-C. In this
study, within-pair differences in 3-day food intake or alcohol did not
explain the observed lipid changes.
The limitations of our study include the cross-sectional design and
the small sample size. It must be acknowledged that this may have
limited our power to detect significant differences in the liver fat
concordant twin pairs. Furthermore, the possibility of residual con-
founding by unmeasured covariates cannot be excluded.
In summary, we demonstrate the diversity of serum lipid profile in a
unique collection of MZ twins discordant for BMI. Among the
BMI-discordant twin pairs, the occurrence of both liver fat discord-
ant and liver fat concordant pairs offered an extraordinary informa-
tive design to study the role of body fat distribution and ectopic fat
on serum lipids. We were able to show that acquired obesity was
associated with a pro-atherogenic lipid profile, in particular when
obesity was accompanied by high liver fat. Of note was that despite
the probable strong impact of genes on the liver fat and lipid profile,
lean individuals remained to a large extent protected from both the
fattening of the liver and from the harmful lipid patterns. Physical
activity together with low liver fat was the most important cardio-
protective factors in this study.O
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Accepted 23 October 2015Objective. To investigate how obesity, insulin resistance and low-grade inflammation
link to circulating metabolites, and whether the connections are due to genetic or
environmental factors.
Subjects and methods. Circulating serum metabolites were determined by proton NMR
spectroscopy. Data from 1368 (531 monozygotic (MZ) and 837 dizygotic (DZ)) twins were
used for bivariate twin modeling to derive the genetic (rg) and environmental (re)
correlations between waist circumference (WC) and serum metabolites. Detailed
examination of the associations between fat distribution (DEXA) and metabolic health
(HOMA-IR, CRP) was performed among 286 twins including 33 BMI-discordant MZ pairs
(intrapair BMI difference ≥3 kg/m2).
Results. Fat, especially in the abdominal area (i.e. WC, android fat % and android to gynoid
fat ratio), together with HOMA-IR and CRP correlated significantly with an atherogenic
lipoprotein profile, higher levels of branched-chain (BCAA) and aromatic amino acids, higher
levels of glycoprotein, and a more saturated fatty acid profile. In contrast, a higher proportion
of gynoid to total fat associated with a favorable metabolite profile. There was a significant
genetic overlap between WC and several metabolites, most strongly with phenylalanine (rg =










112 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 1 1 1 – 1 2 1particle diameter (rg = −0.33) and HDL cholesterol (rg = −0.30). The effect of acquired obesity
within the discordant MZ pairs was particularly strong for atherogenic lipoproteins.
Conclusions. A wide range of unfavorable alterations in the serum metabolome was
associated with abdominal obesity, insulin resistance and low-grade inflammation. Twin
modeling and obesity-discordant twin analysis suggest that these associations are partly
explained by shared genes but also reflect mechanisms independent of genetic liability.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Obesity is often accompanied by a cluster of metabolic
abnormalities including insulin resistance, atherogenic dys-
lipidemia and chronic low-grade inflammation. Although
body mass index (BMI) predicts the incidence of diabetes
and coronary heart disease [1], it cannot by itself identify
obese individuals who remain metabolically healthy and
normal weight individuals who present disturbed lipid or
glucose metabolism and increased cardiovascular risk [2,3].
The assessment of body fat distribution can further improve
the evaluation of the subject’s metabolic risk. Indeed,
observational studies have shown that abdominal obesity,
especially excess visceral [4,5], together with liver fat [3]
accumulation is the main driver of cardiometabolic risk
factors and disease independently of BMI. Traditionally, serum
lipids, glucose and insulin were used as markers of cardiovascu-
lar risk. More recently, the focus has widened to cover a more
global serum metabolomics profile, which has predicted the
incidence of cardiovascular events [6], type 2 diabetes [7] and all-
cause mortality [8] in prospective cohort studies.
Both obesity and serum metabolomics profile are herita-
ble. Genetic factors explain 47%–90% of the interindividual
variation in BMI with the remaining variance being attribut-
able to environmental sources and measurement error [9].
Heritability estimates from direct measures of whole-body
and regional body fat assessed by dual-energy X-ray absorp-
tiometry (DEXA) are generally similar to the estimates
obtained for BMI [10,11]. Genetic and environmental influ-
ences on serum metabolite levels were recently described in
the Finnish twin cohort. Heritability estimates were moderate
and ranged between 23% and 55% for amino acids and other
small-molecule metabolites and were higher for serum lipid
(range: 48%–62%) and lipoprotein (range: 50%–76%) concen-
trations demonstrating a genetic basis for individual differ-
ences in serum metabolite levels [12].
Given these high heritabilities and the significant associ-
ation between adiposity and metabolic traits [13], a question
of interest is whether associations result from potential
causal mechanisms or are confounded by shared genes acting
pleiotropically on both phenotypes. A recently published
Mendelian randomization study suggests causal adverse
effects of adiposity with multiple cardiometabolic risk
markers in adolescents and young adults from four popula-
tion-based cohorts in Finland [13]. Obesity discordant twin
analyses and bivariate twin modeling are also well suited to
explore the extent to which genetic and potential causal
environmental factors explain observed associations. Previ-
ous twin studies have documented a moderate overlap of
both genetic and unique environmental factors thatcontribute to adiposity and lipid traits [14,15]. However, to
the best of our knowledge, they have not yet been extended to
include a more comprehensive set of circulating metabolites.
Thus, in this study of healthy twins, we aimed to 1) estimate
the extent of genetic and environmental overlap between
waist circumference (WC) and the serum metabolome using
bivariate twin modeling techniques; 2) investigate which
adiposity and insulin resistance measures are most strongly
associated with the serum metabolic profile, including lipids,
fatty acids (FAs), and amino acids in twin individuals;
3) examine whether these associations are independent of
genetic and familial influences, by conducting within-pair
analysis in monozygotic (MZ) twins.2. Research Design and Methods
2.1. The Twin Cohorts
The sample was derived from two population-based cohorts,
FinnTwin16 (FT16) and FinnTwin12 (FT12) [16]. Both are
longitudinal studies of behavioral development and health
habits of Finnish twins enrolled during adolescence and
repeatedly assessed by self-report questionnaires. The FT12
study includes five consecutive birth cohorts of Finnish twins
born in 1983–1987. The questionnaires were sent to twin
individuals at age 12 and subsequent follow-up assessments
were made when the twins were aged 14, 17 and as young
adults (mean age 22 years). The FT16 study includes five
consecutive birth cohorts of Finnish twins born in 1975–1979.
The questionnaires were sent to the twin individuals at age 16
and subsequent follow-up assessments were made when the
twins were aged 17, 18.5, ~25 and ~34 years. For both the FT12
and FT16, the baseline and follow-up assessments included
surveys of health-related behaviors, anthropometric charac-
teristics, symptom checklists, and social relationships. Zy-
gosity was determined initially by a validated questionnaire
method and then confirmed by genetic analysis of polymor-
phic markers at the Paternity Testing unit, National Institute
for Health and Welfare, Helsinki, Finland.
The data presented in this article were derived from a
clinical assessment for twins selected from both FT12 and
FT16 after the fourth wave questionnaire collection. Pregnant
women and subjects on cholesterol-lowering drugs were
excluded. Our study population for quantitative genetic
analysis included 1368 subjects (FT12: n = 725, FT16: n = 543
and TwinFat, see below: n = 100; MZ: 531, DZ: 837; age range:
21.0–31.5; 52.5% female). A venous blood sample for serum
metabolite (NMR) analyses was taken in the morning of the
assessment. Height was measured to the nearest millimeter
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nearest 100 g with a calibrated scale wearing light indoor
clothing.WCwasmeasured to the nearest millimeter midway
between the spina iliaca superior and the lower rib.
2.2. TwinFat — the Sub-sample With Detailed
Adiposity Measures
The TwinFat sample was enrolled from the FT12 and FT16
cohorts based on the twins’ BMI at the fourth wave of the data
collection. Twins were selected with the aim of covering the
full BMI range of both normal-weight and obese subjects and
a full range of within-pair differences in BMI. In addition, 100
twin individuals were chosen at random with respect to BMI
(and included in the quantitative genetics analysis sample
described above). The TwinFat subsample consisted of 286
subjects (MZ: 136 DZ: 150; age range: 22.8–36.2; 52.9% female).
33 MZ twin pairs were discordant for BMI (within-pair
difference (Δ) in body mass index ≥3 kg/m2; age range: 22.8–
36.1; 64% female). One twin had type 2 diabetes and used
metformin and insulin. Another obese co-twin had inactive
ulcerative colitis and used mesalazine and azathioprine. All
other participants were healthy (based on medical history,
clinical examination, and structured psychiatric interview),
were normotensive, and did not use any medications except
oral contraceptives. Their weights had been stable for at least
3 months prior to the study. Zygosity was confirmed by
genotyping of ten informative genetic markers [14].
Body composition was measured by DXA (Lunar Prodigy,
Madison,WI, software version 8.8) providing both total body data
and regional results (android, gynoid, arms, legs). Fat percentage
was calculated as fatmass/(fatmass + leanmass + bonemineral
content) for the total body and android and gynoid fat mass and
fat percentage were determined from a total body scan as
described by Wiklund et al. [17]. Venous blood samples were
drawn after a 12-h overnight fast for the measurement of serum
metabolites (NMR), glucose (measured using the spectrophoto-
metric hexokinase and glucose-6-phosphate dehydrogenase;
Roche Diagnostics, Basel, Switzerland), serum insulin (time-
resolved immunofluorometric assay; Perkin Elmer, Waltham,
MA,USA) andhigh sensitivityC-reactive protein (CRP) (CobasCRP
(Latex)HS, Roche Diagnostics). HOMA-IR was calculated as
glucose*insulin/22.5 [18].
A subsample of the TwinFat, 84 MZ subjects (TwinFat
Intensive, age range: 22.8–36.2, 52% female) provided mag-
netic resonance imaging (MRI) measurements for subcutane-
ous (sc) and intra-abdominal (ia) fat volumes and liver fat
content by proton magnetic resonance spectroscopy (MRS) as
previously described [19].
Data collection and analysis were approved by the ethics
committee of the Department of Public Health of the
University of Helsinki, the Institutional Review Board (IRB) of
Indiana University and the Helsinki University Central
Hospital. All subjects provided written informed consent.
2.3. The NMR Metabolomics Platform
All serum samples were analyzed using the same high-
throughput NMR metabolomics platform. The sample prepa-
ration and NMR spectroscopy methods have been describedin detail elsewhere [20,21]. The NMR metabolomics method-
ology provides quantitative information on lipoprotein sub-
class and particle concentrations, serum FAs including, e.g.
omega-3 and omega-6 FAs and low-molecular-weight metab-
olites such as amino acids, 3-hydroxybutyrate, and glycopro-
tein. The total number of metabolites analyzed in the current
study was 56. These measures describe the main metabolic
pathways. A small number of subjects (<2%) have missing
values for some metabolites due to rejection of these values
by automatic sample and measurement quality control.
2.4. Statistical Analyses
Descriptive characteristics of the study samples were
expressed as mean ± SE. Anthropometric measures and
serum metabolite concentrations were standardized by age,
sex and cohort and rank-transformed to normality prior to
statistical analysis. At first, we used the entire sample
treating twins as individuals while accounting for twin pair
clustering by survey methods [22]. Pearson correlations were
used to determine correlations between body composition
and serum metabolites. In an initial analysis in which
variables were only standardized by age and cohort and not
by sex, the correlation coefficients were very similar for men
and women. The confidence intervals for the phenotypic
correlations between WC and serum metabolites in men and
women were wide and overlapping for most variables.
In addition, the interaction terms between sex and each
metabolite in the prediction of WC were tested and not
significant for 54 out of the tested 56 metabolites. Based on
these results, we decided to present the results for men and
women combined in order to increase the statistical power
and to simplify the presentation of the results.
Next, we performed within-pair analyses in MZ twins to
examine how differences in body composition are related to
differences in metabolites between co-twins. Within-pair
differences (Δ) of all measures were calculated by subtracting
the leaner co-twins’ BMI measures from the ones of heavier
co-twins’, irrespective of the magnitude of the intrapair
difference in weight. Likewise, Pearson correlation analyses
were performed to examine how Δbody fat distribution is
related to Δ in serum metabolites. The non-parametric
Wilcoxon signed-rank test for matched samples was used to
compare the untransformed metabolic values between BMI-
discordant co-twins. Because MZ twins raised together share
their genetic material (i.e. are identical at the DNA sequence
level) and a common rearing environment, any observed
associations between obesity measures and the serum
metabolic profile are fully controlled for unmeasured con-
founding by genetic and shared environmental effects.
In individual-level analysis, 16 principal components, and
in within-pair analysis 15 principal components explained
more than 95% of the variance in serum metabolite concen-
trations. This number was used to correct for multiple testing
using the Bonferroni method. The statistical analyses were
performed using the Stata statistical software (release 11.0;
Stata, College Station, TX) and the rank-transformation to
normality was conducted in the statistical software R version
2.15.0 (package GenABEL). Quantitative genetic modeling to
estimate these genetic and environmental variance and
114 M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 5 ( 2 0 1 6 ) 1 1 1 – 1 2 1covariance components is standard in twin studies [23] and
described in more detail in the electronic Supplementary
material (ESM) Methods and ESM Figure.3. Results
Descriptive characteristics of our study cohorts are shown in
Table 1.4. Abdominal Obesity and Serum Metabolites:
Bivariate Models
The sex-, age- and cohort-adjusted phenotypic correla-
tions between WC and circulating serum metabolites in
individual twins are presented in Fig. 1. The actual Pearson
correlation coefficients are shown in ESM Table 1.
4.1. Phenotypic Correlations
WC was significantly correlated with 50 out of the 56
investigated serum metabolites towards an unfavorable
metabolic profile. Specifically, abdominal obesity was posi-
tively correlated with concentrations of triglycerides and very
low-density lipoprotein (VLDL) particles, low-density lipopro-
tein (LDL) particles, and concentrations of small high-density
lipoprotein (HDL) particles, as well as total cholesterol, LDL-C,
intermediate density lipoprotein cholesterol (IDL-C), Apolipo-
protein (Apo) B and the ApoB to ApoA1 ratio. Concentrations
of large HDL particles were negatively correlated with WC.
Serum FAs as a proportion of total FAs were inversely, albeit
weakly correlated with WC, except for the positive correlation
with monounsaturated fatty acids (MUFAs). Branched chain
amino acids (BCAA; valine, leucine, isoleucine), two aromatic
amino acids (phenylalanine and tyrosine), as well as alanineTable 1 – Characteristics of the study cohorts.
FinnTwin TwinFat TwinFat MZ
n = 1368 n = 286 n =136
Age (yrs) 24.3 ± 0.1 28.7 ± 0.2 29.4 ± 0.5
Monozygotic 531 136 136
Dizygotic, same sex 837 150 NA
BMI (kg/m2) 23.6 ± 0.1 25.4 ± 0.3 26.5 ± 0.6
Waist (cm) 80.9 ± 0.4 87.3 ± 0.9 88.3 ± 1.4
Total fat (%) NA 29.0 ± 0.8 31.1 ± 1.3
Android fat (%) NA 35.0 ± 0.9 37.2 ± 1.3
Gynoid fat (%) NA 29.9 ± 0.8 38.5 ± 1.3
Android/gynoid fat ratio NA 1.0 ± 0.0 1.0 ± 0.0
Android fat/Total fat% NA 1.2 ± 0.0 1.2 ± 0.0
Gynoid fat/Total fat% NA 1.3 ± 0.0 1.3 ± 0.0
Subcutaneous fat (cm3) a NA NA 4411.2 ± 271.9
Intra-abdominal fat (cm3) a NA NA 1166.5 ± 110.2
Liver fat (%) a NA NA 2.9 ± 0.6
Glucose (mg/L) NA 5.1 ± 0.0 5.2 ± 0.1
Insulin (mU/L) NA 6.2 ± 0.3 6.0 ± 0.4
Homa IR NA 1.4 ± 0.1 1.4 ± 0.1
hsCRP (mg/L) NA 1.7 ± 0.2 2.0 ± 0.3
Values are mean ± SE. MZ, monozygotic; NA, not assessed.
a n = 84.were positively and glycine negatively correlated with WC.
Among the measures of glycolysis, WC was positively
correlated with pyruvate and negatively correlated with
citrate. WC also correlated positively with glycerol, which
serves as a marker of lipolysis of the triglycerides. The ketone
bodies acetate and 3-hydroxybutyrate were weakly and
inversely correlated with WC. WC was not significantly
correlated with the following metabolites: histidine, glycine,
lactate, acetate, creatinine and urea. The largest positive
correlation was seen with the ApoB to ApoA1 ratio (r = 0.35)
followed by glycoprotein (r = 0.33) and the largest negative
correlationwas observedwith HDL particle diameter (r = −0.33)
followed by the concentration of large HDL particles and the
HDL-C to LDL-C ratio (r = −0.31 for both).
4.2. Genetic and Environmental Correlations
To further investigate the relationship between abdominal
obesity and the circulating serum metabolites, we
decomposed these phenotypic correlations into their genetic
and environmental components (Fig. 1, ESM Table 1). The
significant genetic and environmental correlations which
were observed between WC and many metabolites indicate
that the genetic and environmental factors that influenceWC
overlap partly with those that influence the serum metabo-
lites. However, the strength of the correlations was weak to
modest suggesting that only a fraction of the genetic and
environmental variation is common to abdominal obesity and
the serum metabolites. Overall, we found that genetic and
unique environmental correlations were of about the same
magnitude as phenotypic correlations for most serum me-
tabolites. Exceptions were the metabolites ApoA1, BCAA and
phenylalanine, for which genetic correlations were stronger
than unique environmental correlations. In particular, for
ApoA1, valine and leucine, genetic correlations were signifi-
cant (rg = −0.24, 0.32 and 0.36 respectively) but the unique
environmental correlations were smaller and did not reach
statistical significance. This indicates that shared genetic
factors largely explain the significant associations between
abdominal obesity and these serum metabolites.5. Obesity-related Measures and Serum
Metabolites: Detailed Phenotyping in the
TwinFat Sub-sample
Sex- and age-adjusted phenotypic correlations between
detailed obesity-related measures and serum metabolites in
the TwinFat subsample are presented as a heatmap in Fig. 2.
Overall (BMI, % body fat) and abdominal obesity (WC), android
fat% and android to gynoid ratio correlated positively with an
unfavorable lipoprotein profile (i.e. increased VLDL, IDL, LDL
and small HDL particle concentrations, IDL- and LDL-C,
triglycerides, ApoB and ApoB to ApoA1 ratio and reduced
large HDL particle concentration, HDL-C and diameter). The
strongest correlations were observed between measures of
abdominal obesity and small VLDL particle concentration,
HDL diameter and triglycerides (r ≥ 0.4). Measures of obesity
were not significantly correlated with saturated fatty acids




























































































































































Fig. 1 – Correlations betweenwaist circumference and serummetabolites in 1368 twin individuals. Phenotypic correlations (rp)
are shown in red; genetic correlations (rg) in blue and unique environmental correlations (re) in green. The points indicate the
correlation coefficient and the lines show the 95% confidence intervals. All correlations are adjusted for sex, age and cohort.
The shared genetic variance was calculated as the rg2. Abbreviations: VLDL, very low-density lipoprotein; LDL, low-density
lipoprotein; IDL, intermediate-density-lipoprotein; HDL, high-density-lipoprotein; C, cholesterol; ApoB, Apolipoprotein B;
ApoA1, Apolipoprotein A1; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; FA, fatty acids; DHA,
docosahexaenoic acid; PUFA, polyunsaturated fatty acids. The fatty acid ratios indicate the ratio of different classes of fatty
acids to total fatty acids.
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sity was positively correlated with BCAA and phenylalanine
(rmax = 0.44, p < 0.001), glycoprotein (rmax = 0.47) and to aweaker extent with tyrosine (rmax = 0.27). BMI and measures
of abdominal obesity correlated inversely with glutamine
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Fig. 2 – Pearson correlations between obesity-related measures and serum metabolites in 286 twin individuals. The sample
size for subcutaneous (sc), intra-abdominal (ia) and liver fat was 84. Abbreviations: BMI, body mass index, Waist, waist
circumference; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; CRP, high-sensitive C-reactive protein; VLDL,
very low-density lipoprotein; LDL, low-density lipoprotein; IDL, intermediate-density-lipoprotein; HDL, high-density-
lipoprotein; C, cholesterol; ApoB, Apolipoprotein B; ApoA1, Apolipoprotein A1; SFA, saturated fatty acids; MUFA,
monounsaturated fatty acids; FA, fatty acids; DHA, docosahexaenoic acid; PUFA, polyunsaturated fatty acids; BCAA, branched-
chain amino acids. The fatty acid ratios indicate the ratio of different classes of fatty acids to total fatty acids. Android fat and
gynoid fat indicate the ratio of fat to total tissue in the android/gynoid areas. The color key denotes the magnitude of the
correlation coefficients. All metabolites were rank-transformed and adjusted for sex and age. The P-values denote the
statistical significance after correcting for multiple testing: P-values ****p < 0.00000625; ***p < 0.0000625; **p < 0.000625,
*p < 0.0031.
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metabolites as overall and abdominal obesity although many
correlations were stronger (e.g. medium VLDL: r = 0.58,
triglycerides: r = 0.56 and glycoprotein: r = 0.48–0.50).Additionally, significant inverse correlations were seen be-
tween measures of insulin resistance and LDL diameter,
acetoacetate and 3-hydroxybutyrate. CRP correlated with an
unfavorable metabolic profile and correlations were generally
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except for the considerable correlation between CRP and
glycoprotein (r = 0.48). The associations between the ratio of
gynoid to total fat mass and the metabolic profile were
opposite than with other obesity measures. Correlations were
strongest with HDL diameter (r = 0.41) and the following
metabolites: medium and small VLDL particles, triglycerides,
phenylalanine and glycoprotein (r = −0.43 to −0.48).
The same analysis that was performed in individual twins
was repeated using within-pair differences (Δ) in MZ twin pairs,
thus being able to control for familial and genetic confounding.
Compared with analyses performed in twin individuals, there
was a notable drop in the strength of most correlation
coefficients (Fig. 3). This indicates possible genetic control over
the association between obesity measures, insulin resistance,
inflammation and the serummetabolic profile. However, excep-
tions were the following: Δandroid fat% correlated with lipopro-
tein profile including ΔLDL-C (r = 0.46), ΔLDL particle
concentrations (rmax = 0.49), ΔLDL diameter (r = −0.41) and
ΔApoB (r = 0.47). Similarly, Δinsulin resistance associated with
an unfavorable metabolic profile including ΔVLDL particle
concentration (rmax = 0.56), Δtriglycerides (r = 0.53), ΔPUFAs
(r = −0.41), Δisoleucine (r = 0.46) and Δglutamine (r = −0.43). The
correlations between Δia fat and Δliver fat and ΔLDL particle
concentrations, ΔLDL-C, ΔApoB, ΔApoB to ApoA1 ratio, ΔHDL
diameter, Δacetoacetate, and Δ3-hydroxybutyrate were stronger
than in individual-level analysis. The highest correlation was
seen for correlations betweenΔia fat andΔliver fat and theΔApoB
to ApoA1 ratio (r = 0.61 and 0.58, respectively). This highlights
that acquired accumulation of fat in the abdominal area, and
excess ia and liver fat in particular, are important modifiable
environmental factors that modify the levels of atherogenic
lipoproteins and some other metabolites.
5.1. BMI-discordant Monozygotic Co-twins
We further studied the role of environmental factors by
comparing the serummetabolites between 33 BMI-discordant
MZ twin pairs. The obese co-twins were on average 18 kg
heavier and had 29% more total fat, 36% more fat in the
android and 17% more fat in the gynoid area and 280% more
liver fat. In obese co-twins we indeed found significantly
increased levels of thosemetabolites that correlated strongest
with obesity measures above (ESM Table 2). Obese co-twins
had higher concentrations of VLDL and LDL particles, choles-
terol, triglycerides, ApoB, BCAA, lactate, glycerol, urea and
glycoprotein than their leaner counterparts. Obese co-twins
had lower concentrations of HDL particles, HDL-C and a
smaller HDL diameter. The ratios HDL to LDL, ApoB to ApoA1
and PUFA to total FAs were lower in the obese than lean co-
twins. The particle concentration of most lipoproteins, HDL
particle size and ratios of HDL to LDL and ApoB to ApoA1
remained significantly different between co-twins even after
correction for multiple comparison (adjusted p < 0.0033).6. Discussion
In this study of healthy young adults, abdominal obesity, insulin
resistance and low-grade inflammation were associated withhigher concentrations of atherogenic lipoproteins, aromatic and
BCAA, glycoprotein and lower concentrations of PUFAs and
glutamine. The relative contribution of genetic and modifiable
environmental factors in explaining these associations was
dependent on the metabolite under investigation. Acquired
obesity, independent of genetic factors within the MZ BMI-
discordant twin pairs, was most clearly associated with an
atherogenic lipoprotein profile.
Previous twin studies have reported that genetic correla-
tions are stronger between physiologically similar pheno-
types, such as triglycerides and HDL-C, and weaker for other
pairs of phenotypes, such as obesity and blood pressure
[24,25] or obesity and lipid traits [15,26]. In the present
analysis, we extend these earlier observations by quantifying
the genetic and environmental factors that underlie abdom-
inal obesity and a large number of metabolites, which are
potential novel biomarkers of metabolic diseases. Genetic
correlations between abdominal obesity and metabolites
were highest for HDL-C and diameter, serum triglycerides,
the ApoB to Apoa1 ratio, BCAA, phenylalanine and glycopro-
tein. Future bivariate linkage and genome-wide association
studies are needed to co-localize these correlated traits to a
genetic region. As an evidence of a common genetic basis
between obesity and serum lipids, previous bivariate linkage
studies have reported a pleiotropic quantitative trait locus
(QTL) on chromosome 19 which jointly influences serum
triglycerides and adiposity [27] and an LDL-C–BMI locus on
chromosome 3 [28]. He and colleagues [29] found an inverse
association between a genetic risk score for BMI and HDL-C in
type 2 diabetic women, which was independent of BMI,
indicating that pleiotropic genes could influence both pheno-
types through different pathways. Kilpeläinen et al. [30]
reported that a locus near IRS is associated with lower body
fat percentage and, opposite to what would be expected, with
higher insulin resistance and an adverse lipid profile.
Detailed phenotyping of obesity-related measures in a
subsample of the twins allowed the investigation of which
obesity-related measures were most closely linked to an
adverse metabolic risk profile. As previously reported for
standard lipid measures [17,31], abdominal obesity and
insulin resistance were the strongest correlates of an athero-
genic lipoprotein profile including triglycerides and triglycer-
ides in VLDL and IDL, LDL-C, IDL-C and ApoB, VLDL and LDL
particle subclasses of all sizes as well as small HDL particle
subclasses. Furthermore, obesity correlated negatively with
concentrations of large HDL subclasses, HDL-C and HDL-C to
LDL-C ratio. This increase in total VLDL and LDL concentra-
tion and shift in the lipoprotein subclass distribution towards
larger VLDL and smaller HDL and LDL particles are consistent
with increased cardiovascular disease risk [32].
In the present study, correlations within MZ twin pairs
were generally weaker than in individual-level analysis. This
provides evidence of partial confounding due to genetic
factors, which is consistent with the finding of significant
genetic correlations for abdominal obesity and most metab-
olites in the quantitative genetic modeling. It is also in
agreement with results from large GWAS studies that
identified loci and genes associated with these traits [33].
However, measures of abdominal fat distribution (i.e. android
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Fig. 3 – Pearson correlations betweenwithin-pair differences in obesity-relatedmeasures andwithin-pair differences in serum
metabolites in 68 monozygotic twin pairs. The sample size for subcutaneous (sc), intra-abdominal (ia) and liver fat was 42
pairs. Abbreviations: BMI, body mass index, Waist, waist circumference; HOMA-IR, Homeostatic Model Assessment of Insulin
Resistance; CRP, high-sensitive C-reactive protein; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; IDL,
intermediate-density-lipoprotein; HDL, high-density-lipoprotein; C, cholesterol; ApoB, Apolipoprotein B; ApoA1, Apolipopro-
tein A1; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; FA, fatty acids; DHA, docosahexaenoic acid; PUFA,
polyunsaturated fatty acids; BCAA, branched-chain amino acids. The fatty acid ratios indicate the ratio of different classes of
fatty acids to total fatty acids. Android fat and gynoid fat indicate the ratio of fat to total tissue in the android/gynoid areas. The
color key denotes the magnitude of the correlation coefficients. All metabolites were rank-transformed and adjusted for sex
and age. The P-values denote the statistical significance after correcting for multiple testing: P-values ****p < 0.000006667;
***p < 0.00006667; **p < 0.0006667, *p < 0.0033.
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and LDL diameter in within-pair than in individual-level
analysis. Similarly, the heavier co-twins of MZ twin pairs had280%more liver fat and amore atherogenic lipoprotein profile
even after correcting for multiple testing. The well-known
physiologic role of liver in the lipoprotein metabolism
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higher VLDL, LDL, and ApoB concentrations. In accordance,
lipoprotein kinetic studies in humans have shown that liver
fat drives the overproduction of large VLDL particles and
ApoB, which in turn initiates a number of lipoprotein changes
that increase the risk of atherosclerosis, including hypertri-
glyceridemia, an increase in small, dense LDL particles and
low HDL-C [34].
We found that obesity and insulin resistance were
associated with increased concentrations of MUFAs and
lower concentrations of PUFAs, in particular omega-6 FAs
and to a lesser extend omega-3 FAs. The serum FA profile is
influenced by dietary fat intake over the past few weeks [35],
and we have previously reported a lower proportional dietary
PUFA intake in the heavier co-twins of the discordant MZ
pairs [36]. Rate-limiting enzymes are also important determi-
nants of the serum FA profile; in particular stearoyl-CoA
desaturase-1 (SCD-1) synthesizes MUFA from SFA and D6-
desaturases synthesizes highly unsaturated FAs. Subjects
with obesity or metabolic syndrome have increased activity
of SCD-1 and D6-desaturase [37], which corresponds well with
our finding of more MUFAs and less PUFAs in the serum of
obese subjects. In the present study, fasting insulin and
HOMA-IR remained significantly correlated with lower con-
centrations of PUFAs in analysis that controlled for potential
confounding by familial factors of genes and shared environ-
ment within MZ twins. In two Finnish studies, low concen-
trations of serum omega-6 PUFAs were prospectively
associated with the incidence of impaired fasting glycemia,
diabetes mellitus [38] and metabolic syndrome [39].
In our healthy twin sample of young adults, abdominal
obesity and insulin resistance were the strongest correlates of
BCAA, phenylalanine and tyrosine. It has been known for
many years that obesity is associated with an increase in
these amino acids [7,40]. More recently, it has been shown
that obesity blunts amino acid metabolism in adipose tissue
and profoundly affects BCAA catabolism. In subcutaneous
and visceral adipose tissue obtained during surgery, essential
amino acids, leucine, glutamine and serine and 2-
ketoisocaproic acid differed significantly between obese and
lean subjects [41]. In our earlier study of MZ twin pairs
discordant for obesity, serum levels of insulin secretion-
enhancing BCAA were increased in obese male co-twins and
adipose tissue transcription profiles exposed significant
down-regulation of genes involved with mitochondrial BCAA
catabolism [3,42] indicating that the increase in plasma BCAA
levels may be due to their decreased oxidation in the
peripheral tissues. Our finding of an inverse association
between glutamine and insulin resistance is in accordance
with previously published data from the Framingham Heart
Study and the Malmö Diet and Cancer Study [43]. In the
present study we highlight the complexity in the association
between obesity and amino acid metabolism, which involves
both genetic and environmental factors.
Measures of obesity, insulin resistance and CRP correlated
with glycoprotein, an acute-phase protein that is elevated in
response to inflammation and infection [44]. Alpha-1 acid
glycoprotein has been prospectively associated with both
fasting and postchallenge glucose [45] and with the risk of
developing diabetes [46]. In a recent study among participantsfrom the Estonian biobank, alpha-1 acid glycoprotein was the
strongest circulating biomarker predicting all-cause mortality
after adjusting for conventional risk factors [8].
Among all obesity measures studied, measures of abdom-
inal obesity and the ratio of android to gynoid fat were the
strongest correlates of an unfavorable serum metabolic
profile. In contrast, correlations with the ratio of gynoid to
total fat mass were in the opposite direction, supporting the
view that having proportionally more fat stored in the gynoid
area is metabolically protective. It has been suggested that
gluteofemoral fat functions as a ‘metabolic sink’ to buffer
excess energy, thereby preventing ectopic and visceral fat
deposition [47].
Combining men and women in the analysis can be seen as
a potential limitation. However, we did not observe signifi-
cant differences by sex in the associations of obesity and
metabolites, and therefore combined men and women in the
analysis in order to increase statistical power. A previous
large study of obesity and circulating metabolites that
included 12,664 adolescents and young adults from four
population-based cohorts in Finland found significant sex
interactions for some metabolites; however the absolute
differences were fairly small [13]. The strengths of the present
study include its population-based design, the detailed
phenotyping of body composition, the inclusion of large sets
of serummetabolites and the use of twins to tease out genetic
and environmental factors. Potential shortcomings of the
study must also be acknowledged. First, the young adult and
Caucasian sample utilized in this study limits the generaliza-
tion to other populations. Second, the cross-sectional study
setting does not provide understanding of the temporal
relations, even though the use of the MZ discordant pairs
permits control of genetic and early family confounders.
Finally, multiple comparison correction and the reduced
sample size in MZ within-pair and discordant twin analysis
increase the likelihood of false negatives (type II error).
In conclusion, abdominal obesity and insulin resistance are
associated with changes in the serum metabolome toward
reduced cardiometabolic health. Our results suggest that genes
that influence variation in abdominal obesity partly overlap with
those that influence variation in serum metabolites. However,
genetically identical twins that differ in obesity measures also
differ in the serum lipoprotein profile, therefore indicating that
obesity may be a modifiable environmental factor that leads to
lipid disturbances. Thus, our findings give further credence to
public health efforts aiming to prevent weight gain and closely
linked metabolic abnormalities.
Supplementary data to this article can be found online at
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Inflammation is an important mediator of obesity-related complications such as the 
metabolic syndrome but its causes and mechanisms are unknown. As the complement 
system is a key mediator of inflammation, we studied whether it is activated in acquired 
obesity in subcutaneous adipose tissue (AT) and isolated adipocytes. We used a special 
study design of genetically matched controls of lean and heavy groups, rare monozygotic 
twin pairs discordant for body mass index (BMI) [n = 26, within-pair difference (Δ) in body 
mass index, BMI >3 kg/m2] with as much as 18 kg mean Δweight. Additionally, 14 BMI-
concordant (BMI <3 kg/m2) served as a reference group. The detailed measurements 
included body composition (DEXA), fat distribution (MRI), glucose, insulin, adipokines, 
C3a and SC5b-9 levels, and the expression of complement and insulin signaling path-
way-related genes in AT and adipocytes. In both AT and isolated adipocytes, the clas-
sical and alternative pathway genes were upregulated, and the terminal pathway genes 
downregulated in the heavier co-twins of the BMI-discordant pairs. The upregulated 
genes included C1q, C1s, C2, ficolin-1, factor H, receptors for C3a and C5a (C5aR1), 
and the iC3b receptor (CR3). While the terminal pathway components C5 and C6 were 
downregulated, its inhibitor clusterin was upregulated. Complement gene upregulation 
in AT and adipocytes correlated positively with adiposity and hyperinsulinemia and 
negatively with the expression of insulin signaling-related genes. Plasma C3a, but not 
SC5b-9, levels were elevated in the heavier co-twins. There were no differences between 
the co-twins in BMI-concordant pairs. Obesity is associated with increased expression 
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inTrODUcTiOn
The complement system has a pivotal role in obesity. While it is an 
important innate immune defense system against microbes and 
part of the body’s clearance system, it can also regulate the level 
of inflammation in the adipose tissue (AT) and have metabolic 
effects. Complement is a key innate sensor between viable and 
non-viable cells. It recognizes and opsonizes both foreign targets, 
like microbes, and exposed or damaged endogenous structures, 
and promotes their clearance by macrophages. Altogether, 
the complement system comprises up to 50 proteins that are 
synthesized by several tissues including the liver and various 
cell types of AT (adipocytes, macrophages, and vascular cells) 
(1–3). The complement proteins circulate in blood as activating 
or regulating components or act on cell membranes as receptors 
or protective molecules. Intriguingly, many links exist between 
the complement system and AT, but overall, the meaning and 
relevance of these links are mostly unclear.
The complement system can be activated through the classical, 
the lectin, or the alternative pathway. Specifically, the classical and 
the lectin pathways can recognize targets with specific pattern 
recognition molecules C1q, mannan-binding-lectin (MBL), and 
ficolins 1–3 (FCN1–3) (1–3). In contrast, the alternative pathway 
is continuously active and can amplify efficiently complement 
activation against non-self targets (2–4). All three pathways merge 
to activate the complement component C3, the most abundant 
complement factor in human blood plasma. Factor D (CFD, 
adipsin) is synthesized solely by adipocytes and its plasma levels 
are decreased in obesity (5). Factor D activates complement factor 
B (CFB) allowing the generation of the alternative pathway C3 
convertase C3bBb, which enzymatically cleaves new C3 molecules 
to C3a and C3b (1–3). Opsonization by C3b and by its inactivated 
product iC3b leads to the phagocytosis of target structures (1, 3). 
Activation of the early pathways of the complement system results 
in the generation of C5a, a potent anaphylatoxin, chemoattract-
ant, and leukocyte activator. Together with C3a, C5a can attract 
cytokine-producing macrophages and other leukocytes to the 
area of microbial invasion or tissue damage (1, 3). The completion 
of the cascade, the terminal pathway, leads to formation of the 
membrane attack complex (MAC, C5b-9) that allows sodium and 
calcium influx into cells. Membrane leakage will thus sequentially 
lead to strong metabolic activation, injury, and ultimately death 
of the target cell (4). Soluble complement inhibitors such as factor 
H (CFH), vitronectin and clusterin, and a group of membrane-
bound regulators [complement receptor 1 (CR1)/CD35, CRIg, 
MCP/CD46, DAF/CD55, and protectin/CD59] protect normal 
viable human cells against complement attack (3).
The complement system includes many proteins relevant to 
obesity, e.g., acylation-stimulating protein (ASP, C3a desArg) 
and adipsin (factor D). In addition, the activation-initiating 
complement proteins are related to adiponectin, which is an 
insulin-sensitizing and anti-inflammatory adipokine. Its plasma 
levels decrease in obesity (6). Adiponectin has structural simi-
larity to complement collectins C1q, MBL, surfactant proteins 
SP-A and SP-D, and FCN1–3. They are all multimers of triple-
helical structures, where each subchain has subunits composed 
of a globular and a collagen-like domain (7). Additionally, 
adiponectin participates in the clearance of dying cell material 
by macrophages via a calreticulin-mediated mechanism (8) and 
is an immune-modulator lowering tumor-necrosis factor-alpha 
(TNF-α)-levels (9). ASP is identical to the C3 activation product 
C3a desArg (10). In AT, ASP stimulates glucose uptake and free 
fatty acid storage postprandially (10). In the complement system, 
C3a desArg is mostly devoid of the anaphylatoxin or chemotactic 
activity of C3a. While C3a binds to the C3a receptor (C3aR), C3a 
desArg binds to the C5a receptor type 2 (C5aR2), which often 
mediates anti-inflammatory effects (11). C3aR expression has 
been shown to become upregulated in AT following a high-fat 
diet (12). It is intriguing that the C3a-C3aR (inflammation) and 
C3a desArg-C5aR2 (fat and glucose metabolism) interactions 
have such different effects.
During the progression of obesity, the adipocyte size increases, 
which associates with inflammation (13) and is linked to the devel-
opment of insulin resistance (14, 15). Plasma levels of C3, CFH, 
and CFB correlate positively with body mass index (BMI), waist 
circumference, triglycerides, and inflammatory parameters and 
negatively with insulin sensitivity and HDL cholesterol (16, 17). 
Complement components such as C3 and factor B are overpro-
duced by activated adipocytes in type 2 diabetes mellitus (T2DM) 
(18), and C3 is among the major determinants of metabolic 
syndrome in obese patients (19). Thus, the activated complement 
system is involved in the pathogenesis of cardiovascular disease 
(20). Upregulated complement gene expression by adipocytes 
from subcutaneous (sc) fat associates with insulin resistance (21, 
22). In a population-based cohort study, plasma levels of C3 were 
found to correlate positively with plasma insulin and glucose and 
to associate with the development of type 2 diabetes (23). Since 
complement is a main mediator of inflammation and clearance 
of non-viable tissue components, its role in obesity-related fat 
overload and metabolic disturbances merits more attention.
In humans, most of the studies on the complement system 
have been conducted in unrelated individuals without control 
for genetic variation. It is evident that genetic effects have a 
strong influence on both how complement activation is linked 
to inflammation (24) and on the weight gain (25) as well as for 
the developing complications thereafter. To exclude confounding 
due to shared genetic factors, we undertook a unique approach 
of analyzing complement gene expression in subcutaneous AT 
of genetically identical twins either concordant or discord-
ant for obesity. To exclude the effect of the immune-cell-rich 
of the early, but not late, complement pathway components and of key receptors. The 
twins with acquired obesity have therefore an inflated inflammatory activity in the AT. The 
results suggest that complement is likely involved in orchestrating clearance of apoptotic 
debris and inflammation in the AT.
Keywords: obesity, complement system, gene expression, twin study, monozygotic twins
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stroma-vascular fraction, we further analyzed the complement 
gene-expression profiles of isolated adipocytes. In addition to 
comparing the co-twins (effects of acquired obesity), we wanted 
to know whether complement gene expression is associated with 
adipocyte size, fat distribution (subcutaneous, intra-abdominal, 
and liver fat), systemic inflammation, systemic markers of insulin 
resistance, or the expression of insulin-signaling genes. This was 
explored separately in the AT and isolated adipocytes from the 
twin individuals. Finally, we stained AT biopsies immunohisto-
chemically to investigate the localization and intensity of C1q, the 
key activator of the classical pathway and of C3d, an indicator of 
prolonged complement activation. The results reveal an unprec-
edented coupling of the complement recognition molecules 




The study population has been described in our previous studies 
(26–28). Briefly, the monozygotic (MZ) twin pairs (aged 22–36, 
54% women) were identified through the national population 
registry of Finland from 10 population-based birth cohorts 
(FinnTwin12 and FinnTwin16); 26 pairs being discordant for 
BMI, within-pair difference (Δ) in BMI >3 kg/m2 (mean Δweight 
18 kg), and 14 pairs concordant for BMI (ΔBMI <3 kg/m2) acting 
as their controls. All pairs were of European ancestry (Finnish), 
normotensive, and did not use any other medications than oral 
contraceptives, except for one obese co-twin with T2DM who 
used metformin and insulin, and one obese co-twin with inactive 
ulcerative colitis who used mesalazine and azathioprine. Twenty-
three subjects were habitual smokers. AT biopsies were available 
from all 80 subjects. mRNA was available for gene expression 
analyses in isolated adipocytes from 38 subjects (14  BMI-
discordant and 5 concordant pairs). The clinical characteristics 
within these twin pairs did not differ from the entire group of 80 
twins (Table S1 in Supplementary Material). The protocol was 
designed according to the principles of the Helsinki Declaration 
and all subjects gave their written informed consent. The Ethical 
Committee of the Helsinki University Central Hospital (DNRO 
270/13/03/01/2008) approved the protocol.
serum and Plasma analyses, Body 
composition, aT Biopsies, and adipocyte 
Morphology
Venous blood samples were obtained from all subjects after 
overnight fasting. EDTA plasma and serum samples were 
separated by centrifugation and stored at −80°C until the 
analyses of plasma glucose (spectrophotometric hexokinase and 
glucose-6-phosphate dehydrogenase assay, Roche Diagnostics, 
Basel, Switzerland), serum insulin (by time-resolved immuno-
fluorometric assay; Perkin Elmer, Waltham, MA, USA), plasma 
adiponectin and adipsin (DuoSet ELISA, R&D Systems Europe 
Ltd., Abingdon, UK), and serum high-sensitive C-reactive pro-
tein [hsCRP, Cobas CRP (Latex) HS, Roche Diagnostics] were 
performed. Plasma levels of fluid phase activation products of the 
complement system C3a (cleaved from C3) and SC5b-9 (soluble 
C5b-9) were determined by an enzyme-linked immunosorbent 
assay using MicroVue C3a Plus and C5b-9 Plus enzyme immuno-
assay kits (Quidel Corporation, San Diego, CA, USA) according 
to the manufacturer’s instructions. The absorbances were read at 
450 nm in a FluorStar Optima multidetection microplate reader 
(BMG Labtech GmbH, Ortenberg, Germany), and the concentra-
tions analyzed using Optima’s MARS 2.0 analysis software.
Body composition of the subjects was measured by Dual-
energy X-ray absorptiometry (Lunar Prodigy, Madison, WI, 
USA, software version 8.8). Fat percentage was calculated as fat 
mass/(fat mass + lean mass + bone mineral content) for the total 
body. Magnetic resonance imaging (MRI) was used for measur-
ing the volumes of abdominal subcutaneous and intra-abdominal 
fat, and magnetic resonance spectroscopy for measuring the liver 
fat percentage, as described earlier (29).
Adipose tissue biopsies were obtained from periumbilical 
subcutaneous fat using a surgical technique. RNA was prepared 
from frozen fat tissue (26). Adipocytes were isolated from the fat 
biopsy specimens treated with collagenase (28). The diameter of 
fat cells was measured under a light microscope. Fat-cell volume 
was calculated as described by Heinonen (13) assuming the 
adipocytes as spheres.
Transcriptomics analyses of aT and 
adipocytes
Transcriptomics experiments were performed with Affymetrix 
U133 Plus 2.0 chips. Raw gene expression data were pre-
processed with the GeneChip robust multiarray averaging 
(GCRMA) algorithm using BioConductor (30) in R and by 
using Brainarray custom CDF files for probe annotations (31). 
The data were validated with RT-qPCR as described (32). We 
selected 46 representative genes coding for components of the 
complement system for the expression analyses in the AT (Table 
S2 in Supplementary Material). The following genes from the 
insulin signaling pathway were used in analyses of the relation-
ships between complement system and insulin sensitivity in AT: 
insulin receptor (INSR), insulin-receptor substrate proteins 1–2 
(IRS1–2), and phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA). The following complement 
factors were not included as they were not included in the array 
(C1QTNF4, C1QTNF6, C4, MBL, MASP-2) or were expressed at 
low levels (C8, C9, C4BP, C5aR2, and vitronectin) thereby lacking 
the inter-individual variation. GLUT4 gene was expressed at the 
lowest detection level, lacked inter-individual variation, and was 
therefore excluded from AT analyses.
Isolated adipocyte transcriptomics experiments were per-
formed with Affymetrix U133 Plus 2.0 chips similarly as for the 
AT samples. The expression levels of L-selectin (SELL) and C5aR2 
were not found from adipocyte transcripts. The same insulin 
signaling pathway-related genes than from AT and GLUT4 gene 
transcripts were analyzed.
immunohistochemical staining
We selected two BMI-discordant pairs and two BMI-concordant 
control twin pairs to visualize complement proteins in AT. Paraffin 
blocks of the AT were sectioned at 5 µm and two sections were 
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placed on each slide. One of the sections was used for staining 
with a primary and secondary antibody, while the other served as a 
mock control with buffer pipetted in place of the primary antibody.
First, a standard de-paraffination procedure was applied con-
sisting of 2× xylene (5′), followed by a series of ETOH (2′ each) in 
decreasing concentration and ending up in distilled water where 
samples slides were stored until the following day in preparation 
for staining. An antigen retrieval heat-treatment protocol followed, 
where section slides in EDTA buffer pH8.5 from Sigma (product# 
E1161, Sigma-Aldrich, St. Louis, MO, USA) + 0.05% Tween were 
brought to a boiling point in a microwave oven for 15′ followed by 
cooling in RT for 30′. The actual staining was carried out using 3× 
PBS washed heat-treated slides in a humidity chamber using Bright 
Vision plus Poly-HRP-Anti MS/RB/RT IgG REF DPVB55-HRP 
kit (Immunologic, Duiven, Netherlands). The grease pen limited 
section was subjected for Hydrogen Peroxide Block (UltraVision; 
Thermo Fisher Scientific, Waltham, MA, USA) incubation for 
10′, where after the manufacturer’s protocol for the staining kit 
was followed. The primary antibodies were diluted 1:1,000 in PBS 
(C1q and C3d both Rabbit pAb by DAKO, Glostrup, Denmark). 
The final step of the staining protocol was counterstaining by Gills 
Hematoxylin (2″) rinsing (10′) and finally series of ETOH (2′) 
treatments in increasing concentration finishing in 2× xylene (2′) 
and mounting by Depex. The slides were dried ON in a fume hood 
and stored in RT. Tissue histology was confirmed by standard HE 
staining for each tissue sample. Images of immunohistochemistry 
were collected using Olympus DP Manager (ver. 2.2.1.195) and 
Olympus DP Controller (ver. 2.2.1.227) image capture softwares 
with Olympus BX51 fluorescence microscope camera with 100×, 
200×, and 400× magnifications.
statistical analyses
The statistical analyses were performed using Stata statistical 
software (release 13.0; Stata Corporation). In addition to con-
trolling the effect of gender, the comparison of MZ co-twins 
(almost 100% identical at the DNA sequence level) allows 
controlling for genetic and shared environmental effects. Thus, 
any differences within twin pairs are by definition acquired (in 
our case, through BMI difference). Comparisons of the heavier 
vs. leaner co-twins’ clinical characteristics were analyzed by 
paired t-test (normally distributed) or Wilcoxon’s test (non-
normally distributed variables). Within-pair comparisons of 
the log2-transformed gene expression values were tested by 
paired t-test.
Student’s t-test was used for the co-twin comparison of 
the gene expression data. In addition, we assessed differences 
between genders, and smokers and non-smokers (individual 
twins) with Mann–Whitney U-test. Since some differences in 
the gene expression between smokers vs. non-smokers emerged, 
within-pair analyses were performed first among all twin pairs, 
whereafter habitual smokers were removed from the leaner vs. 
heavier comparison to assess whether the effect of smoking was 
confounding the results. As the differences in the gene expression 
between leaner and heavier co-twins still emerged to the same 
extent before and after exclusion of the smokers, we present the 
results from the whole cohort, with smokers included. Within-
pair analyses are by design adjusted for gender.
Mann–Whitney U-test was used to compare whether the 
characteristics of the leaner and the heavier co-twins in the BMI-
discordant pairs were the same in the whole group for whom AT 
was available and in those for whom data on adipocytes were 
available.
Using twins as individuals, the partial correlation analyses 
were performed to determine the relationships between AT/
adipocyte gene expression and adiposity measures, adipokines, 
and the insulin signaling gene expression. Since differences 
between genders and smokers vs. non-smokers emerged in 
individual twins’ gene expression, their effect was adjusted in 
correlation analyses. Logarithmic corrections were performed 
for log-normally distributed variables prior to the correlation 
analyses. Subsequently, the p values of partial correlates were 




Table  1 summarizes the subjects’ anthropometric and clinical 
characteristics (26–28). In brief, the heavier co-twins of the 
discordant pairs weighed on average 18 kg more, had 28% more 
total fat, 67% more subcutaneous fat, 200% more intra-abdom-
inal fat, and 300% more liver fat than their leaner counterparts. 
Accordingly, the adipocyte volumes of the heavier co-twins were 
57% larger than those of the lean co-twins. Furthermore, the 
heavier co-twins had higher plasma levels of insulin and adipsin, 
and lower adiponectin levels. BMI-concordant pair co-twins did 
not differ in any of the metabolic measures. They were also similar 
for all complement-related measures, which is why we report only 
the results from the discordant pairs.
The early complement Pathway 
components are Upregulated and c3 is 
More activated in heavier co-twins
Initially, we analyzed the effect of obesity on complement gene 
expression. In AT, 20 out of the altogether 46 complement genes 
expressed differently between the leaner and the heavier co-twins 
of the BMI-discordant pairs (Figure 1; Table S2 in Supplementary 
Material). In heavier co-twins of BMI-discordant pairs, the 
C1qA-C genes, those of the classical pathway activation initiat-
ing proteins, were upregulated. Accordingly, the genes for other 
classical pathway components: C1s, the key catalytic component 
of C1, the receptor for C1q (C1QR), C1r-like protease (C1RL), 
and C2 were upregulated. In contrast, the genes of FCN2, coding 
a protein recognizing acetylated carbohydrates in the lectin-
pathway, and C1QTNF7, a C1q and TNF-related protein (CTRP) 
family member, were downregulated in heavier co-twins.
The gene expression of the most abundant complement inhibi-
tor factor H (CFH) of the alternative pathway was upregulated 
in heavier co-twins compared to their leaner counterparts. 
Additionally, complement receptor of the immunoglobulin 
superfamily (CRIg/VSIG4) was upregulated. Thus, while the 
early classical pathway components were upregulated, the result 
suggests that complement activation would continue only up to 
FigUre 1 | The gene expression profile in subcutaneous adipose tissue within monozygotic body mass index-discordant twin pairs (heavier vs. 
leaner) differed in 20 out of 46 genes that code for components of the complement system. Genes that are upregulated in heavier co-twins are indicated 
with red and downregulated genes with blue.
TaBle 1 | The clinical characteristics of the monozygotic twin pairs.
BMi-discordant pairs BMi-concordant pairs (n = 14)













N of current 
smokers
7 7 4 5
BMI 25.28 ± 0.89 31.25 ± 1.02 <0.0001 26.20 ± 0.92 27.65 ± 1.01
Fat percentage (%) 32.25 ± 1.81 41.14 ± 1.32 <0.0001 28.56 ± 2.57 29.89 ± 2.39
Adipocyte volume 
(μm3)a
371.9 ± 34.05 584.4 ± 49.55 <0.0001 364.7 ± 54.11 403.1 ± 46.87
Subcutaneous fat 
(cm3)
3,814 ± 416.9 6,359 ± 540.4 <0.0001 3,084 ± 351.7 3,428 ± 394.0
Intra-abdominal fat 
(cm3)
790.2 ± 179.0 1,644 ± 247.4 <0.0001 1,037 ± 173.2 1,093 ± 200.3
Liver fat% 1.12 ± 0.32 4.52 ± 1.00 <0.0001 1.99 ± 0.90 3.75 ± 1.75
fP-insulin (mU/L)b 4.93 ± 0.51 8.50 ± 1.21 <0.001 5.34 ± 1.13 5.61 ± 0.60
fP-glucose 
(mmol/L)b
5.13 ± 0.07 5.28 ± 0.11 0.174 5.27 ± 0.11 5.44 ± 0.15
hsCRP (mg/L) 2.56 ± 0.70 4.02 ± 1.14 0.065 1.25 ± 0.55 1.11 ± 0.19
Adipsin (pg/L)a 1,192 ± 49.05 1,309 ± 47.34 0.006 1,011 ± 121.7 1,047 ± 81.97
Adiponectin (ng/L) 3,842 ± 284.9 2,820 ± 232.2 0.0001 3,370 ± 539.9 2,603 ± 307.9
fP-C3a (ng/mL) 69.20 ± 4.16 77.82 ± 4.57 0.016 67.70 ± 9.24 61.45 ± 3.28
fP-SC5b-9 (ng/mL) 184.6 ± 10.28 193.64 ± 9.00 0.209 187.0 ± 15.13 184.3 ± 13.19
Wilcoxon signed-ranks test (leaner vs. heavier twin). Within-pair difference BMI >3 kg/m2 in discordant pairs (n = 26 pairs, 9 males), BMI <3 kg/m2 in concordant pairs (n = 14 pairs, 
5 males).
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the C3/C5 convertase level because of upregulation of the main 
inhibitory control factor CFH. In accordance, the plasma levels 
of C3a and adipsin were higher in the heavier, but the levels of 
SC5b-9, a marker of terminal pathway activation, were similar 
between the heavier and the leaner co-twins of BMI-discordant 
pairs (Table  1). This indicates that complement activation in 
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obese individuals indeed occurred up to the C3 activation level 
but not beyond that to the terminal pathway.
Upregulated gene expression of 
complement receptors and complement 
inhibitors and Downregulation of the 
Terminal Pathway in aT of heavier  
co-twins
The genes for C3aR1 and C5aR1, important complement 
receptors found, e.g., on the surfaces of macrophages and 
other immune cells, were upregulated in heavier co-twins’ AT 
(Figure 1; Table S2 in Supplementary Material). Furthermore, 
the heavier co-twins had an upregulated gene expression of 
components of the beta-integrin CD11b/CD18, the major 
phagocytic receptor (CR3) for particles coated with iC3b. 
The genes of the terminal pathway components C5 and C6 
were downregulated, whereas the gene of the soluble terminal 
complement complex binding clusterin (CLU) was strongly 
upregulated in heavier co-twins. This indicates that the ter-
minal pathway is suppressed in obese individuals, whereas 
the receptors for early activation pathway components are 
upregulated to mediate their functional effects.
complement gene expression Profiles of 
isolated adipocytes Differ between BMi-
Discordant co-twins
As AT is a mixture of adipocytes, immune cells, vasculature, 
and the connective tissue stroma, we next wanted to study the 
expression profiles of complement genes in isolated adipocytes. 
The levels of 25 out of 45 complement genes expressed by isolated 
adipocytes differed between heavier and leaner co-twins of the 
BMI-discordant pairs (Table S3 in Supplementary Material). 
Similar to AT, in the adipocytes, the complement genes of the 
classical and alternative pathways were upregulated and genes of 
the terminal pathway were downregulated in heavier co-twins. 
However, a few differences in adipocytes compared to the AT 
expression profile were observed: ADIPOQ, FCN1, CALR, 
and CFH gene expressions were similar between co-twins of 
BMI-discordant pairs, but the gene expressions of C1-inhibitor 
(SERPING1), CD93, C3, CFB, C5AR1, and the MAC-inhibiting 
molecule CD59 (protectin) were upregulated in heavier co-
twins. Again, the gene expression profiles of isolated adipocytes 
of the co-twins of BMI-concordant pairs were similar (data not 
shown).
adiposity Measures associate with 
Upregulated expression of genes in the 
classical and the alternative Pathways 
and Downregulation of genes in the 
Terminal Pathway-related genes
The correlations between adiposity measures, metabolism, 
inflammation, and complement gene expression profiles in AT 
and adipocyte transcripts are presented as heatmaps in Figure 2. 
Table S4 in Supplementary Material shows the corresponding 
r values and p values after correction for multiple parameters.
In AT samples, the complement gene expression levels cor-
related significantly with BMI (18 out of 46 genes), adipocyte 
volume (23/46), sc fat (22/46), intra-abdominal fat (29/46), liver 
fat (22/47), hsCRP (28/46), and plasma adipsin (18/46) levels. The 
correlations of adiposity measures were positive for genes of the 
classical and the alternative pathway components and negative 
for the terminal pathway components C5 and C6. Furthermore, 
SERPING1 and the C1q homologs C1QTNF7 and FCN2 cor-
related negatively with adiposity measures.
The complement gene expression of isolated adipocytes cor-
related most significantly with intra-abdominal fat (24 out of 
45 genes), sc and liver fat (13/45 for both), and hsCRP (23/45). 
The correlations were positive except for C1QTNF7, FCN2, C5, 
and C6.
Upregulation of the classical and 
alternative Pathway components 
associates with hyperinsulinemia and 
Downregulated insulin signaling route
Next, we examined whether the complement gene expression in 
AT and adipocytes was associated with plasma insulin and expres-
sion of genes along the insulin signaling route (INSR, IRS1–2, and 
PIK3CA in both AT and adipocytes, and additionally GLUT4 in 
adipocytes) (Figure 2; Table S4 in Supplementary Material for the 
corresponding r values and p values after correction for multiple 
parameters). A strong inverse correlation between the classical 
and the alternative pathway and insulin signaling route gene 
expression was found both in AT and adipocytes. Plasma insulin 
correlated positively with the expression of 25/46 complement 
genes in AT but only with CR1 gene expression of adipocytes. 
C6, C1QTNF7, FCN2, and FCN3 expression in AT correlated 
negatively with plasma insulin.
Visualization of complement Proteins  
in aT
Finally, we investigated the location of two complement proteins 
by immunohistochemistry from paraffin-embedded AT samples. 
Two complement components were stained: C1q indicating ini-
tiation of the classical pathway and C3d representing the remnant 
of C3b deposition typically observed in prolonged complement 
activation (examples shown in Figures  3A–D). Crown-like 
structures representing tissue macrophages around apoptotic 
adipocytes were observed in both leaner and heavier co-twins 
of the BMI-discordant pairs, even though they seemed to be 
more abundant in heavier co-twins’ AT. C1q stained abundantly 
on cell membranes and intracellularly in the apoptotic cells. 
Occasionally, intense nuclear staining of adipocytes occurred 
adjacent but independently of the crown-like structures. C3d 
stained faintly but evenly on the cell membranes – most likely on 
the basal surface of the stain-positive cells. Additionally, intracel-
lular granular aggregates staining intensively for C3d emerged in 
the crown-like structures, but also in some individual adipocytes.
DiscUssiOn
The present study illustrates how obesity can induce a coordinated 
and synchronized regulation of the complement system genes. 
FigUre 2 | The correlations between the complement gene expression and the obesity measures, inflammation, and insulin signaling-related genes 
in monozygotic (MZ) twin individuals taking into account the effect of gender and smoking. MZ twin individuals, n = 80; cell volume, n = 65; plasma 
adipsin, n = 70; plasma adiponectin, n = 80; insulin, n = 80; adipocyte gene transcripts, n = 38. *Statistical significance, p < 0.05, **p < 0.001, ***p < 0.0001 after 
multiple correction (false-discovery rate, Benjamini–Hochberg). BMI, Body mass index; Cell volume, adipocyte volume; Sc fat, subcutaneous fat; Ia fat, intra-
abdominal fat; Liver fat, liver fat percentage; CRP, high sensitive C-reactive protein; INSR, insulin receptor; IRS1-2, insulin receptor substrate 1-2; PIK3CA, 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha; GLUT4, glucose transporter type 4.
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The expression of a broad spectrum of complement genes was 
analyzed in AT and isolated adipocytes in young adult MZ twins, 
nearly all of whom were free from obesity-related co-morbidities. 
Within BMI-concordant pairs, the co-twins’ gene-expression 
profiles were similar suggesting that the overall expression levels 
of complement genes are largely familial, and probably controlled 
by genetic or shared environmental factors.
Several interesting differences emerged within BMI-discordant 
MZ twins: the expression of genes of complement activating and 
regulating components within AT and isolated adipocytes was 
clearly different in heavier compared with their leaner co-twins. 
Most of the differences in the co-twins remained in isolated adi-
pocytes’ transcripts even after separating them from the immune 
cell-rich stroma-vascular fraction. The main findings were the 
following: in heavier co-twins, the classical and the alternative 
pathway complement gene expressions were mostly upregulated. 
These pathways mediate all main physiological functions of the 
complement system. They recognize microbes, antigen–antibody 
complexes, materials from injured cells and tissues, and other 
targets. Complement activation products promote opsonization, 
chemotaxis, leukocyte recruitment, activation, and phagocytosis. 
These effects are mediated by specific receptors that, accordingly, 
were also upregulated. In line with these results, the plasma levels 
of C3a, a marker of the activation of early complement pathways, 
were elevated in the heavier co-twins. Instead, the levels of the 
soluble terminal pathway complement complex SC5b-9 remained 
unchanged. This matches with the gene expression data, where the 
terminal pathway components C5 and C6 were downregulated, 
while the inhibitor clusterin was upregulated. When combined, 
the results demonstrate that complement is involved in obesity-
related inflammation but not in direct MAC-mediated tissue 
destruction.
Our results demonstrating the effects of excess body weight in 
young adults are in accordance with previous studies reporting 
upregulated complement gene-expression levels in AT in obese, 
dyslipidemic, and diabetic subjects (4, 21, 23). We made several 
interesting new observations on upregulated complement genes 
in the heavier co-twins’ AT and on their association with obesity 
and metabolic disturbances. All the three sub-chains of C1q, 
A-C, were upregulated in obesity. They constitute C1q, a mul-
timeric protein that binds to antigen–antibody complexes and 
to many types of cellular structures, which are either exposed or 
released during cellular damage (phospholipids, mitochondria, 
etc.). Bound C1q is subsequently recognized by macrophage 
receptors that mediate phagocytosis of the targets (34, 35). A 
novel observation was that the C1r-related protein C1RL gene 
expression increases in acquired obesity and associates with 
accumulation of intra-abdominal fat. C1QTNF7, a member of 
the CTRP family and closely related to C1q, was downregulated 
in heavier co-twins. Interestingly, C1QTNF7 responds to caloric 
restriction in mice and therefore has a potential role in the control 
of the energy balance (36). Furthermore, calreticulin, a C1QR, 
showed upregulated gene expression in the heavier co-twins 
and correlated positively with hyperinsulinemia and negatively 
with the genes involved in the insulin signaling route. The results 
from Jalali (37) showing the association between INSR density 
and calreticulin, and Lo (5) demonstrating that calreticulin 
correlates positively with pancreatic insulin secretion increasing 
adipsin, support a potential role for calreticulin in the regulation 
of glucose metabolism.
Another novel observation was that genes of the C3 convertase 
inhibitor CFH and the alternative pathway suppressing VSIG4 
(CRIg), a member of the complement receptor immunoglobu-
lin superfamily, were upregulated in heavier co-twins. VSIG4 
FigUre 3 | immunohistochemistry stain of subcutaneous adipose tissue (aT). (a) Leaner twin AT stained with C1q (400×); (B) leaner twin AT stained with 
C3d (400×); (c) heavier twin AT stained with C1q (400×); (D) heavier twin AT stained with C3d (400×); the arrows point out crown-like structures.
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correlated strongly positively with overall and intra-abdominal 
fat and with plasma insulin levels. VSIG4 inhibits T-cell prolif-
eration, clears complement-opsonized particles, and binds to 
C3b (38). VSIG4 is known as a potential biomarker of severe 
preeclampsia (39). Therefore, despite the upregulation of comple-
ment activating components C3 and CFB in obese subjects, the 
concomitant upregulation of the alternative pathway regulatory 
genes indicates that an excessive activation and amplification of 
this pathway can be suppressed in AT. Alternative pathway activa-
tion occurs in a regulated manner generating C3a, and possibly 
C5a (by the C3/C5 convertases), as well as the C3b inactivation 
product iC3b (by CFH and CFI), but remains at a reasonable level 
to prevent transmission of amplification to the terminal pathway.
The levels of SC5b-9, a soluble equivalent of MAC with only 
one C9 remained unchanged in the heavier co-twins. In the 
heavier co-twins, upregulation of complement inhibitors and 
downregulation of the expression of C5 and C6 indicate that 
excessive early pathway activation in obesity does not translate 
into the terminal pathway. Thus, complement activation is related 
more to increased opsonophagocytic and anaphylatoxic capacity 
than to direct cell damaging activity by MAC. Clusterin gene 
expression showed overall the most significant differences within 
BMI-discordant co-twins and the strongest positive correlation 
between obesity measures, liver fat, hsCRP, hyperinsulinemia, and 
adipsin and negative correlation with insulin signaling route gene 
expression in twin individuals. Our results are in line with Won 
et al. (40), who showed that subjects with metabolic syndrome 
have elevated levels of clusterin in plasma. In fact, clusterin is a 
multifunctional molecule, whose activities extend beyond those 
in the complement system. In addition to being an inhibitor of 
MAC, it can cluster cells and act as an apolipoprotein, hence the 
alternative names SP40, 40, and ApoJ (41).
Clusterin suppresses the terminal pathway by inhibiting forma-
tion of the complement MAC, composed of components C5b, C6, 
C7, C8, and multiple C9 molecules (42). Clusterin prevents inser-
tion of intermediate terminal pathway complexes (C5b-7, C5b-8, 
and C5b-9) to membranes. During this process, it incorporates 
into the complexes. Increased expression of clusterin may thus 
be related to the inhibition of excess complement-mediated cell 
damage that is initiated by increased expression of early pathway 
components, ischemia, or the release of complement-activating 
lipids from adipocytes. In addition, by being an apolipoprotein 
and scavenger for hydrophobic molecules, clusterin could also 
directly bind to hydrophobic particles released from fat tissue and 
play a role in their removal.
Adipocyte cell volume was associated with complement gene 
expression in the AT similarly as the overall obesity measures. 
A positive association emerged for the adipocyte size with the 
classical and the alternative pathway and a negative one with 
the terminal pathway-related genes. The adipocytes undergo 
changes in their cell membranes in the development of the 
obese state and potentially this alters the structural conforma-
tion and type of surface membrane molecules they express (43). 
Large adipocytes act as antigen-presenting cells by expressing 
major histocompatibility class II molecules and take part in 
the generation of pro-inflammatory immune response (43). 
Contrasting and potentially generating a balancing response, 
C1q, a structural homolog of adiponectin, promotes anti-
inflammatory macrophage polarization (35, 44, 45). Thus, 
upregulated C1q expression in AT may be reactive and signal a 
tissue defense mechanism and local immune cell infiltration. It is 
noteworthy that multiple C1q homologs, adiponectin, FCN1–2, 
and C1qTNF7 showed changes in obesity. This suggests their 
involvement in an adipocyte-macrophage collaboration process, 
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possibly related to debris clearance. As we were limited by sample 
availability, the immunohistochemical stains did not provide 
quantifiable data. In the descriptive analyses, a pattern emerged, 
where C1q stain appeared more intense and widespread in the 
obese twins than their lean co-twins. The pattern of C1q may 
reflect ongoing phagocytosis (e.g., of necrotic or apoptotic adi-
pocytes) and/or increased inflammation in the heavier co-twins 
albeit being present also in the leaner.
The associations between intra-abdominal fat, liver fat, crp, 
and the genes of the insulin signaling route and differences in 
most of expression levels of the complement genes remained 
significant in adipocyte transcripts after the contribution of the 
stroma-vascular fraction was excluded. In contrast, the role of 
the stroma may be significant when interpreting the correlations 
between BMI, sc fat. adipocyte cell size, sc fat and insulin. The 
correlations between complement gene expressions and these 
measures were weaker in adipocyte transcripts than in AT. 
Indeed, it is not the obesity per se but the central adiposity and 
ectopic fat in liver that are related to alterations in the comple-
ment gene expression.
Our study of MZ twin pairs is unique in that genetic factors as 
causes for differences in within-pair comparisons can be excluded. 
Esparza-Gordillo (24) estimated that 62% of the complement 
factor H (CFH) phenotypic variation is due to additive genetic 
effects. Nestvold (46) showed that the complement system is reac-
tive to environmental factors as levels of C3 and C4 dropped after 
weight loss. The observed differences within weight-discordant 
pairs emphasize the role of non-genetic influences, including 
environmental factors and acquired obesity in regulating the 
expression and activation of the complement system. Finding 
healthy young adult MZ pairs with significant discordance 
in body weight is extremely difficult, as body weight is tightly 
genetically regulated (47). The experiences and exposures of MZ 
twins are often very similar through childhood and adolescence 
and begin to differ only after moving out of their parental home 
and into individual personal and occupational trajectories (48). 
Therefore, although our sample size is relatively small, the study 
represents perhaps the best-controlled study design available 
in humans because of the full match for genes, age, gender, and 
intrauterine and childhood environment between the lean and 
heavy groups.
The limitations of our study include that due to small biopsy 
materials from the volunteers, we lack protein or functional data 
on the AT samples. However, we documented that circulating 
C3a protein levels were elevated in obesity, potentially indicating 
complement activation also at the whole-body level. Our gene-
expression analyses also lacked the data for some components 
of complement cascade such as the pattern recognition protein 
MBL, C4, C8, and C9. The study setting does not allow direct 
causal conclusions, but indicates that the observed differences 
within BMI-discordant co-twins are not due to confounding 
genetic effects.
In summary, our study shows that characteristic to comple-
ment activation in obese AT is upregulation of the classical and 
the alternative pathway sensors and receptors and downregula-
tion of the terminal pathway. In the AT, the activating factors 
and the receptors were upregulated simultaneously indicating 
preparedness for controlled phagocytosis. In addition to the 
pattern-recognition molecules needed for phagocytic activity, 
similar gene-expression patterns also emerged in isolated adipo-
cytes, which indicates their independent role in inducing changes 
in the complement system in the obese AT. Overall, the study 
reveals the close relationship between the complement system 
and AT in obesity. These results pave the way for further analyses 
of the complement-mediated regulation of inflammation and 
lipid clearance and its potential role leading to adverse metabolic 
complications in obesity.
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